oseltamivir
phosphat
tamiflu
prodrug
oseltamivir
carboxyl
effect
form
oseltamivir
phosphat
dissoci
gastrointestin
tract
form
oseltamivir
absorb
metabolis
oseltamivir
carboxyl
hepat
carboxylesteras
hce
oseltamivir
may
central
depress
action
hama
may
also
inhibit
human
sialidas
li
caus
abnorm
behaviour
inhal
zanamivir
reach
far
lower
plasma
concentr
compar
intraven
administr
cass
treatment
reduc
complic
influenza
exampl
pneumonia
excret
viru
infect
peopl
might
use
public
health
measur
contain
epidem
limit
impact
spread
viru
addit
symptomat
treatment
prophylact
use
interrupt
spread
diseas
inform
pandem
plan
past
decad
three
major
reason
conduct
review
addit
question
efficaci
associ
clinic
use
ni
influenza
influenza
antivir
commonli
use
stockpil
drug
past
futur
pandem
basi
intern
nation
recommend
recommend
base
claim
assum
abil
drug
reduc
complic
transmiss
hh
theori
contain
spread
influenza
allow
time
organis
respons
longerterm
intervent
vaccin
take
time
produc
legitim
reason
doubt
claim
result
previou
cochran
review
ni
adult
jefferson
jefferson
children
shunshin
due
risk
report
bia
includ
certainti
public
bia
doshi
doshi
oseltamivir
list
essenti
drug
amalgam
two
longstand
cochran
review
effect
ni
influenza
healthi
adult
jefferson
also
publish
jefferson
children
matheson
base
assess
trial
clinic
studi
report
regulatori
inform
decis
made
find
substanti
report
bia
journal
public
relev
trial
rational
process
see
appendix
identifi
patient
data
randomis
placebocontrol
phase
iii
treatment
trial
oseltamivir
never
publish
includ
biggest
treatment
trial
ever
undertaken
oseltamivir
peopl
age
exclus
unpublish
data
chang
previou
find
regard
abil
oseltamivir
reduc
complic
influenza
doshi
jefferson
case
mistak
attribut
advers
event
discov
match
summari
tabl
individu
particip
list
gravenstein
peter
modifi
routin
cochran
process
improv
previou
method
consid
inadequ
resolv
inconsist
underreport
chang
approach
longer
includ
trial
data
report
paper
publish
biomed
journal
instead
treat
clinic
studi
report
basic
unit
analysi
clinic
studi
report
often
sent
nation
drug
regul
us
food
drug
administr
fda
european
medicin
agenc
ema
formerli
emea
requir
far
stringent
standard
complet
accuraci
report
biomed
journal
journal
articl
regard
succinct
synthesi
clinic
studi
report
addit
seek
clinic
studi
report
decid
read
review
regulatori
document
fda
particular
ema
far
lesser
extent
make
mani
scientif
review
avail
websit
unlik
cochran
review
author
regul
access
whole
data
set
comment
provid
use
insight
help
achiev
better
understand
trial
programm
clinic
studi
report
gener
remain
hidden
public
view
readili
avail
wider
scientif
scrutini
despit
wealth
inform
contain
will
abl
spend
time
read
despit
call
make
relev
trial
data
public
doshi
godle
well
known
problem
report
bias
mcgauran
wiesel
harm
effect
complic
necessari
provid
patient
policymak
physician
complet
unbias
view
risk
benefit
respons
review
jefferson
jefferson
argu
find
appli
suggest
new
viru
thu
need
new
evid
jaid
maugh
nebehay
nh
nh
novel
new
strain
subtyp
circul
sinc
also
resembl
strain
circul
sinc
cdc
pandem
itoh
influenza
subtyp
inde
circul
clinic
trial
includ
previou
review
addit
oseltamivir
zanamivir
approv
regul
worldwid
treatment
prevent
influenza
type
b
specif
subtyp
strain
influenza
b
expect
regulatori
approv
thu
effect
drug
demonstr
clinic
trial
appli
futur
strain
influenza
b
use
drug
pandem
offlabel
approv
use
assumpt
clinic
trial
evid
underpin
regulatori
approv
appli
novel
review
clinic
trial
evid
expect
result
similar
regul
appli
influenza
virus
modifi
approach
cochran
review
grew
realis
prior
method
employ
review
ni
inadequ
seem
compel
reason
think
lesson
learn
limit
particular
drug
godle
rodger
vedula
vedula
wiesel
reason
independ
scrutini
use
possibl
trial
inform
may
inform
wider
debat
adequaci
exist
regulatori
framework
adopt
new
drug
question
whether
systemat
review
move
new
rigor
approach
focus
trial
programm
rather
singl
trial
eyd
ioannidi
see
glossari
appendix
although
substanti
evid
effect
report
bia
estim
effect
less
known
impact
evid
harm
chou
decid
quantifi
addit
resourc
requir
follow
modifi
methodolog
approach
assess
feasibl
systemat
review
proceed
similar
fashion
see
differ
protocol
review
section
previou
version
object
review
describ
potenti
benefit
harm
ni
influenza
age
group
review
clinic
studi
report
publish
unpublish
randomis
placebocontrol
trial
regulatori
comment
includ
evid
randomis
control
trial
rct
test
effect
ni
prophylaxi
postexposur
prophylaxi
pep
treatment
influenza
prophylaxi
mode
use
ni
expect
possibl
nearfutur
exposur
influenza
pep
use
ni
follow
probabl
exposur
influenza
symptom
develop
treatment
use
ni
person
show
probabl
sign
influenza
due
discrep
publish
unpublish
report
trial
decid
includ
trial
unabridg
clinic
studi
report
exampl
consecut
number
page
even
though
may
part
clinic
studi
report
ie
modul
inform
report
trial
consid
pivot
ie
first
secondlin
evid
regul
support
registr
applic
includ
previous
healthi
peopl
children
adult
previous
healthi
includ
peopl
chronic
ill
asthma
diabet
hypertens
exclud
peopl
ill
signific
effect
immun
system
malign
hiv
infect
includ
trial
peopl
expos
natur
occur
influenza
without
symptom
target
intentiontotreat
itt
safeti
popul
prior
review
discov
compel
evid
intentiontotreatinfluenzainfect
itti
subpopul
deem
influenzainfect
balanc
treatment
group
roch
oseltamivir
trial
addit
estim
itt
popul
generalis
clinic
practic
routin
test
influenza
common
mani
countri
even
use
remain
variabl
accuraci
ni
administ
rout
compar
placebo
period
medic
assum
followup
onand
offtreat
ont
offt
period
influenza
symptomat
asymptomat
alway
laboratori
confirm
influenzalik
ill
ili
hospitalis
complic
interrupt
transmiss
two
compon
reduct
viral
spread
index
case
prevent
onset
influenza
contact
harm
drug
resist
viral
excret
mortal
whilst
overal
symptom
reduct
well
document
interest
particularli
focus
complic
advers
event
evid
current
scarc
inconclus
jefferson
shunshin
preliminari
examin
regulatori
document
publish
version
studi
identifi
symptom
sequela
influenza
pneumonia
classifi
either
complic
influenza
advers
event
treatment
somewhat
confus
intend
analys
compliharm
see
glossari
appendix
irrespect
classif
complic
influenza
advers
event
treatment
appendix
oseltamivir
trial
complic
particular
interest
includ
pneumonia
bronchiti
otiti
media
sinus
secondari
ill
often
collect
roch
oseltamivir
trial
agre
event
clinic
import
initi
construct
tabl
illustr
design
methodolog
use
complic
studi
tabl
tabl
includ
follow
variabl
definit
event
term
complic
complic
first
defin
clinic
studi
report
diagnosi
method
avail
data
stratifi
analysi
method
diagnosi
three
possibl
criteria
laboratoryconfirm
diagnosi
eg
base
radiolog
microbiolog
confirm
evid
infect
clinic
diagnosi
without
laboratori
confirm
diagnos
doctor
clinic
examin
type
diagnosi
self
report
patient
conduct
analysi
complic
pneumonia
bronchiti
otiti
media
sinus
classifi
seriou
led
studi
withdraw
case
influenza
complic
report
pneumonia
bronchiti
sinus
otiti
media
variabl
degre
particip
self
report
investig
mediat
exampl
write
detail
case
report
form
lack
verif
investig
cultur
imag
self
report
investigatormedi
unverifi
titl
relev
complic
breviti
use
sparingli
possibl
harm
limit
frequenc
occurr
advers
event
collect
trial
consequ
metaanalys
seriou
advers
event
advers
event
lead
studi
withdraw
withdraw
advers
event
within
clinic
studi
report
defin
bodi
system
well
small
group
common
advers
event
defin
fda
drug
label
oseltamivir
event
metaanalys
death
seriou
advers
event
bodi
system
event
overal
incid
less
metaanalys
outcom
fewer
event
total
conduct
analys
separ
ontreat
offtreat
period
howev
two
case
ontreat
treatment
effect
borderlin
statist
signific
prophylaxi
oseltamivir
renal
bodi
system
ontreat
psychiatr
bodi
system
ontreat
conduct
addit
analysi
combin
onand
offtreat
period
maximis
statist
power
conduct
doserespons
harm
analysi
two
treatment
trial
combin
one
prophylaxi
studi
trial
investig
activ
agent
multipl
dose
studi
includ
standarddos
highdos
oseltamivir
arm
analys
use
logist
regress
adjust
studi
effect
appropri
ie
two
treatment
trial
test
trend
use
likelihood
ratio
test
test
hypothesi
increas
dose
drug
lead
increas
incid
advers
effect
identifi
trial
manufacturerfund
clinic
trial
programm
ni
well
nonmanufacturerfund
clinic
trial
ni
use
varieti
method
appli
varieti
sourc
literatur
manufactur
regulatori
bodi
method
well
methodolog
identifi
obtain
relev
clinic
studi
report
detail
appendix
appendix
appendix
use
electron
search
identifi
trial
identifi
method
outlin
appendix
particularli
nonmanufacturerfund
clinic
trial
see
appendix
detail
review
updat
search
electron
databas
publish
studi
previous
carri
cochran
review
ni
children
matheson
healthi
adult
jefferson
updat
search
juli
descript
search
regulatori
inform
fda
ema
roch
glaxosmithklin
gsk
japanes
pharmaceut
medic
devic
agenc
pmda
see
appendix
collect
inventori
evid
base
facilit
tool
specif
develop
review
appendix
overal
risk
bia
present
graphic
figur
summaris
figur
review
two
author
pd
tj
reappli
inclus
criteria
oseltamivir
clinic
studi
report
resolv
disagr
discuss
two
review
author
es
io
appli
criteria
zanamivir
clinic
studi
report
one
review
author
ch
arbitr
procedur
follow
review
see
appendix
appendix
sizeabl
quantiti
avail
data
led
us
subdivid
extract
apprais
analysi
data
twostag
exercis
stage
assess
reliabl
complet
identifi
trial
data
decid
includ
stage
review
full
analysi
follow
standard
cochran
method
data
satisfi
follow
three
criteria
complet
clinic
studi
reportsunpublish
report
includ
identifi
consort
statementspecifi
method
enabl
replic
studi
identifi
consort
statementspecifi
result
primari
outcom
tabl
appendic
must
avail
intern
consist
part
exampl
denomin
clinic
studi
reportsunpublish
report
broadli
consist
extern
consist
consist
data
report
regulatori
document
version
clinic
studi
reportsunpublish
report
refer
establish
crosscheck
differ
approach
use
previou
version
current
review
jefferson
sinc
incomplet
inform
time
appli
second
third
criteria
detail
use
consortbas
extract
templat
assess
stage
inclus
jefferson
review
see
appendix
review
assess
inclus
stage
part
inclus
procedur
stage
one
review
author
extract
data
second
review
author
check
extract
data
onto
standard
form
check
record
use
regulatori
inform
assess
possibl
correl
citat
frequenc
oseltamivir
treatment
trial
fda
regulatori
document
trial
size
public
protocol
decemb
valid
consortbas
extract
northern
hemispher
spring
decid
carri
analys
call
postprotocol
analys
test
five
null
hypothes
formul
read
summaris
reconstruct
clinic
studi
report
hypothes
origin
observ
discrep
unexpect
observ
clinic
studi
report
data
inform
read
regulatori
inform
appendix
report
rational
method
formul
test
result
hypothes
hypothes
reflect
uncertainti
prevail
evid
base
time
full
clinic
studi
report
avail
studi
previou
studi
compar
regulatori
publish
intern
compani
sourc
evid
report
varieti
differ
bias
affect
medic
knowledg
chou
maclean
mcgauran
wiesel
report
detail
elsewher
comment
use
cochran
risk
bia
tool
higgin
apprais
clinic
studi
report
trial
programm
effort
construct
instrument
assess
risk
bia
complet
clinic
studi
report
full
descript
method
use
quantifi
bias
publish
anoth
paper
estim
treatment
effect
first
calcul
risk
ratio
rr
use
averag
mean
control
event
rate
pool
rr
report
figur
calcul
risk
differ
rd
consist
adopt
method
summari
find
tabl
rd
report
text
analysi
chose
report
rr
consist
across
studi
report
heterogen
pool
rr
reinterpret
result
use
rd
result
applic
clinic
decisionmak
calcul
mean
differ
md
time
first
allevi
symptom
time
first
allevi
symptom
also
estim
treatment
effect
percentag
reduct
averag
time
first
allevi
symptom
placebo
group
zanamivir
clinic
studi
report
report
treatment
effect
term
median
treatment
group
well
p
valu
hypothesi
test
compar
timetoev
distribut
data
insuffici
conduct
metaanalysi
howev
often
suffici
timetoev
data
report
allow
us
estim
restrict
mean
standard
deviat
restrict
mean
base
maximum
time
report
allevi
occur
patient
allevi
censor
maximum
followup
time
therefor
restrict
mean
underestim
true
mean
howev
proport
patient
censor
gener
low
similar
treatment
arm
henc
limit
unlik
led
bia
length
followup
vari
across
trial
led
high
variat
estim
mean
standard
deviat
sd
across
trial
post
hoc
analysi
undertaken
discov
seven
zanamivir
trial
provid
data
time
first
allevi
symptom
without
relief
medic
patient
studi
may
may
taken
relief
medic
trial
allevi
symptom
may
occur
patient
take
relief
medic
standard
comparison
made
use
scenario
howev
addit
analysi
use
stricter
definit
allevi
symptom
could
achiev
without
use
relief
medic
exampl
patient
may
achiev
allevi
use
relief
medic
five
day
took
seven
day
achiev
allevi
without
use
relief
medic
comparison
report
patient
use
stricter
definit
zanamivir
group
allevi
without
relief
medic
less
strict
definit
placebo
group
allevi
relief
medic
plan
use
tridimension
doserelated
time
patient
suscept
dot
methodolog
assess
likelihood
harm
causal
aronson
qualiti
data
avail
allow
problem
unit
analysi
describ
risk
bia
postprotocol
hypothes
section
develop
comprehens
strategi
deal
data
know
miss
trial
level
ie
unpublish
trial
see
search
method
identif
studi
section
appendix
appendix
appendix
unreli
publish
record
concentr
summari
clinic
studi
report
exampl
oseltamivir
trial
programm
trial
clinic
studi
report
eg
consist
page
greater
length
compar
publish
version
dutkowski
consist
seven
page
purpos
review
provid
complet
pictur
possibl
trial
programm
without
relianc
publish
literatur
appendix
report
exampl
content
typic
roch
clinic
studi
report
use
tau
invers
varianc
method
statist
estim
betweenstudi
varianc
measur
level
statist
heterogen
chi
test
test
heterogen
carri
assess
report
bias
compar
clinic
studi
report
relev
public
first
public
version
complet
clinic
studi
report
trial
programm
two
drug
expect
find
relev
inform
document
adopt
binari
assess
high
risk
low
risk
unclear
bia
use
randomeffect
approach
dersimonian
laird
base
md
analysi
time
first
allevi
symptom
outcom
use
randomeffect
approach
binari
data
dersimonian
laird
tau
estim
use
invers
varianc
method
whilst
overal
symptom
reduct
well
document
interest
particularli
focus
complic
advers
event
evid
current
scarc
inconclus
jefferson
matheson
shunshin
preliminari
examin
clinic
studi
report
identifi
symptom
sequela
influenza
pneumonia
classifi
either
complic
influenza
advers
event
treatment
call
somewhat
confus
classif
compliharm
decid
deal
compliharm
follow
identifi
complic
particular
clinic
interest
pneumonia
bronchiti
otiti
media
sinus
tabul
type
data
captur
use
complic
secondari
ill
studi
includ
follow
variabl
definit
event
term
complic
part
clinic
studi
report
captur
data
complic
report
captur
data
diagnost
method
use
whether
diagnost
pathway
usual
form
whether
prescript
treatment
captur
aim
stratifi
analysi
method
diagnosi
three
possibl
criteria
laboratoryconfirm
diagnosi
eg
base
radiologicalor
microbiologicallyconfirm
evid
infect
clinic
diagnosi
without
laboratoryconfirm
diagnos
doctorinvestig
clinic
examin
type
diagnosi
selfreport
patient
also
conduct
analysi
complic
pneumonia
bronchiti
otiti
media
sinus
classifi
seriou
led
studi
withdraw
test
effect
oseltamivir
prophylaxi
influenza
influenzalik
ill
howev
clinic
studi
report
prophylaxi
trial
defin
influenzalik
ill
report
eight
differ
definit
influenza
laboratoryconfirm
see
web
extra
influenza
definit
complex
confus
set
definit
exampl
definit
upper
respiratori
tract
infect
urti
system
disturb
one
definit
asymptomat
influenza
discov
absenc
definit
influenzalik
ill
complex
confus
definit
laboratoryconfirm
influenza
classifi
influenzalik
ill
two
symptom
follow
nasal
congest
headach
chillssweat
sore
throat
cough
fatigu
myalgia
fever
symptom
report
efficaci
list
individu
patient
modul
prophylaxi
trial
clinic
studi
report
two
oseltamivir
treatment
trial
one
prophylaxi
studi
three
treatment
arm
compar
placebo
standard
dose
high
dose
time
first
allevi
symptom
restrict
comparison
placebo
versu
standard
dose
report
origin
report
howev
outcom
combin
standard
highdos
treatment
arm
littl
appar
differ
incid
outcom
standard
highdos
arm
combin
arm
appear
caus
heterogen
howev
two
case
evid
doserespons
effect
case
describ
fulli
result
section
analysi
harm
major
zanamivir
trial
compar
placebo
inhal
zanamivir
howev
trial
also
includ
intranas
zanamivir
treatment
arm
combin
arm
inhal
intranas
treatment
multipl
zanamivir
arm
gener
combin
metaanalysi
effect
appear
similar
appear
caus
heterogen
investig
robust
complic
outcom
use
subgroup
analysi
method
diagnosi
investig
high
estim
heterogen
possibl
use
subgroup
analysi
exampl
conduct
subgroup
analysi
time
first
allevi
symptom
studi
oseltamivir
treatment
children
partit
studi
otherwis
healthi
children
children
chronic
ill
asthma
base
refere
comment
conduct
subgroup
analysi
time
first
allevi
symptom
infect
statu
zanamivir
could
similar
analysi
oseltamivir
data
noninfluenzainfect
patient
could
correctli
identifi
patient
influenza
infect
due
effect
oseltamivir
antibodi
trial
programm
oseltamivir
zanamivir
larg
variat
treatment
effect
pneumonia
across
popul
studi
ie
adult
children
well
treatment
prophylaxi
henc
conduct
metaregress
investig
heterogen
includ
studi
report
pneumonia
studi
total
investig
four
binari
factor
age
group
adult
versu
children
drug
oseltamivir
versu
zanamivir
indic
treatment
versu
prophylaxi
method
diagnosi
oseltamivir
studi
method
diagnosi
either
base
data
collect
nonspecif
advers
event
secondaryintercurr
ill
form
data
collect
specif
diagnosi
secondari
ill
form
includ
object
criteria
xray
confirm
zanamivir
two
trial
includ
xray
confirm
pneumonia
conduct
metaregress
statas
version
window
use
metareg
command
studi
one
treatment
group
zero
event
therefor
ad
event
treatment
group
studi
prior
analysi
depend
variabl
regress
log
rel
risk
post
hoc
analysi
undertaken
discov
seven
trial
provid
data
time
first
allevi
symptom
without
relief
medic
patient
studi
may
may
taken
relief
medic
trial
allevi
symptom
may
occur
patient
take
relief
medic
standard
comparison
made
use
scenario
howev
addit
analysi
use
stricter
definit
allevi
symptom
could
achiev
without
use
relief
medic
exampl
patient
may
achiev
allevi
use
relief
medic
five
day
took
seven
day
achiev
allevi
without
use
relief
medic
comparison
report
patient
use
stricter
definit
zanamivir
group
allevi
without
relief
medic
less
strict
definit
placebo
group
allevi
relief
medic
sensit
analys
applic
postprotocol
analys
cover
earlier
method
section
review
use
fixedeffect
method
mantel
haenszel
sensit
analysi
supplement
primari
analys
use
randomeffect
method
dersimonian
laird
randomeffect
metaanalysi
known
overli
conserv
spars
data
henc
conduct
sensit
analysi
use
peto
method
two
occas
spars
data
borderlin
statist
signific
result
prophylaxi
oseltamivir
renal
bodi
system
ontreat
psychiatr
bodi
system
ontreat
search
trial
registri
electron
databas
regulatori
archiv
correspond
manufactur
identifi
trial
request
clinic
studi
report
although
review
focus
primari
data
sourc
manufactur
check
publish
randomis
control
trial
rct
nonmanufactur
sourc
run
electron
search
follow
databas
abl
download
page
fda
websit
tabl
content
tabl
tabl
tabl
tabl
use
page
identifi
trial
conduct
within
drug
trial
programm
correl
citat
frequenc
oseltamivir
treatment
trial
fda
regulatori
document
trial
size
biggest
treatment
trial
cite
four
time
three
document
contemporari
treatment
trial
cite
far
exampl
cite
time
fda
document
howev
combin
enrol
denomin
four
treatment
trial
complet
time
smaller
suggest
fda
regulatori
evalu
roch
new
drug
applic
base
predominantli
roch
offer
pivot
trial
best
demonstr
properti
oseltamivir
complet
evid
base
oseltamivir
trial
one
possibl
altern
explan
observ
could
interv
trial
complet
gener
report
new
drug
applic
nda
submiss
explan
support
rel
brief
interv
complet
trial
februari
submiss
april
nda
fda
howev
core
part
submiss
clinic
develop
programm
contain
data
two
time
ongo
trial
basi
select
trial
regul
therefor
unclear
appear
dictat
criteria
avail
size
import
trial
manufactur
possibl
regul
may
base
criteria
systemat
review
would
use
ie
capabl
trial
answer
question
due
vast
size
fda
document
sometim
hundr
page
long
difficult
determin
import
emerg
theme
sole
read
identifi
item
interest
fda
comment
use
word
cloud
feinberg
word
cloud
give
greater
promin
word
appear
frequent
sourc
document
result
graphic
represent
show
word
diari
baselin
heavili
mention
relev
abridg
text
fda
medic
offic
review
fda
pdf
page
examin
diari
entri
detail
found
follow
fda
comment
major
subject
particip
treatment
trial
use
first
diari
card
second
diari
card
issu
particip
respons
fda
request
applic
provid
summari
diari
card
dispens
submiss
becam
appar
instruct
start
second
diari
card
uniformli
follow
trial
exampl
patient
allevi
symptom
yet
also
receiv
second
diari
card
convers
also
exampl
patient
allevi
symptom
receiv
second
diari
card
thu
second
diari
card
use
inconsist
view
flaw
trial
lack
consist
collect
symptom
inform
allevi
preclud
complet
document
symptom
fluctuat
also
miss
second
diari
card
subject
allevi
symptom
respons
major
censor
data
may
potenti
influenc
result
efficaci
analysi
order
address
impact
censor
applic
perform
sever
sensit
analys
summar
integr
summari
efficaci
comment
highlight
problem
followup
procedur
treatment
trial
may
impair
regul
abil
draw
conclus
durat
effect
oseltamivir
also
provid
good
exampl
graphic
method
help
identifi
crucial
comment
vast
regulatori
file
sever
experi
text
fda
document
show
choic
text
repres
word
cloud
heavili
influenc
cloud
construct
visibl
word
henc
abil
detect
import
comment
reason
decid
adopt
mix
approach
map
citat
read
fda
comment
integr
comment
apprais
evid
regulatori
comment
import
time
develop
method
clinic
studi
report
comment
help
identifi
gap
knowledg
trial
programm
tabl
content
construct
postul
given
huge
work
involv
review
lot
regulatori
file
new
instrument
could
also
help
us
indic
part
import
other
thu
focus
effort
experi
varieti
method
report
data
collect
analysi
section
prolong
correspond
media
pressur
appendix
abl
access
trial
programm
oseltamivir
zanamivir
without
claus
restrict
access
third
parti
two
review
author
cdm
mt
independ
scan
titl
abstract
electron
search
three
identifi
studi
publish
version
trial
possibl
unknown
us
wrote
first
trial
author
ask
clinic
studi
report
equival
novemb
confirm
trial
complet
absenc
document
trial
programm
drug
list
sponsor
trial
complet
underway
meant
reli
varieti
sourc
reconstruct
trial
programm
identif
relev
clinic
studi
report
complex
reflect
flowchart
present
figur
illustr
studi
select
process
review
two
main
pathway
spontan
releas
full
clinic
studi
report
roch
long
request
request
regulatori
author
gsk
relev
report
drug
list
sponsor
trial
complet
underway
reli
varieti
sourc
reconstruct
trial
programm
retriev
relev
clinic
studi
report
complex
reflect
flowchart
illustr
studi
select
process
review
two
main
pathway
spontan
releas
clinic
full
clinic
studi
report
roch
request
regulatori
author
gsk
relev
report
overlap
trial
report
retriev
follow
differ
pathway
carri
inclus
stage
use
clinic
studi
report
titl
abstract
relev
inform
process
identifi
potenti
relev
studi
oseltamivir
trial
zanamivir
trial
eight
peramivir
trial
includ
stage
uncommon
one
trial
report
clinic
studi
report
either
due
amalgam
two
trial
low
influenza
viru
circul
difficulti
recruit
exampl
trial
bore
differ
id
number
realiti
follow
protocol
albeit
two
differ
hemispher
exampl
also
identifi
six
complet
ongo
studi
peramivir
doserespons
placebocontrol
studi
includ
trial
predominantli
conduct
adult
influenza
season
hemispher
small
number
studi
conduct
older
peopl
resid
care
home
peopl
underli
respiratori
diseas
trial
sponsor
manufactur
oseltamivir
trial
stage
multicentr
trial
conduct
northern
southern
hemispher
eight
done
one
countri
usa
five
japan
two
china
one
total
particip
includ
treatment
trial
prophylaxi
trial
age
particip
rang
year
durat
followup
vari
day
two
trial
conduct
within
nurs
home
within
freeliv
popul
one
perform
inand
outpati
depart
three
trial
conduct
children
particip
trial
adult
trial
elig
popul
includ
particip
increas
risk
influenza
complic
diagnos
asthma
chronic
obstruct
pulmonari
diseas
major
includ
otherwis
healthi
adult
one
trial
particip
stratifi
smoke
statu
anoth
trial
stratifi
presenc
absenc
otiti
media
trial
compar
oral
administ
oseltamivir
either
capsul
reconstitut
powder
placebo
trial
includ
rct
analysi
examin
use
oseltamivir
compar
placebo
two
exclud
metaanalysi
synopsi
report
anoth
full
clinic
studi
report
final
includ
oseltamivir
trial
stage
treatment
adult
four
children
five
prophylaxi
two
adult
two
elderli
one
household
includ
treatment
trial
oseltamivir
three
success
recruit
priori
plan
sampl
size
includ
zanamivir
trial
multicentr
trial
done
northern
southern
hemispher
done
one
countri
japan
five
usa
three
finland
germani
one
total
particip
includ
treatment
trial
prophylaxi
trial
particip
age
rang
year
durat
followup
vari
day
two
trial
perform
within
nurs
home
sever
within
freeliv
popul
one
perform
within
univers
student
popul
trial
elig
popul
includ
particip
increas
risk
influenza
complic
diagnos
asthma
chronic
obstruct
pulmonari
diseas
major
includ
adult
otherwis
healthi
zanamivir
administ
intranas
spray
inhal
combin
placebo
design
match
administr
particip
major
trial
nurs
staff
trial
within
nurs
home
twentytwo
trial
compar
inhal
zanamivir
placebo
six
trial
compar
inhal
zanamivir
intranas
zanamivir
placebo
usual
care
trial
includ
rct
analysi
examin
use
zanamivir
compar
placebo
two
exclud
metaanalysi
one
synopsi
one
compar
zanamivir
usual
care
placebo
final
includ
zanamivir
trial
treatment
adult
two
children
trial
prophylaxi
attempt
collect
suffici
inform
regulatori
file
reconstruct
miss
clinic
studi
report
also
fail
inform
appear
insuffici
reliabl
reconstruct
exclud
studi
enter
stage
variou
reason
pharmacokinet
studi
activ
compar
compar
higherversu
lowerdos
schedul
ongo
trial
trial
await
assess
characterist
studi
await
classif
studi
level
assess
report
risk
bia
tabl
address
problem
report
bia
ignor
publish
trial
report
direct
attent
clinic
studi
report
regulatori
inform
problem
review
copiou
materi
dispos
identifi
analys
import
detail
midst
thousand
page
inform
construct
coher
apprais
larg
complex
trial
programm
addit
sinc
gain
unrestrict
access
full
clinic
studi
report
apart
person
deidentifi
redact
took
view
inform
need
judg
risk
bia
present
therefor
inform
avail
judg
correspond
risk
bia
element
high
risk
bia
exampl
detail
random
sequenc
gener
miss
journal
public
clinic
trial
customari
record
unknown
risk
bia
judgment
usual
carri
assumpt
random
sequenc
gener
detail
avail
detail
report
detail
still
miss
even
full
clinic
studi
report
chose
rate
risk
bia
element
high
risk
bia
follow
paragraph
report
salient
find
use
current
cochran
format
appli
logic
review
regulatori
data
oseltamivir
studi
includ
stage
descript
random
sequenc
gener
miss
report
zanamivir
trial
one
bias
absenc
descript
random
sequenc
gener
placebo
activ
drug
capsul
cap
ident
trial
oseltamivir
may
compromis
blind
particip
one
zanamivir
trial
certif
analysi
enabl
us
reconstruct
appear
tast
textur
two
principl
addit
miss
diari
card
three
treatment
trial
see
result
search
section
unabl
identifi
data
outcom
oseltamivir
trial
eight
zanamivir
trial
exampl
hospitalis
report
zanamivir
trial
inconsist
report
oseltamivir
trial
relev
data
review
come
tabl
hospitalis
sent
us
roch
late
addit
trial
unabl
track
individu
particip
tabl
narr
individu
list
issu
compliharm
imped
ascertain
harm
oseltamivir
treatment
trial
appendix
difficulti
follow
logic
compliharm
even
access
full
clinic
studi
report
definit
advers
event
rct
oseltamivir
zanamivir
differ
ordinari
definit
intern
confer
harmonis
technic
requir
registr
pharmaceut
human
use
ich
guidelin
follow
advers
event
ae
untoward
medic
occurr
patient
administ
medicin
product
necessarili
causal
relationship
treatment
advers
event
therefor
unfavour
unintend
sign
exampl
abnorm
laboratori
find
symptom
diseas
tempor
associ
use
medicin
product
whether
consid
relat
medicin
product
http
wwwichorgfileadminpubl
web
siteich
product
guidelinepdf
access
decemb
exampl
definit
advers
event
studi
follow
pdf
page
follow
allevi
influenzalik
symptom
recurr
singl
respiratori
constitut
symptom
record
advers
event
howev
reappear
one
symptom
record
influenzalik
syndrom
ie
secondari
ill
therefor
appear
advers
event
advers
chang
subject
baselin
pretreat
condit
occur
cours
studi
treatment
start
whether
consid
relat
treatment
treatment
includ
investig
agent
includ
placebo
compar
agent
administ
cours
studi
emphasi
consequ
advers
event
similar
symptom
influenza
headach
mild
gastrointestin
advers
event
tend
exclud
treatment
trial
identifi
report
site
inspect
adult
prophylaxi
trial
fda
carri
inspect
septemb
variou
trial
site
us
includ
west
virginia
site
respons
enrol
mani
hundr
particip
fda
offici
letter
report
sever
violat
includ
failur
report
seriou
harm
sponsor
roch
protocol
requir
addit
state
view
statement
payment
section
consent
form
use
studi
subject
receiv
particip
complet
studi
payment
made
withdraw
studi
person
reason
improp
procedur
subject
paid
particip
studi
payment
prorat
subject
actual
particip
studi
order
avoid
possibl
coercion
fda
pdf
page
howev
fda
allow
data
publish
year
earlier
prime
journal
stand
support
roch
applic
prophylaxi
indic
know
whether
particip
contract
standard
ie
whether
observ
possibl
improp
procedur
could
generalis
site
trial
document
cite
fda
inspector
subject
one
yet
unfulfil
freedom
inform
foi
request
possibl
financi
pressur
confirm
could
serious
confound
dropout
rate
harm
caus
prophylaxi
trial
significantli
higher
incid
diarrhoea
placebo
recipi
treatment
trial
identifi
fda
review
remark
diarrhea
report
frequent
among
subject
receiv
placebo
among
subject
receiv
ro
oseltamivir
diarrhoea
although
specifi
inclus
criterion
document
clinic
manifest
influenza
infect
reduct
incid
diarrhoea
treatment
group
compar
placebo
group
could
consid
possibl
treatment
effect
ro
fda
howev
accord
japanes
summari
basi
approv
jsba
oseltamivir
capsul
prophylaxi
diarrhoea
report
frequent
oseltamivir
arm
placebo
group
summaris
tabl
advers
event
three
trial
find
inconsist
explan
fda
oseltamivir
trial
almost
half
zanamivir
trial
select
report
oseltamivir
trial
show
consist
trend
miss
origin
protocol
except
chang
outcom
definit
trial
run
protocol
amend
even
trial
complet
inconsist
approach
outcom
data
collect
miss
statist
analysi
plan
miss
date
unblind
use
self
report
outcom
pneumonia
repres
pneumonia
event
data
exampl
trial
secondari
ill
patient
report
bodi
clinic
studi
report
state
complic
requir
antibiot
treatment
specifi
priori
even
final
version
protocol
full
text
predefin
list
secondari
ill
ie
mention
pneumonia
bronchiti
sinus
otiti
protocol
complic
anyth
antibiot
treatment
accord
protocol
case
report
form
mention
specif
secondari
ill
name
zanamivir
trial
report
outcom
specifi
protocol
provid
found
evid
possibl
select
report
bia
analys
jsba
data
prophylaxi
regulatori
data
report
tabl
individu
trial
well
page
summaris
tabl
three
trial
prophylaxi
tabl
individu
trial
includ
data
highdos
arm
report
psychiatr
advers
event
overal
howev
summaris
tabl
list
varieti
psychiatr
advers
event
includ
psychot
suicid
advers
event
advers
event
highdos
group
preliminari
exploratori
analysi
combin
follow
suspect
seriou
advers
event
collect
hallucin
delus
classifi
grade
seriou
nation
cancer
institutecommon
toxic
criteria
version
ncictc
psychosi
hallucin
delus
two
major
symptom
diseas
suicid
attempt
classifi
grade
seriou
common
terminolog
criteria
advers
event
ctcae
version
ctcae
hostil
includ
aggress
hostil
violenc
murder
commonli
consid
seriou
event
though
list
ncictc
ctcae
number
suspect
seriou
psychoticsuicid
advers
event
includ
hallucin
psychosi
schizophrenia
paranoia
aggressionhostil
attempt
suicid
five
oseltamivir
group
zero
placebo
group
ontreat
period
offtreat
period
data
ad
total
eight
versu
one
prophylaxi
programm
crucial
understand
harm
profil
drug
potenti
harm
wit
confound
appar
numer
symptom
sign
influenza
infect
far
less
mani
particip
becom
infect
influenza
make
causal
assess
straightforward
three
oseltamivir
treatment
trial
underrecruit
sever
zanamivir
trial
also
underrecruit
note
use
differ
relief
medic
across
differ
centr
within
trial
one
zanamivir
trial
accord
protocol
particip
receiv
antibiot
bacteri
respiratori
tract
infect
exclud
trial
happen
zanamivir
trial
definit
confirm
influenza
amend
protocol
closur
also
note
sever
item
includ
full
clinic
studi
report
studi
protocol
date
prior
particip
enrol
miss
mani
oseltamivir
trial
certif
analysi
interventionplacebo
prepar
patient
enrol
date
explicitli
report
trial
incept
cessat
date
given
zanamivir
trial
partial
redact
explicitli
report
date
trial
unblind
frequent
note
statement
databas
author
xxxx
identifi
unblind
date
explicit
date
import
report
case
date
unblind
report
actual
date
within
month
redact
practic
also
appli
zanamivir
protocol
amend
authorship
account
write
clinic
studi
report
statist
analysi
plan
case
patient
consent
form
miss
zanamivir
trial
patient
inform
form
miss
zanamivir
trial
list
randomis
code
variabl
includ
case
report
form
templat
zanamivir
trial
allow
determin
complet
form
patient
clinician
core
data
sheet
import
document
includ
studi
manual
procedur
minut
safeti
data
monitor
committe
meet
placebo
intervent
set
trial
may
contain
activ
substanc
placebo
zanamivir
trial
contain
lactos
powder
potenti
caus
bronchospasm
placebo
oseltamivir
trial
contain
dehydrochol
acid
dibas
calcium
phosphat
dehydr
caus
gastrointestin
symptom
data
particip
influenzainfect
statu
treatment
trial
particip
influenzalik
ill
prophylaxi
trial
report
oseltamivir
clinic
studi
report
final
data
effect
rescu
relief
medic
mainli
paracetamolacetaminophen
incomplet
clinic
studi
report
oseltamivir
trial
report
separ
zanamivir
trial
adult
treatment
oseltamivir
reduc
time
first
allevi
symptom
hour
confid
interv
ci
hour
statist
repres
reduct
day
day
analysi
figur
signific
effect
asthmat
children
increas
hour
ci
hour
lower
hour
higher
statist
effect
otherwis
healthi
children
base
one
trial
hour
ci
hour
p
analysi
zanamivir
reduc
time
first
allevi
symptom
adult
day
ci
day
statist
equat
hour
reduct
symptom
day
day
analysi
figur
signific
effect
children
time
first
allevi
symptom
day
lower
zanamivir
group
ci
lower
day
higher
statist
analysi
eight
zanamivir
trial
report
use
relief
medic
particip
median
day
allevi
placebo
treatment
arm
less
compar
use
relief
medic
tabl
seven
zanamivir
trial
time
first
allevi
symptom
also
report
without
rescu
medic
use
data
abl
compar
zanamivir
without
rescu
medic
placebo
rescu
medic
overal
nonsignific
day
decreas
ci
day
lower
day
higher
statist
time
first
allevi
symptom
placebo
rescu
medic
group
suggest
zanamivir
better
rescu
medic
possibl
even
less
effect
although
vari
level
use
rescu
medic
seven
trial
give
rise
larg
heterogen
analysi
figur
subgroup
analysi
time
first
allevi
symptom
adult
infect
statu
found
evid
differ
treatment
effect
zanamivir
influenzainfect
subgroup
compar
noninfluenzainfect
subgroup
p
treatment
effect
day
ci
day
statist
influenzainfect
patient
day
ci
day
statist
noninfluenzainfect
patient
analysi
oseltamivir
treatment
adult
signific
differ
hospitalis
rate
treatment
group
risk
ratio
rr
ci
statist
analysi
treatment
children
rr
ci
statist
analysi
wide
ci
prophylaxi
rr
ci
statist
analysi
data
hospitalis
zanamivir
studi
report
adult
treatment
trial
oseltamivir
significantli
reduc
self
report
investigatormedi
unverifi
pneumonia
rr
ci
statist
risk
differ
rd
ci
number
need
treat
benefit
nntb
ci
treat
popul
effect
signific
six
trial
collect
data
nonspecif
advers
event
secondaryintercurr
ill
form
rr
ci
statist
rd
ci
nntb
ci
howev
signific
five
trial
two
clinic
studi
report
use
detail
diagnost
data
collect
form
studi
report
radiolog
confirm
pneumonia
figur
analysi
signific
effect
pneumonia
children
rr
ci
statist
analysi
two
zanamivir
adult
trial
pneumonia
report
base
stricter
definit
xray
confirm
also
signific
treatment
effect
rr
ci
analysi
nine
zanamivir
trial
pneumonia
self
report
investigatormedi
unverifi
outcom
figur
figur
overal
signific
effect
zanamivir
mix
verifi
unverifi
pneumonia
adult
treatment
rr
ci
statist
analysi
analysi
show
prophylaxi
trial
zanamivir
reduc
risk
self
report
investigatormedi
unverifi
pneumonia
adult
rr
ci
statist
rd
ci
nntb
ci
metaregress
pneumonia
base
studi
treatment
effect
statist
differ
age
group
p
drug
p
indic
p
howev
treatment
effect
statist
differ
method
diagnosi
p
unclear
object
diagnosi
pneumonia
treatment
effect
rr
ci
statist
wherea
object
diagnosi
data
collect
pneumonia
treatment
effect
ci
statist
subgroup
analysi
pneumonia
studi
method
diagnosi
shown
analysi
pleas
note
estim
subgroup
analysi
slightli
differ
obtain
metaregress
due
differ
methodolog
oseltamivir
trial
treatment
significantli
affect
complic
classifi
seriou
led
withdraw
trial
adult
rr
ci
statist
analysi
children
rr
ci
statist
analysi
outcom
could
assess
oseltamivir
prophylaxi
due
insuffici
number
event
signific
effect
zanamivir
adult
treatment
reduc
risk
complic
classifi
seriou
led
studi
withdraw
rr
ci
statist
analysi
prophylaxi
rr
ci
statist
analysi
outcom
could
assess
children
due
insuffici
number
event
neither
zanamivir
analysi
analysi
oseltamivir
analysi
analysi
significantli
reduc
risk
bronchiti
sinus
prophylaxi
trial
adult
treatment
oseltamivir
significantli
reduc
risk
bronchiti
rr
ci
statist
analysi
reduc
risk
sinus
analysi
otiti
media
analysi
children
zanamivir
treatment
significantli
reduc
risk
sinus
rr
ci
statist
analysi
otiti
media
rr
ci
statist
analysi
see
tabl
summari
methodolog
use
collect
assess
complic
oseltamivir
treatment
trial
see
tabl
overal
result
oseltamivir
adult
tabl
children
see
tabl
overal
result
zanamivir
adult
tabl
children
symptomat
influenza
lower
oseltamivir
arm
compar
placebo
studi
prophylaxi
rr
ci
statist
rd
ci
nntb
ci
analysi
differ
influenza
outcom
includ
overal
influenzalikeil
report
advers
event
ontreat
household
prophylaxi
one
small
studi
miss
outcom
data
select
report
includ
particip
show
signific
reduct
symptomat
influenza
oseltamivir
arm
compar
placebo
rr
ci
rd
ci
analysi
studi
signific
reduct
asymptomat
influenza
rr
ci
analysi
asymptomat
influenza
significantli
reduc
noninfluenza
influenzalik
ill
report
throughout
studi
period
prophylaxi
trial
could
analys
effect
influenzalik
ill
lack
definit
clinic
studi
report
howev
use
definit
see
method
oseltamivir
reduc
influenzalik
ill
particip
rr
ci
roch
trial
programm
assess
effect
oseltamivir
postexposur
prophylaxi
pep
submit
fda
may
consist
two
trial
includ
trial
placebocontrol
doubleblind
clusterrandomis
trial
contact
cluster
index
case
randomis
oseltamivir
mg
day
placebo
seven
day
manufactur
conclud
trial
prove
oseltamivir
could
prevent
influenza
contact
interrupt
transmiss
index
case
interrupt
transmiss
two
compon
reduct
viral
spread
index
case
measur
nasal
shed
influenza
virus
prevent
onset
influenza
contact
measur
mixtur
symptom
sign
laboratori
confirm
ie
viral
cultur
upper
airway
andor
least
fourfold
rise
antibodi
titr
measur
baselin
two
three
week
later
design
weak
index
case
left
untreat
except
paracetamol
rescu
pack
make
imposs
assess
effect
oseltamivir
nasal
voidanc
index
case
nasal
viral
voidanc
measur
symptomat
particip
therebi
miss
potenti
asymptomat
infect
peopl
zanamivir
howev
reduc
risk
asymptomat
influenza
prophylaxi
individu
rr
statist
analysi
asymptomat
individu
postexposur
prophylaxi
household
rr
ci
statist
analysi
see
tabl
overal
result
oseltamivir
adult
tabl
children
see
tabl
tabl
overal
result
zanamivir
adult
tabl
children
oseltamivir
treatment
oseltamivir
treatment
adult
associ
increas
risk
nausea
rr
ci
statist
rd
ci
number
need
treat
harm
nnth
ci
analysi
vomit
rr
ci
statist
rd
ci
nnth
ci
analysi
associ
decreas
risk
diarrhoea
rr
ci
statist
rd
ci
nntb
ci
analysi
compar
placebo
ontreat
period
nausea
vomit
associ
signific
heterogen
treatment
effect
appear
larger
otherwis
healthi
adult
compar
elderli
chronic
ill
howev
one
trial
otherwis
healthi
adult
also
show
smaller
effect
vomit
common
children
oseltamivir
treatment
compar
placebo
rr
ci
statist
rd
ci
nnth
ci
analysi
cardiac
effect
oseltamivir
unclear
exposur
oseltamivir
may
reduc
cardiac
gener
event
compar
placebo
rr
ci
statist
rd
ci
nntb
ci
exclud
ecg
includ
safeti
paramet
analysi
howev
exposur
oseltamivir
may
increas
qtc
prolong
includ
borderlin
report
trial
rd
ci
nnth
ci
compar
placebo
ontreat
period
treatment
trial
signific
increas
risk
oseltamivir
ontreat
psychiatr
advers
event
overal
analysi
howev
doserespons
effect
two
pivot
treatment
trial
ident
design
trial
two
activ
treatment
group
mg
standard
dose
mg
high
dose
oseltamivir
per
day
doserespons
analysi
increas
risk
psychiatr
bodi
system
advers
event
entir
followup
period
p
base
likelihood
ratio
test
trial
event
rate
placebo
mg
mg
arm
respect
wherea
trial
rate
respect
proport
patient
diagnos
influenzainfect
oseltamivir
treatment
adult
significantli
lower
treat
compar
control
group
rr
ci
statist
analysi
proport
patient
fourfold
increas
antibodi
titr
significantli
lower
treat
group
compar
control
group
rr
ci
statist
analysi
repres
absolut
differ
treatment
group
lower
proport
children
oseltamivir
fourfold
increas
antibodi
rr
ci
statist
analysi
oseltamivir
prophylaxi
increas
risk
headach
ontreat
rr
ci
statist
rd
ci
nnth
ci
analysi
figur
nausea
ontreat
rr
ci
statist
rd
ci
nnth
ci
analysi
also
doserespons
effect
headach
studi
p
base
likelihood
ratio
test
ontreat
rate
placebo
standarddos
highdos
arm
respect
figur
analysi
show
prophylaxi
trial
oseltamivir
signific
increas
patient
psychiatr
advers
event
onand
offtreat
period
rr
ci
statist
rd
ci
nnth
ci
initi
analysi
patient
psychiatr
advers
event
ontreat
period
show
borderlin
statist
signific
result
p
henc
conduct
sensit
analysi
use
peto
method
p
well
analysi
report
figur
tabl
show
summari
psychiatr
advers
event
oseltamivir
prophylaxi
trial
particular
note
oseltamivir
patient
studi
sever
confus
day
hospitalis
day
patient
taken
medic
event
resolv
day
patient
discharg
hospit
subsequ
resum
medic
howev
confus
reappear
day
initi
event
misclassifi
clinic
studi
report
mental
impair
sinc
correct
erratum
publish
journal
publish
origin
trial
manuscript
gravenstein
peter
nonsignific
increas
renal
event
ontreat
rr
ci
statist
rd
ci
nnth
ci
nnth
nntb
analysi
howev
sensit
analysi
use
peto
method
result
renal
event
statist
signific
p
signific
effect
seriou
advers
event
adult
treatment
trial
rr
ci
statist
analysi
treatment
trial
signific
effect
diarrhoea
adult
rr
ci
statist
analysi
headach
rr
ci
statist
analysi
howev
ontreat
phase
nausea
vomit
significantli
less
frequent
zanamivir
arm
rr
ci
statist
rd
ci
nntb
ci
analysi
signific
effect
observ
renal
system
rr
ci
statist
analysi
psychiatr
system
rr
ci
statist
analysi
adult
treatment
trial
zanamivir
significantli
increas
risk
report
advers
event
signific
increas
advers
effect
observ
prophylaxi
trial
includ
psychiatr
analysi
renal
effect
analysi
ontreat
signific
increas
harm
associ
zanamivir
treatment
children
data
spars
signific
effect
zanamivir
treatment
influenza
diagnosi
analysi
probabl
fourfold
increas
antibodi
titr
analysi
analysi
oseltamivir
treatment
trial
one
death
overal
event
occur
due
acut
respiratori
syndrom
placebo
patient
without
influenza
studi
prophylaxi
trial
four
death
total
elderli
patient
two
placebo
group
two
oseltamivir
group
caus
death
report
two
cancer
one
myocardi
infarct
one
intestin
perfor
howev
death
oseltamivir
arm
particip
experienc
acut
renal
failur
ontreat
prior
death
eight
death
total
zanamivir
trial
six
death
caus
neoplasia
cardiovascular
event
elderli
patient
multipl
patholog
howev
two
death
report
due
influenza
pneumonia
one
particip
inhal
rimantadin
plu
placebo
zanamivir
result
postprotocol
hypothes
appendix
oseltamivir
zanamivir
small
nonspecif
effect
reduc
time
allevi
influenzalik
ill
symptom
adult
asthmat
children
use
either
drug
prophylaxi
reduc
risk
develop
symptomat
influenza
treatment
trial
oseltamivir
zanamivir
settl
question
whether
complic
influenza
pneumonia
reduc
lack
diagnost
definit
use
oseltamivir
increas
risk
advers
effect
nausea
vomit
psychiatr
effect
renal
event
adult
risk
vomit
children
lower
bioavail
may
explain
lower
toxic
zanamivir
compar
oseltamivir
influenza
virusspecif
mechan
action
propos
produc
fit
clinic
evid
call
incorpor
unpublish
data
supplement
publish
trial
data
systemat
review
metaanalys
highlight
defici
current
method
obtain
complet
understand
drug
effect
godle
methodolog
approach
entail
comprehens
search
unpublish
sourc
particular
emphasi
obtain
unpublish
intern
report
drug
manufactur
intend
regulatori
submiss
comment
nation
regulatori
bodi
decis
use
publish
evid
basi
trial
apprais
data
extract
meant
reconcil
synthesis
inform
multipl
unpublish
sourc
devis
new
method
search
index
retriev
review
trial
data
combin
understand
regulatori
comment
produc
inform
review
first
step
process
entail
need
develop
reconstruct
trial
programm
without
initi
help
outsid
sourc
reconstruct
list
trial
programm
took
wholetimeequival
wte
research
day
compil
due
complex
task
suggest
futur
essenti
phase
trial
id
check
conduct
pair
one
comment
receiv
protocol
suggest
discrep
publish
unpublish
version
data
set
could
due
mistak
nonpeer
review
unedit
clinic
studi
report
may
correct
time
public
experi
especi
nonreport
seriou
advers
event
point
opposit
case
jefferson
consid
fact
unintent
error
occur
believ
respons
resort
publish
paper
accur
best
unit
analysi
rather
clinic
studi
report
far
comprehens
record
trial
remain
key
unit
analysi
expect
amend
kept
accur
possibl
time
complet
document
reason
amend
believ
result
review
would
undermin
without
access
complet
bodi
evid
knew
outsid
public
domain
theori
trial
regist
would
expect
provid
comprehens
pictur
drug
trial
programm
howev
regist
primari
instrument
reconstruct
zanamivir
oseltamivir
trial
programm
drug
programm
mainli
run
late
trial
registr
becam
norm
addit
regist
may
suffer
problem
tri
address
bourgeoi
audit
entri
trial
five
major
class
drug
clinicaltrialsgov
biggest
prospect
regist
clinic
trial
found
evid
risk
report
bia
delay
report
result
anoth
review
trial
found
descript
trial
sampl
chang
least
one
key
element
time
registr
public
frequent
chang
regard
outcom
huic
despit
current
limit
regist
specif
review
way
run
updat
believ
regist
obviou
first
choic
start
reconstruct
trial
programm
search
unpublish
materi
yet
becom
standard
practic
conduct
cochran
review
van
driel
current
variabl
report
ghersi
index
review
regulatori
file
also
labori
task
took
wte
research
three
day
review
us
food
drug
administr
fda
regul
comment
gain
basic
understand
content
four
addit
day
need
read
annot
fda
zanamivir
file
day
read
annot
oseltamivir
file
build
reason
yield
compar
boolean
strategi
would
faster
yield
citat
two
strategi
six
seven
tracker
studi
use
boolean
string
consider
faster
averag
versu
hour
termbyterm
strategi
nation
institut
clinic
excel
nice
submiss
citat
took
two
hour
list
toc
use
boolean
strategi
adopt
boolean
search
strategi
construct
toc
ultim
possibl
search
trial
numer
may
suffici
identifi
vast
major
citat
valid
method
search
method
repeat
set
regulatori
document
reconstruct
trial
programm
submit
result
glaxosmithklin
gsk
roch
input
receiv
detail
feedback
late
roch
list
trial
incomplet
despit
labori
method
believ
end
far
comprehens
less
bias
set
evid
avail
current
system
journalbas
public
shift
data
synthesi
paradigm
made
necessari
numer
document
discrep
regulatori
publish
evid
sizeabl
risk
public
bia
oseltamivir
trial
programm
import
reconstruct
trial
programm
first
gener
complet
trial
list
reinforc
upon
discov
bia
oversight
regul
handl
trial
programm
regul
focu
mutual
agre
pivot
trial
whose
data
analys
replic
fda
european
medicin
agenc
ema
larg
ignor
trial
largest
oseltamivir
treatment
trial
conduct
prior
initi
registr
drug
still
unpublish
manufactur
may
offer
pivot
trial
far
smaller
even
ongo
studi
includ
evid
base
support
roch
year
new
drug
applic
number
treatment
uncompl
acut
ill
due
influenza
infect
adult
symptomat
two
day
depth
ema
scrutini
harder
assess
could
find
report
trial
site
visit
data
analysi
replic
identifi
pool
analysi
treatment
review
huge
quantiti
complic
data
link
comment
difficult
delic
process
main
problem
much
apprais
follow
standard
rule
possibl
synthesi
data
review
publish
inform
reconstruct
logic
thread
trial
programm
gener
huge
amount
data
need
apprais
also
manufactur
full
regulatori
submiss
may
even
inform
full
clinic
studi
report
remain
confidenti
essenti
data
requir
avail
clinic
studi
report
togeth
mass
less
import
data
explain
even
case
may
import
omiss
mislaid
diari
card
followup
manufactur
oblig
provid
regul
data
request
enabl
reach
decis
produc
vast
submiss
none
author
experienc
systemat
review
experi
review
regulatori
inform
given
labori
painstak
process
tri
identifi
quicker
equal
reliabl
way
review
regulatori
inform
could
find
obviou
shortcut
howev
believ
provid
critic
overview
trial
programm
rather
minut
dissect
trial
necessari
done
identifi
import
topic
trial
programm
effect
drug
symptom
infect
complic
transmiss
wellb
follow
throughout
programm
knit
evid
coher
narr
includ
carri
highlevel
overview
mode
action
drug
differ
popul
differ
indic
understand
drug
mode
action
core
correct
report
strength
limit
addit
larg
part
regulatori
submiss
made
chemistri
microbiolog
anim
model
pharmacodynam
pharmacokinet
studi
import
shed
light
trial
programm
seldom
featur
systemat
review
unsur
whether
inform
could
consid
core
inform
exhaust
review
trial
programm
includ
review
dedic
topic
method
crucial
discov
major
concern
trial
conduct
valid
includ
lack
compar
arm
induc
subset
analysi
randomisationanalysi
fork
high
posit
rate
influenza
high
gastrointestin
event
placebo
arm
possibl
activ
placebo
content
possibl
procedur
breach
sever
trial
concern
overal
safest
conserv
option
appear
carri
analys
basi
intentiontotreat
itt
popul
unit
randomis
analysi
mani
potenti
problem
list
either
present
minimis
novel
methodolog
remain
work
progress
review
regulatori
comment
essenti
way
deepen
understand
trial
programm
earli
review
hope
close
read
regulatori
materi
would
allow
us
understand
reason
discrep
us
european
regul
conclus
regard
effect
oseltamivir
particularli
limit
purport
effect
complic
doshi
request
specif
document
packag
inform
especi
import
allow
effici
time
review
process
confront
larg
volum
evid
could
peripher
valu
request
specif
document
like
dealt
far
effici
gener
request
document
relat
oseltamivir
one
reason
develop
toc
drug
famili
drug
matter
timeconsum
absolut
prerequisit
seriou
attempt
review
regulatori
evid
introduc
anoth
difficult
problem
handl
huge
quantiti
structur
inform
ethic
draw
conclus
still
fragmentari
albeit
sizeabl
evid
base
overal
fda
assess
perform
oseltamivir
modest
adject
appear
six
time
review
document
fda
exampl
divis
director
memorandum
date
octob
head
public
health
role
antivir
treatment
fda
state
clinic
relev
modest
treatment
benefit
highli
subject
question
fda
pdf
page
fda
refus
accept
claim
oseltamivir
effect
influenza
complic
fals
mislead
statement
promot
materi
fda
fda
warn
letter
seem
impli
exampl
oseltamivir
mode
action
propos
possibl
propos
manufactur
ie
certain
fda
howev
fda
review
appear
miss
import
problem
roch
clinic
trial
imbal
number
individu
classifi
influenzainfect
oseltamivir
treatment
trial
one
seem
question
coher
evid
propos
mode
action
drug
first
time
cochran
review
base
relev
full
clinic
studi
report
class
drug
integr
regulatori
comment
also
first
time
clinic
studi
report
trial
manufactur
programm
regardless
relev
review
avail
reader
without
restrict
apart
minim
redact
protect
anonym
role
roch
gsk
make
possibl
recognis
well
bmj
kept
issu
public
eye
resolv
evid
present
synthesis
show
neuraminidas
inhibitor
ni
review
symptomreliev
effect
especi
self
report
outcom
appear
symptomreliev
properti
make
peopl
influenzalik
ill
self
report
investigatormedi
unverifi
pneumonia
feel
better
shorten
symptom
durat
reduc
frequenc
symptom
cough
oseltamivir
effect
perhap
extend
cardiac
symptom
despit
short
durat
treatment
five
day
unsur
make
find
think
deserv
investig
issu
trigger
chang
evidenceseek
method
partli
resolv
definit
secondari
ill
given
anywher
clinic
studi
report
exampl
pneumonia
defin
pneumonia
case
report
form
tabl
diagnost
criteria
given
clinic
diagnosi
absenc
criteria
without
xray
moder
chanc
correct
could
decid
level
diagnost
ascertain
diagnosi
pneumonia
complic
unclear
clinic
studi
report
definit
pneumonia
given
algorithm
classif
event
pneumonia
suppli
oseltamivir
trial
case
report
form
trigger
record
advers
event
secondari
ill
question
particip
pose
investig
typic
phrase
follow
secondari
ill
remind
patient
report
sinus
otiti
bronchiti
chest
infect
pneumonia
sinc
baselin
follow
yesno
box
tick
addit
form
fill
investig
collect
detail
secondari
ill
record
medic
outsid
trial
alloc
elicit
addit
particip
diari
card
origin
medic
dictionari
regulatori
activ
meddra
term
suggest
diagnos
secondari
ill
advers
event
indic
origin
prefer
term
assign
therefor
consid
outcom
self
report
investigatormedi
unverifi
outcom
subset
trial
secondaryintercurr
ill
advers
event
data
collect
singl
onepag
form
metaanalys
call
subanalysi
trial
collect
data
nonspecif
advers
event
secondaryintercurr
ill
form
differ
subset
trial
case
report
form
contain
space
record
diagnost
test
chest
xray
tympanometri
sinu
xray
secondari
ill
report
variabl
clinic
studi
report
figur
figur
figur
figur
metaanalys
call
subanalysi
trial
collect
data
specif
diagnosi
secondari
ill
form
none
complic
defin
primari
outcom
trial
may
explain
poverti
data
definit
metaregress
includ
studi
report
pneumonia
found
evid
treatment
effect
pneumonia
statist
differ
depend
method
diagnosi
unclear
object
diagnosi
associ
appar
reduct
pneumonia
due
treatment
neuraminidas
inhibitor
wherea
use
object
criteria
data
collect
show
evid
effect
risk
ratio
rr
age
group
adult
versu
children
drug
oseltamivir
versu
zanamivir
indic
treatment
versu
prophylaxi
show
evid
associ
treatment
effect
meaning
conclus
effect
either
ni
complic
influenza
difficult
draw
base
trial
evid
part
due
lack
standardis
definit
addit
metaanalys
outcom
lack
definit
base
event
therefor
robust
caution
therefor
urg
interpret
metaanalysi
result
suggest
patient
need
treat
oseltamivir
one
less
self
report
investigatormedi
unverifi
pneumonia
appli
zanamivir
treatment
result
suggest
reduc
risk
self
report
investigatormedi
unverifi
bronchiti
adult
number
need
treat
benefit
nntb
confid
interv
ci
evid
suggest
oseltamivir
similar
effect
although
result
nonsignific
state
evid
definit
complic
either
paediatr
elderli
adult
trial
ever
prepar
incorpor
trial
design
therefor
report
case
otiti
media
pneumonia
sinus
bronchiti
unclear
signific
import
make
imposs
attribut
caus
draw
conclus
fda
probabl
us
food
drug
administr
fda
approv
oseltamivir
packag
insert
sinc
novemb
consist
state
seriou
bacteri
infect
may
begin
influenzalik
symptom
may
coexist
occur
complic
cours
influenza
tamiflu
shown
prevent
complic
origin
product
label
contain
statement
april
oseltamivir
approv
sale
unit
state
fda
sent
roch
untitl
letter
mislead
efficaci
claim
fda
note
roch
promot
materi
fda
pdf
page
one
statement
roch
made
tamiflu
reduc
incid
secondari
complic
ie
bacteri
infect
fda
comment
claim
reduct
sever
incid
secondari
infect
tamiflu
mislead
support
substanti
evid
fda
pdf
page
know
roch
respond
fda
subsequ
avail
roch
promot
materi
inform
roch
statement
consist
fda
demand
doshi
uncertainti
complic
secondari
ill
outcom
definit
therefor
carri
analysi
data
adult
treatment
trial
complic
classifi
seriou
led
studi
withdraw
oseltamivir
evid
treatment
affect
complic
risk
differ
rd
ci
analysi
analysi
outcom
could
assess
oseltamivir
prophylaxi
due
insuffici
number
event
zanamivir
signific
evid
treatment
effect
complic
rd
ci
analysi
analysi
outcom
could
assess
children
due
insuffici
number
event
contrari
fda
european
medicin
agenc
ema
oseltamivir
summari
product
characterist
state
oseltamivir
significantli
reduc
incid
specifi
lower
respiratori
tract
complic
mainli
bronchiti
treat
antibiot
individu
year
age
older
claim
base
pool
analysi
influenzaposit
adult
adolesc
n
enrol
treatment
studi
placebo
group
oseltamivirtr
popul
ema
statement
appear
ema
file
earli
emea
exact
denomin
appear
kaiser
metaanalysi
design
trial
defin
protocol
amend
statist
analysi
plan
case
report
form
allow
infer
effect
outcom
origin
consid
secondari
tertiari
import
bronchiti
pneumonia
would
clarifi
better
clinic
definit
investig
seriou
advers
event
benefit
paragraphlength
narr
report
salient
featur
event
previou
decis
analys
effect
oseltamivir
zanamivir
itt
popul
confirm
oseltamivir
demonstr
effect
antibodi
respons
particip
treatment
trial
although
effect
discern
zanamivir
effect
lead
introduct
select
bia
significantli
reduc
probabl
diagnos
influenza
imbal
two
arm
intentiontotreatinfluenzainfect
itti
popul
analys
effect
oseltamivir
antibodi
appear
carri
children
influenzalik
ill
find
contradict
statement
made
manufactur
seem
incompar
arm
influenzainfect
subpopul
oseltamivir
trial
rais
question
appropri
analysi
conduct
influenzainfect
group
compar
appear
case
zanamivir
treatment
trial
appropri
analysi
strategi
base
senn
would
determin
first
effect
treatment
itt
popul
evid
treatment
effect
treatment
infect
statu
interact
could
test
evid
interact
estim
treatment
effect
could
deriv
separ
influenzainfect
noninfluenzainfect
subpopul
howev
analysi
conduct
itt
popul
use
singl
appropri
statist
model
obviat
need
conduct
separ
analysi
influenzainfect
subpopul
roch
use
geometr
mean
titr
indic
antibodi
respons
itti
popul
support
statement
oseltamivir
affect
antibodi
respons
exampl
tabl
link
text
modul
trial
howev
use
measur
mislead
requir
analysi
data
mani
itt
popul
particip
respond
arm
level
antibodi
respons
mani
test
data
could
identifi
certainti
effect
choos
subpopul
analysi
itti
treatment
trial
ittiinab
itt
influenzainfect
index
case
neg
virolog
baselin
prophylaxi
trial
primari
analysi
restrict
generalis
result
especi
case
design
flaw
exampl
case
postexposur
prophylaxi
trial
index
case
treat
around
particip
drop
ittiinab
analysi
clustertri
design
household
includ
randomeffect
analysi
take
account
withinhousehold
correl
signific
slight
reduct
proport
serum
antibodi
mostli
haemagglutin
inhibit
hai
antibodi
titr
rise
fourfold
among
test
shown
review
consist
evid
anim
test
use
subclin
dose
oseltamivir
influenza
mice
takahashi
takahashi
report
nonsignific
slight
reduct
haemagglutinin
ha
specif
igg
antibodi
serum
spleen
report
signific
reduct
ha
specif
secretori
iga
antibodi
siga
ab
nasal
wash
bronchoalveolar
fluid
balf
day
evid
warn
risk
reinfect
may
increas
patient
show
low
mucos
iga
antibodi
respons
follow
oseltamivir
administr
experi
done
unexpect
find
paediatr
influenza
patient
treat
oral
oseltamivir
five
day
significantli
low
level
reduct
day
five
antiinfluenza
siga
nasopharyng
fluid
compar
level
patient
treat
oseltamivir
sawabuchi
find
consist
find
serum
ha
inhibit
hai
antibodi
respons
decreas
oseltamivir
administr
though
sigg
ab
could
analys
studi
data
report
clinic
studi
report
sawabuchi
takahashi
find
also
consist
evid
mode
action
oseltamivir
anim
model
modul
mendel
viral
challeng
randomis
placebocontrol
studi
human
proinflammatori
cytokin
includ
interleukin
tumour
necrosi
factor
alpha
interferon
gamma
complet
suppress
oseltamivir
administ
hour
experiment
inocul
influenza
viru
reduct
viral
titr
nasal
lavag
partial
decis
evid
administr
oseltamivir
anim
challeng
respiratori
syncyti
viru
rsv
lack
neuraminidas
gene
show
symptomreliev
effect
decreas
weight
loss
inhibit
viral
clearanc
effect
accompani
decreas
cell
surfac
sialoglycosphingolipid
level
regul
endogen
sialidaseneuraminidas
respons
viral
challeng
along
suppress
cytokin
express
consist
find
pharmaceut
compani
investig
find
studi
moor
suggest
risk
infect
exacerb
infect
pathogen
influenza
viru
spite
appar
reduct
symptom
infect
suffici
plasma
concentr
oseltamivir
carboxyl
oral
administ
oseltamivir
phosphat
may
act
directli
host
endogen
neuraminidas
reduc
suppress
immun
respons
even
dose
mg
twice
day
five
day
howev
bioavail
inhal
zanamivir
seem
broad
estim
area
curv
auc
data
inhal
intraven
studi
japanes
summari
basi
approv
jsba
differ
peak
concentr
cmax
much
larger
mean
inhal
zanamivir
could
reach
high
enough
concentr
reduc
immun
respons
administ
high
dose
long
period
patient
suscept
fact
doubleblind
placebocontrol
trial
use
healthi
volunt
investig
effect
zanamivir
treatment
mgday
day
humor
immun
respons
influenza
vaccin
show
zanamivir
group
respond
significantli
lower
antibodi
titr
cox
proinflammatori
cytokin
includ
chemokin
almost
complet
suppress
viral
challeng
randomis
control
trial
rct
use
high
dose
mg
intraven
zanamivir
inocul
influenza
viru
human
adult
fritz
find
suggest
low
immun
respons
low
level
proinflammatori
cytokin
induc
action
oseltamivir
carboxyl
may
reduc
symptom
influenza
irrespect
inhibit
influenza
viru
replic
wide
believ
main
mode
action
ni
addit
potenti
hypotherm
antipyret
effect
oseltamivir
zanamivir
central
nervou
system
depress
may
also
contribut
appar
reduct
host
symptom
ono
ono
zanamivir
effect
pneumonia
symptom
treatment
trial
even
diagnosi
support
chest
xray
affect
antibodi
respons
affect
bronchiti
think
show
undeni
symptomreliev
effect
drug
also
appli
sever
undefin
syndrom
drug
reliev
influenzalik
ill
symptom
around
day
although
first
relief
necessarili
complet
relief
case
oseltamivir
mix
followup
card
allow
us
draw
conclus
possibl
length
durat
symptom
relief
also
note
fact
import
inform
came
light
fda
report
clinic
studi
report
relev
trial
point
incomplet
natur
report
clinic
studi
report
import
role
summari
basi
approv
sba
regulatori
inform
subgroup
analysi
found
evid
differ
treatment
effect
zanamivir
time
first
allevi
symptom
adult
influenzainfect
noninfluenzainfect
subgroup
subgroup
show
strong
evid
treatment
effect
day
reduct
time
first
allevi
symptom
strongli
support
hypothesi
drug
influenzaspecif
effect
oseltamivir
reliev
symptom
otherwis
healthi
children
effect
note
zanamivir
may
due
limit
power
two
elig
trial
children
total
howev
oseltamivir
effect
asthmat
children
influenzalik
ill
popul
benefit
use
one
explan
find
natur
young
asthmat
popul
well
care
use
regular
power
medic
close
followup
increment
benefit
oseltamivir
thu
like
undetect
popul
altern
explan
could
higher
suscept
immun
system
suppress
oseltamivir
carboxyl
asthmat
children
compar
placebo
group
find
oseltamivir
administ
asthmat
children
reduc
symptom
faster
placebo
recipi
begin
studi
offtreat
period
recov
later
administ
placebo
give
support
explan
evid
effect
oseltamivir
hospitalis
hospitalis
import
poorli
defin
outcom
oseltamivir
protocol
inconsist
report
clinic
studi
report
overlook
zanamivir
protocol
report
oseltamivir
trial
detect
influenzarel
death
reflect
rel
benign
natur
influenza
studi
popul
zanamivir
trial
detect
eight
death
two
like
due
influenza
occur
intervent
arm
trial
like
underpow
detect
differenti
effect
mortal
absenc
death
placebo
recipi
underlin
benign
natur
influenza
fact
mortal
japan
influenza
outbreak
among
million
influenza
patient
one
infect
earli
deterior
lead
death
observ
frequent
oseltamivir
compar
zanamivir
antivir
recipi
overal
two
drug
similar
benefit
quit
differ
toxic
profil
averag
everi
adult
treat
oseltamivir
one
report
nausea
everi
adult
children
one
report
vomit
oseltamivir
seem
appar
protect
effect
diarrhoea
contrari
evid
gastrointestin
disturb
find
might
effect
placebo
contain
dehydrochol
acid
might
one
result
influenzalik
ill
symptomreliev
effect
similar
relief
tachycardia
palpit
appar
gastrointestin
event
nausea
vomit
may
result
central
nervou
disord
indic
day
increas
vomit
treatment
trial
children
everi
adult
expos
zanamivir
one
less
case
nausea
vomit
effect
visibl
children
probabl
lack
power
zanamivir
appear
affect
frequenc
bowel
movement
prophylaxi
data
set
influenza
without
laboratori
confirm
ie
influenzalik
ill
partial
report
oseltamivir
clinic
studi
report
report
zanamivir
clinic
studi
report
except
signific
reduct
observ
versu
consequ
unabl
report
outcom
size
reduct
influenza
symptom
oseltamivir
prophylact
trial
inferior
magnitud
seen
hand
wash
prevent
sever
acut
respiratori
syndrom
sar
base
seven
casecontrol
studi
odd
ratio
ci
statist
rd
statist
nntb
approxim
prophylaxi
oseltamivir
eight
hand
wash
jefferson
signific
reduct
proport
patient
symptomat
influenza
ni
howev
find
reflect
true
efficaci
prevent
influenza
conceal
posit
laboratori
test
measur
test
viral
shed
fourfold
antibodi
titr
rise
found
appar
prophylact
effect
zanamivir
pneumonia
defin
case
report
form
use
day
howev
found
evid
signific
effect
complic
evid
effect
oseltamivir
complic
hospitalis
oseltamivir
induc
nausea
peopl
undergo
prophylaxi
insuffici
evid
show
associ
vomit
ontreat
renal
advers
event
three
time
common
oseltamivir
arm
compar
placebo
arm
treat
patient
lead
one
addit
event
two
particip
die
oseltamivir
arm
experienc
acut
renal
failur
ontreat
although
one
event
list
advers
event
unlist
event
old
femal
withdrawn
studi
studi
day
estim
creatinin
clearanc
less
ml
min
screen
laboratori
examin
carri
day
start
studi
treatment
normal
hyperglycaem
advers
event
aggrav
diabet
mellitu
hyperglycaemia
also
common
oseltamivir
arm
eight
event
total
one
two
five
compar
none
correspond
placebo
arm
data
present
descript
metaanalys
formal
prespecifi
analysi
plan
final
oseltamivir
caus
headach
psychiatr
harm
adult
prophylaxi
trial
headach
one
promin
harm
oseltamivir
evid
doserespons
effect
prophylaxi
trial
p
headach
observ
particip
placebo
oseltamivir
mg
daili
mg
twice
daili
arm
respect
psychiatr
categori
sever
rare
sever
singl
event
nervous
aggress
hallucin
psychosi
suicid
ideat
paranoia
report
significantli
frequent
intervent
arm
ad
frequent
report
significantli
differ
event
depress
confus
gave
larg
effect
rel
small
number
need
treat
harm
import
find
lie
distribut
oseltamivir
larg
number
asymptomat
individu
follow
pandem
plan
prophylaxi
trial
children
met
inclus
criteria
therefor
report
prophylaxi
harm
import
popul
question
oseltamivir
treatment
trial
fail
identifi
clear
associ
oseltamivir
psychiatr
harm
although
weak
dosedepend
associ
observ
moot
point
possibl
influenzalik
ill
influenza
symptom
mask
harm
alreadi
symptomat
therefor
recruit
treatment
trial
influenzatyp
symptom
exclud
advers
event
report
report
issu
compliharm
may
help
mask
event
altern
could
event
rare
popul
studi
insuffici
power
detect
associ
ci
wide
rule
doubl
risk
due
treatment
found
prophylaxi
trial
also
possibl
risk
psychiatr
harm
increas
increas
dose
data
trial
suggest
increas
durat
treatment
prophylaxi
trial
suggest
toovey
assess
issu
fail
find
associ
neurolog
psychiatr
advers
event
oseltamivir
exposur
outcom
studi
base
priori
definit
psychiatr
advers
event
defin
clinic
studi
report
definit
construct
post
hoc
base
select
group
advers
event
taken
psychiatr
neurolog
injuri
bodi
system
report
issu
describ
fulli
jone
toovey
respons
toovey
toovey
review
retrospect
observ
studi
review
three
prospect
cohort
studi
conduct
japan
metaanalysi
three
prospect
cohort
studi
neuropsychiatr
advers
event
npae
japanes
children
show
pool
odd
ratio
abnorm
behaviour
due
oseltamivir
exposur
ci
p
without
signific
heterogen
hama
one
prospect
studi
sever
thousand
children
influenza
carri
test
hypothesi
causal
relat
oseltamivir
neuropsychiatr
event
abnorm
behaviour
observ
frequent
oseltamivir
recipi
children
control
rr
ci
abnorm
behaviour
observ
per
person
day
oseltamivir
group
compar
per
personday
control
group
yorifuji
reanalysi
studi
popul
focus
delirium
unconsci
also
show
signific
associ
oseltamivir
neuropsychiatr
event
especi
earli
phase
ill
within
day
commenc
fever
fuiita
indic
prospect
intent
collect
scale
particip
may
necessari
treatment
rct
anim
toxic
studi
result
firmli
support
effect
oseltamivir
central
nervou
system
one
hypotherm
effect
oseltamivir
zanamivir
administ
oral
intraperiton
ono
ono
intracerebroventricularli
ono
intraduoden
intraven
administr
oseltamivir
matur
rat
induc
respiratori
arrest
shortli
follow
cardiac
arrest
studi
clearli
show
central
depress
effect
oseltamivir
kimura
moreov
postmarket
toxicolog
phase
studi
roch
mani
symptom
manufactur
consid
itemrel
observ
alter
respir
includ
decreas
respiratori
rategasp
alter
mucou
membran
skin
colour
pale
prior
death
although
manufactur
deni
causal
freichel
symptom
two
hour
administr
show
doserel
increas
lack
olfactori
orient
lack
cliff
avers
low
low
arous
twentyfour
pup
exhibit
cliff
avers
later
found
dead
fourteen
anim
low
low
arous
die
thereaft
find
consist
clinic
observ
psychiatr
symptom
rct
postmarket
spontan
report
zanamivir
well
toler
howev
potenti
activ
placebo
may
mask
occurr
bronchospasm
zanamivir
trial
treatment
trial
mostli
underrecruit
often
result
pool
post
hoc
two
even
three
trial
yet
show
high
influenza
posit
rate
one
possibl
explan
lie
intens
surveil
carri
predefin
trial
centr
area
restrict
time
span
recruit
high
likelihood
posit
period
may
mani
centr
low
level
recruit
list
clinic
studi
report
limit
generalis
result
everyday
life
primari
secondari
prophylaxi
indic
postul
central
effect
oseltamivir
confin
suppress
symptom
infect
prevent
even
oseltamivir
administ
prior
inocul
influenza
viru
anim
mendel
human
prophylaxi
trial
howev
central
problem
remain
incompat
two
contrast
claim
activ
antibodi
product
report
mani
document
oseltamivir
interfer
antibodi
product
see
exampl
fda
roch
investig
guid
possibl
oseltamivir
prevent
case
influenza
part
definit
prevent
case
oseltamivir
trial
base
absenc
antibodi
respons
appar
abil
oseltamivir
interfer
antibodi
respons
call
question
mode
action
drug
put
doubt
propos
effect
oseltamivir
one
possibl
treatment
trial
oseltamivir
administr
interf
antibodi
product
effect
select
strongest
antibodi
respond
itti
subpopul
individu
classifi
influenza
case
includ
oseltamivir
arm
itti
popul
select
subpopul
probabl
repres
healthiest
least
like
experi
complic
altern
consequ
could
interfer
antibodi
product
oseltamivir
arm
led
activ
arm
particip
like
develop
complic
due
impair
immun
function
evid
prophylaxi
secondari
prophylaxi
trial
suggest
addit
appar
similar
mode
action
treatment
studi
suppress
viral
shed
nasal
swab
may
import
former
particip
becom
posit
ie
subsequ
classifi
case
influenza
oseltamivir
arm
mount
strong
respons
despit
oseltamivir
interfer
remaind
significantli
placebo
arm
classifi
prevent
avoid
case
howev
prophylaxi
clinic
studi
report
report
antibodi
respons
viral
isol
result
itt
popul
either
imposs
tell
whether
propos
mode
action
fit
evid
effect
oseltamivir
nasal
shed
consist
propos
mode
action
ni
prevent
viru
leav
host
respiratori
epitheli
cell
cover
mucou
layer
compar
rather
small
reduct
symptom
influenzalik
ill
reduct
antibodi
rise
oseltamivir
zanamivir
extent
reduct
symptomat
influenza
almost
half
may
due
reduct
influenza
virus
nasal
swab
sampl
prophylaxi
evid
oseltamivir
reduc
symptomat
influenzalik
ill
oseltamivir
reduc
number
prophylaxi
particip
test
posit
base
antibodi
rise
andor
cultur
test
howev
find
weaken
oseltamivir
interfer
viral
replic
swab
effect
antibodi
product
addit
oseltamivir
affect
asymptomat
influenza
evid
interfer
persontoperson
spread
similarli
fda
fda
fda
problem
design
studi
could
draw
conclus
abil
oseltamivir
interrupt
viral
transmiss
import
result
trial
form
part
rational
use
drug
interrupt
transmiss
person
person
allow
time
arriv
vaccin
event
pandem
furnish
seemingli
power
rational
stockpil
oseltamivir
show
import
avail
full
clinic
studi
report
someth
antibodi
suppress
seem
stronger
oseltamivir
zanamivir
probabl
due
differ
bioavail
may
evid
effect
hyperglycaemia
renal
impair
though
signific
margin
prophylaxi
trial
may
due
inhibit
host
endogen
neuraminidas
impair
cell
function
variou
organ
hama
overal
signific
oseltamivir
nasal
shed
unclear
problem
sampl
cultur
undermin
claim
secondari
prophylact
properti
fda
made
clear
respons
fda
doserespons
increas
psychiatr
event
pivot
oseltamivir
treatment
trial
increas
vomit
day
one
treatment
trial
children
may
due
sudden
onset
central
action
unchang
oseltamivir
hama
brain
concentr
unchang
oseltamivir
increas
earli
phase
influenza
juvenil
anim
freichel
due
reduc
low
function
pglycoprotein
major
transport
oseltamivir
bloodbrain
barrier
hama
kimura
like
central
mediat
mode
action
oseltamivir
support
find
advers
event
healthi
peopl
prophylaxi
trial
howev
effect
may
also
deriv
delay
action
associ
host
endogen
neuraminidas
inhibit
oseltamivir
hama
appear
week
exposur
drug
last
two
week
effect
pain
limb
hyperglycaemia
diabet
event
reduct
antibodi
rise
reduct
cytokin
induct
may
also
due
suppress
host
endogen
neuraminidas
oseltamivir
pain
limb
metabol
control
event
mainli
hyperglycaemia
excess
oseltamivir
arm
carri
formal
metaanalysi
prespecifi
analysi
plan
number
event
metabol
event
statement
made
capac
oseltamivir
interrupt
viral
transmiss
reduc
complic
support
data
abl
access
review
ni
laninamivir
peramivir
antivir
adamantan
amantadin
rimantadin
antipyreticantiinflammatori
agent
either
laninamivir
peramivir
may
potent
ni
bioavail
far
higher
zanamivir
may
affect
host
endogen
neuraminidas
adamantan
well
known
central
activ
agent
may
harm
oseltamivir
zanamivir
antiinflammatori
antipyret
except
paracetamol
may
toxic
ni
hama
henc
ni
adamantan
antiinflammatori
antipyret
may
altern
oseltamivir
zanamivir
use
cochran
sevendomain
risk
bia
instrument
assess
bia
avail
partial
complet
clinic
studi
report
decreas
uncertainti
allow
definit
judgement
made
previou
unclear
risk
bia
becam
certainti
bia
certainti
absenc
bia
certainti
low
level
uncertainti
due
expect
regard
complet
clinic
studi
report
expect
relev
consist
inform
avail
review
judgement
chang
found
gap
avail
inform
inconsist
inform
still
uncertain
whether
complet
studi
report
repres
exhaust
coher
sourc
trial
narr
data
case
treatment
trial
conclus
generalis
drawn
subpopul
two
arm
appear
compar
due
appar
abil
oseltamivir
interfer
influenza
antibodi
product
effect
oseltamivir
gastrointestin
tract
appear
notabl
although
definit
statement
possibl
mode
action
dosag
dibas
calcium
phosphat
dihydr
dehydrochol
acid
clarifi
high
percentag
influenza
infect
appear
contrast
need
pool
delay
sever
trial
small
recruit
size
other
lack
influenza
circul
case
postexposur
prophylaxi
trial
select
infect
popul
effect
exclud
analysi
larg
percentag
case
particip
bring
generalis
result
trial
question
much
made
trial
programm
viral
nasal
voidanc
marker
effect
howev
measur
unreli
treatment
trial
verbatim
quot
fda
review
show
durat
viral
shed
measur
treatment
initi
time
first
neg
viru
cultur
subsequ
posit
cultur
upon
review
list
viral
shed
pattern
provid
applic
two
problem
emerg
pattern
viru
shed
fluctuat
least
subject
ie
posnegposneg
without
subsequ
neg
result
least
subject
last
viru
shed
sampl
first
neg
sampl
sequenc
mean
subsequ
neg
confirm
given
fluctuat
pattern
viru
shed
estim
durat
viral
shed
base
occurr
singl
first
neg
data
pose
high
level
uncertainti
fda
programm
effect
complic
base
unclear
potenti
unreli
definit
often
discret
local
clinician
confirm
eg
radiolog
confirm
pneumonia
consist
report
occur
itt
popul
correct
popul
analysi
credibl
effect
oseltamivir
pneumonia
signific
term
pneumonia
clarifi
case
postexposur
prophylaxi
trial
nasal
voidanc
measur
symptomat
subject
adjunct
protocol
version
h
howev
prevent
manufactur
make
claim
effect
outcom
gener
requir
present
within
hour
rais
question
generalis
research
evid
howev
underli
doubt
conflict
evid
mode
action
drug
trial
substanti
underrecruit
insuffici
power
individu
answer
research
question
assess
full
clinic
studi
report
relev
trial
main
limit
studi
rel
inexperi
deal
larg
quantiti
inform
lack
familiar
certain
trial
document
randomis
list
randomis
list
appear
two
type
first
prerandomis
list
random
code
particip
id
match
particip
id
use
within
section
clinic
studi
report
second
post
hoc
randomis
list
individu
particip
match
origin
gener
code
shown
case
truli
random
gener
sequenc
could
properli
assess
either
origin
code
provid
origin
code
match
patient
creat
method
procedur
address
risk
report
bia
identifi
publish
trial
remain
uncertain
success
new
method
hernan
lipsitch
evalu
lower
respiratori
tract
complic
found
statist
signific
smaller
reduct
risk
complic
hernan
lipsitch
omit
evalu
kaiser
paper
conclus
oseltamivir
reduc
risk
hospitalis
wrote
possibl
assess
potenti
benefit
highrisk
particip
hospitalis
sampl
size
studi
small
consid
hospitalis
outcom
hernan
lipsitch
elabor
highlight
appar
methodolog
disagr
kaiser
analysi
reflect
news
articl
publish
harvard
websit
entitl
oseltamivir
effect
complic
confirm
reanalysi
http
ccddhsphharvardedunewsev
oseltamivirreanalysi
fact
hernan
lipsitch
confirm
one
key
conclus
kaiser
paper
review
team
approach
hernan
lipsitch
took
analys
data
insuffici
provid
credibl
independ
check
valid
reinforc
import
detail
critic
assess
entir
trial
programm
access
fulllength
studi
report
analysi
question
coher
evid
propos
mode
action
oseltamivir
ebel
review
conclud
evid
oseltamivir
reduc
likelihood
hospitalis
pneumonia
combin
outcom
pneumonia
otiti
media
sinus
itt
popul
conclus
base
modul
kaiser
trial
plu
trial
hernan
basi
find
review
clinician
healthcar
policymak
urgent
revis
current
recommend
use
neuraminidas
inhibitor
ni
individu
influenza
find
confirm
oseltamivir
zanamivir
reduc
time
symptomat
improv
adult
asthmat
children
influenzalik
ill
size
effect
small
approxim
half
day
unclear
whether
superior
treatment
commonli
use
antipyret
medic
howev
find
credibl
evid
either
oseltamivir
zanamivir
reduc
risk
complic
influenza
particularli
pneumonia
reduc
risk
hospitalis
death
moreov
even
individu
higher
risk
complic
children
asthma
elderli
found
evid
benefici
effect
reduc
risk
complic
base
find
appear
evid
patient
clinician
policymak
use
drug
prevent
seriou
outcom
annual
influenza
pandem
influenza
outbreak
practic
recommend
drug
label
need
chang
reflect
find
use
prophylact
agent
prevent
occurr
influenza
individu
famili
find
suggest
minim
effect
prevent
base
littl
support
use
prophylact
agent
exampl
influenza
epidem
given
oseltamivir
recommend
essenti
medicin
treatment
serious
ill
patient
higherrisk
group
influenza
concern
reason
prophylaxi
treatment
clinic
meaning
includ
accord
model
studi
prophylact
treatment
effect
popul
requir
least
eight
week
treatment
triall
longini
model
assum
rel
risk
reduct
observ
low
risk
popul
transfer
directli
popul
higher
risk
ie
absolut
treatment
effect
approxim
higher
absolut
effect
observ
prophylaxi
trial
longini
high
proport
peopl
least
twothird
requir
recognis
influenza
symptom
treatment
effect
asymptomat
symptomat
infect
model
studi
asymptomat
infect
assum
infecti
symptomat
infect
longini
influenza
season
last
four
five
month
secondari
strategi
vaccin
would
wide
avail
end
eight
week
treatment
period
full
understand
effect
treatment
prophylaxi
unknown
symptomat
influenzalikeil
without
laboratoryconfirm
fulli
report
one
studi
studi
show
differ
proport
patient
symptomat
influenzalikeil
without
lab
confirm
rr
ci
small
benefit
note
symptomat
improv
lack
credibl
evid
effect
seriou
complic
need
balanc
advers
effect
found
drug
metaanalys
especi
diabetichyperglycaem
renal
neuropsychiatr
effect
peopl
world
health
organ
recommend
use
result
discount
potenti
benefit
use
zanamivir
oseltamivir
individu
particular
situat
exampl
immunocompromis
compassion
case
therapeut
option
may
exist
howev
ni
may
immunosuppress
find
support
stockpil
ni
oseltamivir
inclus
list
essenti
drug
rational
undertak
current
review
method
pressur
need
employ
obtain
evalu
evid
drug
signific
implic
robust
scrutini
new
drug
undergo
prior
enter
widespread
clinic
use
believ
sever
step
need
put
place
provid
patient
clinician
policymak
transpar
assess
rel
benefit
risk
new
drug
first
find
impli
numer
nation
intern
bodi
appear
will
accept
bias
incomplet
trial
report
seemingli
face
valu
readi
willing
contrast
consider
time
effort
need
chang
recommend
second
publish
trial
unlik
provid
level
detail
allow
result
drug
trial
properli
evalu
risk
present
partial
potenti
bias
report
trial
conduct
find
implic
report
trial
also
weight
appli
publish
studi
alon
third
clinician
policymak
cautiou
interpret
use
find
systemat
review
includ
publish
studi
particularli
compris
portion
entir
drug
trial
programm
contain
portion
result
trial
mani
systemat
review
ni
none
assess
full
trial
programm
full
trial
result
thu
limit
valid
suspect
similar
situat
exist
drug
fourth
clinic
policymak
nation
intern
level
rais
level
scrutini
need
case
drug
like
use
larg
number
peopl
either
asymptomat
short
self
limit
ill
influenza
public
health
drug
potenti
benefit
harm
vital
given
weight
decis
seriou
implic
correct
incorrect
decis
policymak
face
barrier
deni
access
sponsor
regard
commerci
sensit
inform
without
concert
effort
multipl
stakehold
put
measur
place
possibl
provid
object
assess
benefit
risk
new
drug
risk
patient
potenti
miss
effect
treatment
also
patient
expos
either
ineffect
harm
treatment
find
implic
research
mechan
action
ni
special
regard
direct
central
action
oseltamivir
inhibitori
effect
host
endogen
neuraminidas
variou
organ
system
could
reach
consensu
whether
trial
warrant
whether
current
trial
discontinu
consider
bodi
evid
randomis
control
trial
rct
includ
review
indic
either
effect
rel
small
absolut
effect
size
complic
influenza
effect
even
statist
signific
would
small
warrant
treatment
ni
primari
care
set
especi
sinc
effect
diagnosi
treatment
rare
complic
pneumonia
avail
lack
evid
effect
hospitalis
probabl
indic
lack
sever
first
place
assum
influenza
incid
rate
similar
control
arm
oseltamivir
treatment
trial
detect
clinic
signific
reduct
pneumonia
particip
would
enrol
clinic
trial
calcul
like
underestim
popul
size
incid
rate
deriv
trial
use
enhanc
ad
hoc
surveil
system
trial
design
would
ensur
presenc
complic
ascertain
use
object
diagnost
criteria
exampl
confirm
use
imag
laboratori
test
pneumonia
trial
would
also
consid
ethic
implic
conduct
studi
estim
benefit
base
rct
otherwis
healthi
peopl
like
small
would
balanc
appar
risk
advers
effect
ni
think
research
aim
effect
prevent
measur
earli
identif
complic
base
length
time
taken
provid
definit
answer
efficaci
ni
challeng
obtain
full
inform
method
need
develop
conduct
evid
synthesi
believ
main
implic
review
need
reform
multipl
compon
research
develop
regulatori
assess
pathway
new
drug
pharmaceut
sponsor
drug
trial
follow
data
access
share
procedur
similar
european
medicin
agenc
ema
sponsor
make
full
clinic
studi
report
avail
download
websit
share
freeli
regulatori
decis
made
redact
kept
minimum
part
process
need
includ
full
list
entir
drug
develop
programm
avoid
assess
incomplet
set
trial
research
industri
employe
list
trial
document
consid
legal
respons
conduct
report
trial
regul
post
inventori
documentari
hold
websit
brief
descript
main
content
size
file
make
inform
avail
shortli
make
registr
decis
drug
within
reason
time
period
inform
electron
format
anonymis
ie
particip
detail
remov
prevent
person
identifi
trial
registri
improv
report
new
trial
howev
adequ
resolv
problem
encount
complet
trial
registri
need
test
random
sampl
procedur
clear
instruct
report
updat
content
promulg
penalti
impos
breach
procedur
trial
registr
includ
origin
final
version
trial
protocol
full
declar
date
amend
procedur
trial
unblind
date
unblind
routin
report
registr
made
compulsori
studi
human
be
randomli
assign
experiment
arm
ethic
consent
procedur
trial
includ
oblig
trial
sponsor
ensur
result
made
public
failur
report
exist
trial
human
make
result
avail
consid
ethic
breach
conduct
subject
appropri
penalti
method
use
conduct
evid
synthesi
need
repeat
across
intervent
research
may
need
refin
given
consider
resourc
involv
use
method
system
need
prioritis
review
import
drug
method
reserv
drug
meet
certain
condit
prioriti
could
perhap
given
first
drug
new
famili
drug
consid
innov
like
big
market
impact
review
publicli
fund
independ
regul
manufactur
research
conduct
high
scrutini
review
need
free
recent
tie
either
govern
pharmaceut
industri
systemat
review
group
cochran
collabor
consid
adopt
method
drug
whether
perhap
scrutinis
publish
review
prioritis
drug
final
documentari
evid
relat
trial
human
includ
clinic
studi
report
regulatori
document
evid
synthes
archiv
electron
statut
limit
author
note
review
gb
data
possibl
mistak
author
would
grate
reader
could
identifi
promis
concur
record
amend
accordingli
studi
singl
blind
singl
administrationphas
data
file
studi
singl
blind
singl
administrationphas
data
file
studi
singl
blind
singl
administrationphas
data
file
studi
singl
blind
singl
administrationphas
data
file
zanamivir
trial
titl
unknown
data
file
nasogastr
administr
op
infect
patient
respiratori
failur
data
file
oseltamivir
pharmacokinet
morbid
obes
data
file
openlabel
pharmacokinet
oseltamivir
healthi
obes
thai
adult
subject
data
file
random
doubleblind
control
trial
compar
high
vs
standard
dose
oseltamivir
sever
influenza
infect
icu
rosii
studi
data
file
probe
function
express
carboxyl
esteras
preterm
neonat
use
oseltamivir
pragmat
observ
studi
data
file
plasma
level
oseltamivir
infect
patient
support
extracorpor
membran
oxygen
singlecentr
cohort
studi
data
file
effect
probenecid
pharmacokinet
oseltamivir
data
file
prospect
studi
assess
household
transmiss
influenza
emerg
transmiss
drug
resist
oseltamivir
follow
treatment
children
influenza
b
data
file
highdos
versu
standarddos
oseltamivir
treatment
sever
influenza
avian
influenza
phase
ii
doubleblind
random
clinic
trial
data
file
studi
higherdos
oseltamivir
treatment
impact
viral
clearanc
clinic
recoveri
adult
hospit
influenza
data
file
studi
pharmacolog
oseltamivir
tamiflu
pregnanc
data
file
pharmacokinet
oseltamivir
patient
receiv
extracorpor
membran
oxygen
ecmo
continu
venoven
hemodialysi
cvvhd
data
file
pharmacokinet
oseltamivir
critic
ill
adult
patient
data
file
observ
studi
pharmacokinet
oseltamivir
treatment
influenza
lactat
data
file
phase
openlabel
studi
evalu
steadyst
serum
pulmonari
pharmacokinet
follow
intraven
administr
zanamivir
healthi
adult
subject
data
file
phase
openlabel
studi
evalu
potenti
pharmacokinet
interact
orallyadminist
oseltamivir
intraven
zanamivir
healthi
thai
adult
subject
data
file
doubleblind
randomis
placebocontrol
studi
evalu
effect
inhal
zanamivir
mg
od
day
antihaemagglutinin
antibodi
product
hai
titr
follow
coadministr
trival
influenza
vaccin
healthi
adult
subject
data
file
open
label
random
evalu
direct
measur
zanamivir
concentr
respiratori
secret
follow
singl
dose
inhal
mg
via
diskhal
health
volunt
data
file
openlabel
multicent
studi
patient
instruct
leaflet
relenza
diskhal
data
file
pharmacokinet
zanamivir
follow
inhal
administr
pediatr
subject
sign
symptom
respiratori
ill
data
file
oseltamivir
treatment
children
less
month
age
influenza
data
file
openlabel
random
crossov
studi
investig
pharmacodynam
pharmacokinet
safeti
toler
warfarin
pharmacokinet
safeti
toler
oseltamivir
given
combin
data
file
open
label
prospect
pharmacokinet
pharmacodynam
safeti
evalu
oseltamivir
treatment
infant
month
age
confirm
influenza
infect
data
file
method
doubleblind
randomis
placebocontrol
parallelgroup
multicentr
studi
zanamivir
prophylaxi
influenza
infect
particip
abl
take
first
dose
studi
medic
follow
notif
influenza
outbreak
investig
particip
will
abl
give
written
inform
consent
particip
studi
subject
age
less
year
old
written
inform
consent
necessari
subject
parent
author
abl
use
diskhal
properli
particip
will
abl
adher
protocol
instruct
investig
particip
opinion
investig
could
complet
symptomdiari
card
exclus
criteria
particip
influenzalik
ill
one
fever
headach
sore
throat
feverish
muscl
joint
pain
cough
prior
studi
influenza
season
particip
underli
ill
could
influenc
efficaci
safeti
assess
particip
known
suspect
hypersensit
compon
studi
medic
lactos
relief
medic
acetaminophen
dextromethorphan
particip
receiv
investig
drug
previou
month
particip
receiv
influenza
antivir
therapi
previou
day
eg
amantadin
particip
pregnant
breastfeed
intend
becom
pregnant
studi
evid
histori
thing
alcohol
drug
abus
psychiatr
disord
condit
investig
decid
inappropri
particip
studi
definit
patient
popul
analysi
intentiontotreat
popul
n
zanamivir
placebo
number
randomis
irrespect
studi
medic
secondari
popul
analysi
efficaci
data
popul
efficaci
analysi
full
analysi
set
fa
n
zanamivir
placebo
randomis
particip
except
take
least
dose
studi
agent
whose
efficaci
data
avail
secondari
popul
analysi
efficaci
nonvaccin
set
nv
n
zanamivir
placebo
nonvaccin
randomis
particip
took
least
dose
studi
drug
primari
popul
analysi
efficaci
zanamivir
mg
twice
daili
day
zanamivir
mg
twice
daili
day
low
placebo
twice
daili
day
high
placebo
twice
daili
day
outcom
primari
time
allevi
major
influenza
symptom
fever
headach
myalgia
secondari
time
allevi
major
influenza
symptom
fever
headach
myalgia
cough
sore
throat
proport
subject
individu
influenzalik
symptom
fever
headach
myalgia
feverish
cough
sore
throat
arthralgia
lumbago
chill
fatigu
nasal
symptom
diarrhoea
poor
appetit
safeti
incid
abnorm
symptomsabnorm
laboratori
chang
deni
causal
investig
continu
primari
secondari
outcom
defin
protocol
patient
suspect
bacteri
infect
patient
unstabl
chronic
diseas
pregnanc
suspicion
pregnanc
well
person
plan
becom
pregnant
cours
studi
nurs
mother
patient
prescrib
investig
medic
within
last
month
patient
prescrib
amantadin
within
last
day
patient
investig
determin
inappropri
studi
safeti
measur
incid
abnorm
symptomsabnorm
laboratori
chang
includ
exclud
causal
deni
abnorm
symptom
abnorm
laboratori
find
advers
event
defin
newli
observ
remark
worsen
symptom
treatment
start
abnorm
worsen
laboratori
find
compar
treatment
irrespect
causal
assess
zanamivir
mg
twice
daili
day
zanamivir
mg
twice
daili
day
low
placebo
twice
daili
day
high
placebo
twice
daili
day
outcom
primari
time
allevi
major
influenza
symptom
influenza
fever
headach
secondari
time
allevi
major
influenza
symptom
chang
antibodi
titr
intervent
distinguish
appear
avail
studi
report
document
japanes
design
method
similar
wv
pivot
treatment
trial
adult
trial
intend
bridg
western
trial
programm
report
contain
support
data
ie
statist
analysi
plan
protocol
amend
certif
analysi
audit
randomis
list
list
investig
irb
clearanc
individu
list
avail
clinic
studi
report
document
translat
english
japanes
origin
design
method
similar
wv
pivot
prophylaxi
trial
adult
trial
meant
bridg
western
trial
programm
report
contain
support
data
ie
statist
analysi
plan
protocol
amend
certif
analysi
audit
randomis
list
list
investig
irb
clearanc
individu
list
femal
patient
childbear
potenti
unabl
use
effect
method
contracept
throughout
studi
period
reproduct
cycl
follow
cessat
studi
therapi
allergi
excipi
capsul
section
oseltamivirro
acetaminophen
paracetamol
patient
experienc
previou
episod
acut
upper
respiratori
tract
infect
urti
otiti
bronchiti
sinus
within
week
prior
studi
day
receiv
antivir
therapi
influenza
within
week
prior
studi
day
particip
clinic
studi
investig
drug
within
week
prior
studi
entri
clinic
relev
histori
abus
alcohol
drug
popul
primari
analysi
popul
use
summari
analys
efficaci
paramet
consist
patient
itt
popul
exclud
patient
laboratoryconfirm
infect
patient
analys
accord
group
randomis
itt
popul
n
itt
popul
consist
patient
took
least
dose
studi
medic
least
efficaci
measur
patient
protocol
violat
deviat
retain
itt
popul
patient
analys
accord
group
randomis
safeti
popul
n
defin
standard
popul
n
popul
use
summari
select
efficaci
paramet
includ
patient
randomis
major
protocol
violat
deviat
laboratoryconfirm
influenza
receiv
least
first
schedul
dose
studi
period
reproduct
cycl
follow
cessat
studi
therapi
femal
childbear
potenti
must
neg
urin
pregnanc
test
prior
drug
dose
exclus
criteria
present
hour
post
onset
feel
unwel
patient
activ
clinic
signific
renal
cardiac
pulmonari
vascular
neurolog
metabol
diabet
thyroid
disord
adren
diseas
immunodefici
disord
cancer
hepat
cirrhosi
high
likelihood
bacteri
infect
base
sign
symptom
laboratori
test
eg
wbc
x
l
n
patient
take
steroid
immunosuppress
therapi
allergi
excipi
capsul
see
section
paracetamol
asthmat
patient
copd
patient
experienc
previou
episod
acut
upper
respiratori
tract
infect
urti
otiti
bronchiti
sinus
receiv
antibiot
urti
otiti
sinus
bronchiti
antivir
therapi
influenza
eg
amantadin
rimantadin
within
week
prior
studi
day
dementia
psychiatr
condit
might
interfer
patient
abil
assess
influenza
symptomatolog
particip
clinic
studi
investig
drug
within
week
prior
studi
entri
administr
influenza
vaccin
less
month
prior
studi
day
clinic
relev
histori
abus
alcohol
drug
pregnant
breastfeed
femal
transplant
recipi
known
hiv
infect
popul
primari
efficaci
analys
intentiontotreatinfect
itti
popul
compris
randomis
particip
receiv
least
dose
studi
drug
laboratoryconfirm
influenza
posit
cultur
day
andor
increas
hai
antibodi
baselin
day
studi
itt
popul
consist
particip
took
least
dose
studi
medic
safeti
popul
includ
particip
receiv
least
dose
studi
medic
least
safeti
followup
whether
withdrawn
prematur
safeti
popul
n
defin
ing
treatment
group
provid
although
primari
analysi
primari
paramet
done
use
itti
popul
addit
analysi
primari
paramet
done
use
itt
popul
secondari
outcom
blind
outcom
assess
detect
bia
outcom
inadequ
inform
avail
ascertain
whether
outcom
assessor
awar
treatment
group
assign
randomis
doubleblind
placebocontrol
parallelgroup
multicentr
studi
investig
efficaci
safeti
inhal
zanamivir
mg
administ
twice
daili
day
treatment
influenza
patient
age
year
diagnos
asthma
copd
locat
number
centr
usa
centr
uk
franc
south
africa
norway
canada
australia
germani
slovakia
austria
belgium
denmark
sweden
blind
particip
personnel
perform
bia
outcom
blind
outcom
assess
detect
bia
outcom
low
risk
seal
envelop
case
emerg
knowledg
studi
drug
essenti
clinic
manag
welfar
subject
investig
could
unblind
subject
treatment
assign
randomis
doubleblind
placebocontrol
parallelgroup
multicentr
studi
investig
efficaci
safeti
zanamivir
mg
administ
inhal
twice
daili
day
treatment
symptomat
influenza
b
viral
infect
children
age
locat
number
centr
usa
centr
canada
franc
germani
belgium
finland
spain
russia
sweden
proport
randomis
famili
least
randomis
contact
develop
laboratoryconfirm
influenza
b
infect
symptom
began
anytim
start
treatment
day
proport
randomis
famili
least
randomis
contact
develop
febril
ill
day
proport
randomis
famili
least
contact
case
develop
laboratoryconfirm
influenza
infect
time
allevi
clinic
signific
symptom
randomis
index
case
time
allevi
clinic
signific
symptom
use
relief
medic
randomis
index
case
number
day
unabl
perform
normal
activ
number
day
use
relief
medic
proport
randomis
famili
least
randomis
contact
develop
secondari
infect
temperatur
randomis
index
case
clinic
visit
studi
day
europ
discov
clinic
suppli
incorrectli
pack
csf
pg
recruit
stop
procedur
put
place
correct
error
randomis
famili
member
receiv
treatment
index
case
csf
pg
studi
period
octob
may
studi
involv
chang
endpoint
remov
laboratori
test
well
includ
new
exclus
criteria
europ
discov
clinic
suppli
incorrectli
pack
recruit
stop
procedur
put
place
correct
error
randomis
famili
member
receiv
treatment
index
case
blind
particip
personnel
perform
bia
outcom
time
allevi
individu
symptom
time
afebril
statu
use
suppli
paracetamol
global
assess
symptom
investig
time
return
felt
influenza
ill
time
return
normal
activ
viral
titr
level
day
day
day
particip
placebo
group
highrisk
medic
condit
compar
zanamivir
group
itt
influenzaposit
popul
death
report
neither
consid
relat
drug
case
narr
blank
blind
outcom
assess
detect
bia
outcom
break
code
open
hidden
portion
detach
drug
label
hidden
entri
envelop
expressli
forbidden
case
emerg
knowledg
studi
drug
essenti
clinic
manag
welfar
particip
could
investig
unblind
particip
treatment
assign
investig
reveal
blind
monitor
randomis
doubleblind
placebocontrol
parallelgroup
multicentr
studi
investig
efficaci
safeti
inhal
zanamivir
mg
administ
twice
daili
day
treatment
symptomat
influenza
b
infect
arm
servic
personnel
blind
particip
personnel
perform
bia
outcom
blind
outcom
assess
detect
bia
outcom
low
risk
investig
receiv
hidden
entri
envelop
contain
code
break
treatment
number
break
code
open
hidden
entri
envelop
expressli
forbidden
except
event
medic
emerg
ident
drug
necessari
order
treat
particip
properli
event
emerg
request
investig
make
everi
effort
contact
studi
monitor
designe
prior
break
code
randomis
doubleblind
placebocontrol
multicentr
studi
parallel
group
investig
efficaci
safeti
inhal
zanamivir
mg
bid
via
diskhal
day
highrisk
patient
symptomat
influenza
andor
b
infect
particip
elig
particip
adult
age
year
symptomat
influenza
b
infect
feverish
least
follow
symptom
headach
muscl
pain
myalgia
sore
throat
cough
also
influenzaquicktest
posit
categoris
high
risk
high
risk
defin
male
femal
age
year
particip
live
old
peopl
home
particip
respiratori
disord
includ
copd
asthma
particip
diabet
mellitu
chronic
renal
failur
cardiovascular
disord
exclus
includ
pregnant
women
women
risk
becom
pregnant
studi
particip
suspect
bacteri
respiratori
infect
particip
known
sensit
compon
intervent
placebo
treatment
emerg
medic
zanamivir
inhal
mg
per
inhal
twice
daili
day
placebo
inhal
mg
per
inhal
twice
daili
day
particip
addit
provid
paracetamol
cough
syrup
symptomat
medic
guidanc
take
acut
need
outcom
primari
outcom
time
allevi
fever
time
first
measur
temperatur
maintain
follow
hour
secondari
outcom
time
allevi
clinic
relev
symptom
time
return
normal
activ
incid
complic
loss
product
assess
number
day
taken
work
use
medic
servic
note
synopsi
provid
trial
full
clinic
studi
report
avail
total
number
patient
analys
clearli
report
appear
intentiontotreat
analysi
perform
randomis
particip
took
studi
drug
exclud
analysi
accord
prespecifi
exclus
criteria
temperatur
low
diari
avail
fever
stop
medic
taken
clinic
research
associ
find
investig
site
incomplet
outcom
data
attrit
bia
complic
influenza
high
risk
particip
exclud
analysi
efficaci
due
insuffici
diari
card
data
incomplet
outcom
data
attrit
bia
safeti
data
high
risk
particip
exclud
analysi
efficaci
due
insuffici
diari
card
data
select
report
report
bia
high
risk
primari
endpoint
origin
time
allevi
main
signssymptom
influenza
later
adjust
time
allevi
fever
presenc
fever
indic
particip
valu
record
particip
data
particip
therefor
exclud
perprotocol
analysi
bia
low
risk
low
number
dropout
group
reason
report
particip
includ
safeti
popul
protocol
amend
blind
particip
personnel
perform
bia
outcom
high
risk
ident
rotadisk
use
group
placebo
report
lactos
certif
analysi
provid
blind
outcom
assess
detect
bia
outcom
low
risk
investig
allow
break
studi
blind
emerg
knowledg
particip
studi
medic
essenti
clinic
ground
randomis
doubleblind
placebocontrol
parallelgroup
multicentr
studi
investig
efficaci
safeti
inhal
zanamivir
mg
administ
day
day
prevent
transmiss
symptomat
influenza
b
viral
infect
within
household
index
case
first
household
member
clinic
diagnosi
ili
could
made
proport
randomis
household
least
randomis
contact
case
develop
laboratoryconfirm
influenza
infect
proport
randomis
household
least
randomis
contact
case
develop
symptomat
influenzalik
ill
irrespect
laboratori
confirm
proport
randomis
household
least
randomis
contact
case
develop
symptomat
laboratoryconfirm
influenza
infect
exclud
failur
occur
within
day
start
prophylaxi
proport
randomis
household
least
randomis
contact
case
develop
laboratoryconfirm
influenza
febril
ill
number
day
least
randomis
contact
case
unabl
perform
normal
activ
number
day
least
randomis
contact
case
record
use
relief
medic
proport
randomis
household
least
randomis
contact
case
develop
secondari
complic
influenza
proport
randomis
household
least
randomis
contact
case
develop
symptomat
laboratoryconfirm
influenza
flu
type
index
case
match
contact
case
develop
influenza
time
allevi
clinic
signific
symptom
influenza
contact
case
develop
symptomat
laboratoryconfirm
influenza
prophylaxi
outcom
clinic
studi
report
list
protocol
proport
randomis
particip
develop
influenza
confirm
cultureserolog
proport
randomis
particip
prophylaxi
develop
influenzalik
ill
ili
develop
febril
ill
note
protocol
state
sever
secondari
outcom
measur
modif
list
protocol
amend
section
total
number
overthecount
medic
use
proport
randomis
particip
requir
prescript
medic
total
number
prescript
medic
use
proport
randomis
particip
unschedul
healthcar
contact
total
number
unschedul
healthcar
contact
zanamivir
provid
solut
intranas
administr
concentr
mgml
salin
dri
powder
inhal
placebo
normal
salin
intranas
spray
dri
lactos
powder
match
zanamivir
inhal
combin
symptom
analysi
secondari
endpoint
ad
final
analysi
plan
trial
commenc
may
symptom
feverish
headach
myalgia
cough
sore
throat
summaris
mean
symptom
score
provid
measur
overal
sever
blind
outcom
assess
detect
bia
outcom
low
risk
investig
provid
seal
envelop
contain
individu
codebreak
envelop
patient
centr
open
medic
emerg
knowledg
studi
treatment
essenti
manag
patient
method
multicentr
randomis
doubleblind
placebocontrol
trial
design
investig
efficaci
safeti
zanamivir
inhal
intranas
inhal
combin
intranas
versu
placebo
prevent
andor
reduct
progress
influenza
postexposur
prophylaxi
individu
without
flu
symptom
age
year
age
year
european
countri
risk
develop
influenza
close
contact
index
case
intervent
zanamivir
mgml
intranas
spray
per
nostril
ml
per
spray
twice
daili
plu
placebo
inhal
twice
daili
zanamivir
mg
per
inhal
inhal
twice
daili
plu
placebo
spray
per
nostril
twice
daili
zanamivir
mg
per
inhal
inhal
twice
daili
plu
zanamivir
mgml
intranas
spray
per
nostril
ml
per
spray
twice
daili
placebo
inhal
twice
daili
plu
placebo
spray
per
nostril
twice
daili
outcom
primari
proport
symptomat
influenza
laboratori
confirm
treatment
period
secondari
proport
patient
fever
temperatur
treatment
period
number
day
studi
period
day
patient
record
symptom
diari
card
none
mild
number
day
studi
period
day
patient
record
overal
symptom
assess
diari
card
none
mild
investigatorr
global
assess
symptom
ga
studi
aim
recruit
randomis
particip
protocol
amend
time
chang
patient
popul
subset
patient
centr
experi
virolog
x
patient
c
core
centr
patient
centr
experi
virolog
target
patient
patient
symptom
assess
diari
card
review
studi
site
personnel
x
patient
defin
target
patient
popul
everi
patient
except
core
centr
patient
target
addit
facetofac
diari
card
review
clinic
symptom
assess
site
studi
staff
day
modifi
advers
event
includ
tempor
relat
studi
drug
administr
clarifi
clinic
symptom
assess
diari
card
review
core
centr
target
patient
ad
section
unschedul
visit
clarifi
withdraw
inform
revis
statist
method
section
chang
exclus
criterion
patient
influenza
vaccin
administ
sinc
august
patient
influenza
vaccin
administ
sinc
octob
author
judgement
support
judgement
high
risk
describ
randomis
procedur
gener
randomis
schedul
avail
alloc
conceal
select
bia
low
risk
central
gener
pharmacycontrol
randomis
investig
provid
seal
envelop
contain
individu
code
break
envelop
patient
centr
low
risk
withdraw
includ
itt
analys
efficaci
safeti
data
infect
noninfect
particip
avail
minist
investig
provid
seal
envelop
contain
individu
codebreak
envelop
patient
centr
open
medic
emerg
knowledg
studi
treatment
essenti
manag
patient
randomis
doubleblind
placebocontrol
multicentr
trial
investig
efficaci
safeti
zanamivir
prevent
progress
influenza
b
asymptomat
symptomat
among
case
expos
suspect
index
case
particip
elig
particip
age
year
sign
symptom
influenza
intervent
zanamivir
mgml
intranas
spray
per
nostril
ml
per
spray
twice
day
plu
placebo
inhal
twice
day
zanamivir
inhal
mg
per
inhal
twice
day
plu
placebo
spray
per
nostril
twice
day
zanamivir
inhal
mg
per
inhal
twice
day
plu
zanamivir
mgml
intranas
spray
per
nostril
ml
per
spray
twice
day
placebo
inhal
twice
day
plu
placebo
spray
per
nostril
twice
day
outcom
primari
outcom
proport
patient
laboratoryconfirm
influenza
treatment
plu
least
clinic
signific
symptom
influenza
moder
sever
sever
studi
treatment
period
secondari
outcom
proport
patient
influenza
proport
patient
fever
temperatur
treatment
period
number
day
studi
period
day
patient
record
symptom
diari
card
moder
sever
number
day
studi
period
day
patient
record
overal
symptom
assess
diari
card
moder
sever
number
day
studi
period
day
patient
record
moder
sever
sleep
disturb
number
day
studi
period
day
patient
record
unabl
perform
normal
activ
aim
recruit
particip
contact
case
particip
recruit
randomis
blind
outcom
assess
detect
bia
outcom
investig
staff
particip
studi
monitor
blind
studi
treatment
administ
break
code
open
hidden
portion
detach
drug
label
expressli
forbidden
except
event
medic
emerg
ident
drug
known
order
treat
particip
properli
randomis
doubleblind
placebocontrol
multicentr
trial
investig
efficaci
safeti
inhal
zanamivir
compar
standard
care
control
outbreak
influenza
nurs
home
particip
particip
nurs
home
randomis
healthi
follow
outbreak
influenza
declar
nurs
home
intervent
zanamivir
inhal
mg
per
inhal
day
plu
placebo
tablet
day
placebo
inhal
day
plu
rimantadin
tablet
mg
day
outcom
primari
outcom
proport
randomis
particip
prophylaxi
develop
new
sign
symptom
laboratori
confirm
influenza
infect
secondari
outcom
proport
randomis
particip
prophylaxi
develop
febril
ill
proport
randomis
particip
prophylaxi
day
anytim
studi
day
develop
complic
influenza
subsequ
associ
laboratori
confirm
influenza
infect
proport
randomis
particip
prophylaxi
day
anytim
studi
day
took
antibiot
due
complic
influenza
subsequ
associ
laboratori
confirm
influenza
infect
proport
randomis
particip
day
prophylaxi
develop
new
sign
symptom
subsequ
associ
laboratori
confirm
influenza
infect
proport
randomis
particip
prophylaxi
laboratoryconfirm
influenza
infect
note
protocol
amend
made
appear
influenc
outcom
advers
event
data
extract
studi
exposur
rimantadin
blind
outcom
assess
detect
bia
outcom
studi
doubleblind
investig
particip
studi
monitor
unawar
treatment
particip
randomli
assign
receiv
break
code
open
hidden
portion
detach
drug
label
expressli
forbidden
except
event
medic
emerg
ident
drug
necessari
order
treat
particip
properli
randomis
placebocontrol
multicentr
trial
perform
nurs
home
lithuania
netherland
israel
particip
without
ili
live
nurs
home
outcom
primari
proport
randomis
particip
prophylaxi
develop
new
sign
symptom
laboratori
confirm
influenza
infect
secondari
proport
randomis
particip
prophylaxi
develop
febril
ill
defin
temperatur
laboratori
confirm
influenza
infect
proport
randomis
particip
prophylaxi
day
anytim
studi
day
develop
complic
influenza
laboratori
confirm
influenza
infect
proport
randomis
particip
prophylaxi
day
anytim
studi
day
took
antibiot
due
complic
influenza
laboratori
confirm
influenza
infect
proport
randomis
particip
day
prophylaxi
develop
new
sign
symptom
laboratori
confirm
influenza
infect
proport
randomis
particip
prophylaxi
laboratoryconfirm
influenza
infect
note
sae
studi
death
caus
follow
mi
postprophylaxi
followup
liver
cirrhosi
congest
heart
failur
month
studi
complet
pleural
effus
probabl
lung
cancer
month
studi
rerandomis
patient
occur
random
sequenc
gener
select
bia
method
sequenc
gener
specifi
alloc
conceal
select
bia
low
risk
pharmacycontrol
randomis
incomplet
outcom
data
attrit
bia
symptom
low
risk
symptom
outcom
report
use
intentiontotreat
popul
randomis
specifi
protocol
analysi
plan
incomplet
outcom
data
attrit
bia
complic
influenza
low
risk
outcom
report
use
intentiontotreat
popul
randomis
specifi
protocol
analysi
plan
incomplet
outcom
data
attrit
bia
safeti
data
low
risk
safeti
outcom
report
use
safeti
popul
randomis
took
least
dose
studi
medic
specifi
protocol
analysi
plan
select
report
report
bia
low
risk
outcom
report
specifi
protocol
analysi
plan
bia
high
risk
protocol
amend
time
twice
allow
interim
safeti
analysi
allow
extra
recruit
rerandomis
patient
occur
blind
particip
personnel
perform
bia
outcom
blind
outcom
assess
detect
bia
outcom
low
risk
investig
particip
studi
monitor
unawar
treatment
particip
randomli
assign
receiv
break
code
open
hidden
portion
detach
drug
label
expressli
forbidden
except
event
medic
emerg
ident
drug
necessari
order
treat
particip
properli
randomis
doubleblind
placebocontrol
parallelgroup
multicentr
studi
design
investig
efficaci
safeti
zanamivir
given
inhal
rout
prevent
symptomat
diseas
caus
influenza
ondari
complic
influenza
irrespect
laboratori
confirm
influenza
proport
randomis
particip
requir
antibiot
proport
randomis
particip
requir
otc
medic
proport
randomis
particip
requir
prescrib
medic
proport
randomis
particip
unschedul
healthcar
contact
plu
mean
number
unschedul
healthcar
contact
proport
randomis
particip
confin
bedincapacit
plu
mean
durat
incapac
influenza
proport
randomis
particip
miss
least
day
work
school
influenza
mean
durat
miss
workschool
note
itt
popul
compris
randomis
particip
howev
patient
diari
card
data
day
withdrawn
prematur
studi
treatment
includ
patient
risk
develop
complic
exclud
studi
investig
list
complic
outcom
inconsist
occur
protocol
summari
studi
plan
studi
procedur
protocol
amend
cough
sore
throat
list
primari
symptom
clinic
studi
report
protocol
investig
global
assess
list
protocol
list
clinic
studi
report
studi
perform
prior
influenza
season
blind
particip
personnel
perform
bia
outcom
high
risk
placebo
describ
match
certif
analysi
provid
blind
outcom
assess
detect
bia
outcom
low
risk
break
code
open
hidden
portion
detach
drug
label
expressli
forbidden
except
event
medic
emerg
ident
drug
known
order
treat
particip
properli
randomis
doubleblind
placebocontrol
parallelgroup
multicentr
studi
investig
efficaci
safeti
inhal
intranas
zanamivir
treatment
influenza
b
viral
infect
locat
number
centr
belgium
centr
finland
franc
germani
itali
netherland
norway
spain
receiv
investig
drug
previou
day
evid
histori
abus
drug
substanc
use
antibiot
within
previou
day
intoler
lactos
definit
patient
popul
analysi
influenzaposit
popul
n
particip
itt
popul
laboratoryconfirm
influenza
determin
either
pretreat
diagnost
sampl
posit
serolog
result
diagnost
sampl
serolog
posit
indic
differ
influenza
type
influenza
type
assign
accord
diagnost
sampl
result
secondari
popul
assess
efficaci
randomis
particip
includ
treatment
group
assign
even
medic
taken
primari
popul
assess
efficaci
safeti
n
particip
randomis
treatment
took
least
dose
studi
medic
particip
exclud
clear
evid
failur
take
studi
medic
use
safeti
data
zanamivir
mg
per
inhal
inhal
twice
day
plu
placebo
spray
per
nostril
ml
per
spray
twice
day
zanamivir
mg
per
inhal
inhal
twice
day
plu
zanamivir
mgml
spray
per
nostril
ml
per
spray
equival
mg
zanamivir
twice
day
placebo
inhal
twice
day
plu
placebo
spray
per
nostril
ml
per
spray
twice
day
treatment
period
day
followup
period
day
posttreat
cointervent
relief
medic
describ
measur
outcom
clear
whether
administ
cointervent
outcom
primari
outcom
time
allevi
major
influenza
symptom
secondari
outcom
time
day
initi
treatment
erad
major
sign
symptom
influenza
combin
symptom
analysi
mean
daili
temperatur
studi
treatment
period
day
number
day
initi
treatment
patient
abl
return
normal
activ
number
day
day
patient
record
symptom
moder
sever
number
day
day
patient
record
overal
symptom
assess
osa
moder
sever
number
day
day
patient
record
sleep
disturb
moder
sever
mean
support
drug
use
investig
global
assess
symptom
day
viral
shed
fell
limit
quantit
core
centr
area
viral
shed
curv
core
centr
origin
intent
patient
patient
per
treatment
group
recruit
due
rel
low
incid
influenza
target
achiev
protocol
studi
amend
twice
amend
implement
prior
commenc
recruit
result
intern
discuss
extern
discuss
regulatori
author
statist
method
employ
substanti
differ
document
protocol
cough
sore
throat
report
major
symptom
clinic
studi
report
protocol
discrep
occur
protocol
clinic
studi
report
regard
evalu
viral
shed
studi
period
novemb
april
outcom
studi
treatment
administ
blind
maintain
ensur
trial
medic
placebo
ident
appear
shape
administr
schedul
smell
tast
envelop
open
patient
month
conclus
treatment
time
treatment
seen
affect
trial
blind
broken
patient
enter
studi
randomis
doubleblind
placebocontrol
parallelgroup
multicentr
studi
design
evalu
efficaci
safeti
inhal
zanamivir
prevent
progress
influenza
b
viral
infect
particip
male
femal
year
expos
index
case
symptom
influenzalik
ill
within
previou
hour
outcom
primari
outcom
proport
patient
laboratoryconfirm
influenza
treatment
plu
least
clinic
signific
symptom
influenza
moder
sever
sever
studi
treatment
period
secondari
outcom
proport
patient
document
fever
studi
temperatur
number
day
moder
sever
symptom
number
day
overal
assess
symptom
moder
sever
number
day
moder
sever
sleep
disturb
number
day
patient
unabl
perform
normal
activ
investig
global
assess
statist
method
section
revis
allow
stratif
vaccin
particip
efficaci
evalu
nasal
symptom
nasal
congest
rhinorrhoea
chang
nasal
congest
block
runni
nose
safeti
nonvaccin
popul
defin
protocol
male
femal
age
year
age
age
centr
laboratoryconfirm
influenza
influenzalik
ill
defin
symptom
feverish
least
follow
headach
myalgia
cough
sore
throat
less
equal
hour
durat
time
day
initi
treatment
allevi
individu
symptom
influenza
feverish
headach
myalgia
cough
sore
throat
nasal
congest
weak
loss
appetit
allevi
influenza
symptom
defin
score
none
mild
maintain
next
hour
time
day
initi
treatment
patient
return
normal
activ
maintain
follow
hour
time
day
initi
treatment
patient
abl
return
usual
daili
activ
perform
well
normal
mean
symptom
score
symptom
feverish
headach
myalgia
cough
sore
throat
summaris
mean
symptom
score
day
treatment
number
day
studi
period
day
patient
record
overal
symptom
assess
osa
moder
sever
number
day
studi
period
day
least
symptom
rate
moder
sever
number
day
studi
period
day
sleep
disturb
record
moder
sever
maximum
daili
temperatur
summaris
studi
treatment
period
day
mean
daili
paracetamol
use
studi
treatment
period
day
investigatorr
global
assess
symptom
ga
influenza
infect
statu
patient
rate
investig
posttreat
visit
none
mild
moder
sever
incid
secondari
infect
due
logist
difficulti
receiv
result
influenza
diagnost
test
within
hour
influenza
symptom
onset
patient
recruit
basi
clinic
diagnosi
influenza
cough
sore
throat
report
major
symptom
clinic
studi
report
protocol
protocol
amend
necessit
revis
definit
seriou
advers
event
time
line
chang
report
advers
event
amend
also
made
definit
primari
secondari
efficaci
paramet
statist
analys
modifi
protocol
amend
made
age
rang
includ
year
year
year
respect
inclus
exclus
patient
asthma
meet
local
regulatori
ethic
committe
requir
studi
period
may
may
blind
particip
personnel
perform
bia
outcom
investig
provid
seal
envelop
contain
individu
codebreak
envelop
patient
centr
colour
appear
report
certif
analysi
provid
blind
outcom
assess
detect
bia
outcom
low
risk
monitor
blind
studi
treatment
administ
investig
broke
blind
studi
medic
prior
trial
complet
randomis
doubleblind
placebocontrol
parallelgroup
multicentr
studi
investig
efficaci
safeti
inhal
zanamivir
administ
twice
daili
treatment
influenza
b
viral
infect
adult
locat
number
centr
australia
centr
new
zealand
influenza
analysi
high
risk
popul
restrict
primari
endpoint
complic
advers
event
incid
seriou
advers
event
incid
particip
year
popul
addit
condit
thought
predispos
patient
greater
risk
complic
influenza
includ
concurr
cardiovascular
condit
exclud
hypertens
concurr
respiratori
condit
asthmat
exclud
unmed
concurr
metabol
condit
immunocompromis
zanamivir
mg
per
inhal
inhal
twice
day
placebo
inhal
twice
day
treatment
period
day
followup
period
day
posttreat
cointervent
paracetamol
cough
mixtur
provid
symptomat
relief
outcom
primari
outcom
time
allevi
major
sign
symptom
influenza
secondari
outcom
time
erad
major
sign
symptom
influenza
major
sign
symptom
symptom
influenza
defin
fever
headach
myalgia
sore
throat
cough
erad
defin
score
none
symptom
maintain
next
hour
time
allevi
diari
card
symptom
calcul
separ
time
patient
return
normal
activ
defin
first
day
patient
record
abl
carri
usual
daili
activ
requir
maintain
hour
consecut
diari
card
entri
mean
symptom
score
posttreat
assess
day
day
maximum
daili
temperatur
maximum
temperatur
obtain
day
weight
mean
valu
calcul
studi
treatment
period
auc
calcul
use
trapezoid
method
sleep
disturb
definit
sleep
disturb
describ
protocol
ie
mean
number
day
sleep
disturb
slightli
chang
number
day
day
patient
record
moder
quit
bit
sever
sleep
disturb
chang
made
prior
blind
studi
describ
data
analysi
plan
dap
number
tablet
paracetamol
taken
treatment
period
day
day
number
spoon
cough
mixtur
taken
treatment
period
day
day
incid
complic
influenza
associ
antibiot
use
investig
global
assess
symptom
studi
conduct
investig
countri
australia
new
zealand
south
africa
investig
recruit
patient
protocol
defin
influenzaposit
popul
subset
intentiontotreat
popul
chang
data
analysi
plan
subset
safeti
popul
studi
popul
chang
irrelev
investig
global
assess
symptom
describ
protocol
plan
prior
blind
studi
protocol
amend
australian
centr
addit
studi
protocol
design
collect
pharmacoeconom
data
instig
involv
interview
influenzaposit
patient
day
visit
studi
period
recruit
commenc
may
roll
randomis
doubleblind
placebocontrol
parallelgroup
multicentr
studi
investig
efficaci
safeti
inhal
zanamivir
mg
administ
twice
day
day
treatment
symptomat
influenza
b
viral
infect
adolesc
adult
locat
number
centr
multicentr
studi
europ
belgium
centr
denmark
finland
franc
germani
holland
itali
norway
spain
sweden
randomis
particip
regardless
whether
studi
drug
taken
studi
complet
particip
take
medic
randomis
includ
treatment
group
assign
secondari
popul
assess
efficaci
safeti
popul
n
particip
took
least
dose
studi
medic
particip
exclud
safeti
popul
clear
evid
failur
take
studi
medic
particip
take
medic
randomis
would
includ
treatment
group
actual
medic
took
major
time
primari
popul
analysi
safeti
data
high
risk
n
defin
could
experi
prolong
sever
ill
suffer
complic
influenza
due
age
underli
medic
condit
total
number
spoon
suppli
cough
mixtur
global
assess
symptom
posttreat
visit
incid
complic
influenza
associ
antibiot
use
note
protocol
amend
refer
ml
spoon
dextromethorphan
delet
studi
personnel
record
whether
first
dose
studi
medic
given
hour
secondari
complic
record
crf
second
diari
card
includ
symptom
assess
relief
medic
use
complet
twice
day
question
relat
product
normal
activ
complet
day
consent
form
amend
includ
statement
particip
doctornurs
would
also
need
take
throat
swab
day
categori
use
document
influenza
complic
defin
protocol
amend
appli
centr
denmark
franc
holland
itali
signific
differ
outcom
group
though
trend
favour
oseltamivir
report
secondari
outcom
base
diari
symptom
appear
show
faster
recoveri
reduc
rate
complic
reduc
use
antibiot
oseltamivir
group
term
safeti
overal
incid
advers
event
higher
oseltamivir
group
placebo
group
versu
mainli
due
higher
incid
gastrointestin
event
versu
vomit
versu
signific
definit
modul
clear
page
pdf
review
despit
page
page
review
thing
eg
certif
analysi
found
protocol
amend
statist
analysi
plan
amend
also
report
addit
inform
chang
origin
summari
risk
bia
individu
investig
diagnos
symptom
influenza
b
follow
criteria
individu
satisfi
follow
condit
influenza
infect
commenc
symptom
first
present
particip
centr
will
particip
studi
could
expect
follow
investig
order
particip
feverish
temperatur
greater
first
present
least
follow
headach
muscl
pain
sore
throat
cough
contact
person
follow
chanc
contact
index
case
within
day
commenc
influenza
symptom
index
case
diagnos
may
infect
influenza
sleep
room
index
case
inpati
work
room
index
case
cowork
live
home
index
case
famili
particip
least
year
old
understand
use
investig
agent
intend
cooper
studi
could
expect
follow
investig
order
exclus
criteria
person
feverish
within
hour
prior
first
present
day
temperatur
first
present
day
person
symptom
follow
symptom
within
hour
prior
first
present
day
headach
muscl
pain
sore
throat
cough
nasal
symptom
gener
fatigu
person
least
follow
symptom
score
headach
muscl
pain
sore
throat
cough
nasal
symptom
gener
fatigu
person
suspect
bacteri
infect
patient
unstabl
chronic
diseas
pregnanc
suspicion
pregnanc
well
person
plan
becom
pregnant
cours
studi
nurs
mother
patient
prescrib
investig
medic
within
last
month
patient
receiv
influenza
vaccin
within
last
year
patient
investig
determin
inappropri
studi
safeti
measur
incid
abnorm
symptomsabnorm
laboratori
chang
causal
determin
complet
deni
abnorm
symptom
abnorm
laboratori
find
advers
event
defin
newli
observ
remark
worsen
symptom
treatment
start
clinic
untoward
abnorm
abnorm
chang
laboratori
find
treatment
start
irrespect
causal
assess
oral
inhal
zanamivir
mg
intranas
nebulis
placebo
oral
inhal
placebo
intranas
nebulis
zanamivir
mg
oral
inhal
zanamivir
mg
intranas
nebulis
zanamivir
mg
oral
inhal
placebo
intranas
nebulis
placebo
outcom
primari
proport
subject
prophylaxi
day
day
develop
symptomat
influenza
secondari
proport
subject
prophylaxi
day
day
develop
symptomat
influenza
proport
subject
prophylaxi
day
day
develop
symptomat
influenza
number
proport
subject
prophylaxi
day
day
day
day
develop
symptomat
influenza
will
utilis
effect
method
contracept
throughout
studi
period
reproduct
cycl
follow
cessat
studi
therapi
neg
urin
pregnanc
test
prior
drug
treatment
femal
childbear
potenti
purpos
analysi
definit
studi
popul
criteria
adjust
accept
baselin
temperatur
entri
studi
hour
post
onset
ill
therebi
account
differ
criteria
evalu
time
entri
criteria
time
first
dose
exclus
criteria
activ
clinic
signific
renal
cardiac
pulmonari
vascular
neurolog
metabol
diabet
thyroid
disord
adren
diseas
immunodefici
disord
cancer
hepat
cirrhosi
transplant
recipi
use
steroid
immunosuppress
therapi
pregnant
breastfeed
femal
known
hiv
infect
allergi
excipi
capsul
paracetamol
asthmat
receipt
chronic
therapi
asthma
particip
experienc
previou
episod
acut
upper
respiratori
tract
infect
urti
otiti
bronchiti
sinus
within
week
prior
studi
day
receipt
antibiot
urti
otiti
sinus
bronchiti
antivir
therapi
influenza
within
week
prior
studi
day
particip
clinic
studi
investig
drug
within
week
prior
screenstudi
day
administr
influenza
vaccin
less
month
prior
studi
day
particip
discov
infect
laboratoryconfirm
influenza
itt
popul
n
randomis
particip
irrespect
influenza
statu
influenza
infect
caus
new
human
pathogen
influenza
die
result
viru
previous
associ
avian
influenza
appar
cross
speci
result
pathogen
infect
man
vast
major
influenza
infect
occur
hong
kong
time
studi
nonvirul
strain
type
influenza
influenza
b
howev
consid
view
appar
virul
strain
type
particip
enrol
studi
placebocontrol
might
place
undu
risk
risk
specif
hong
kong
strain
type
far
identifi
outsid
region
influenza
viru
type
known
sensit
amantadin
throat
swab
taken
particip
enter
trial
prior
first
dose
studi
drug
hong
kong
region
rapid
diagnost
techniqu
polymeras
chain
reaction
pcr
use
test
swab
eluat
presenc
absenc
influenza
particip
found
harbour
strain
type
withdrawn
studi
without
break
blind
offer
amantadin
discret
investig
particip
condit
merit
intervent
februari
revis
analys
definit
secondari
tertiari
paramet
studi
follow
experi
assess
use
standardis
protocol
quantit
viral
cultur
signific
variabl
detect
virolog
laboratori
respect
assay
work
continu
order
elucid
mechan
variabl
valid
method
howev
due
lengthi
period
time
requir
complet
work
viru
titr
remov
secondari
paramet
studi
inform
analys
postdatabas
close
major
virolog
paramet
studi
thu
becam
durat
viru
shed
follow
inclus
trial
also
believ
peak
viru
titr
might
occur
prior
baselin
signific
number
particip
enter
trial
henc
particular
paramet
analys
studi
period
decemb
april
author
judgement
support
judgement
high
risk
discrep
note
modul
summari
regard
treatment
group
assign
particip
experienc
advers
event
necessarili
affect
method
gener
randomis
sequenc
could
affect
itt
safeti
popul
alloc
conceal
select
bia
low
risk
randomis
number
gener
central
randomis
servic
icti
interact
clinic
technolog
inc
princeton
nj
usa
investig
telephon
centr
report
particip
initi
date
birth
smoke
histori
randomis
num
ber
suppli
centr
form
messag
interact
voic
respons
system
ivr
investig
enter
randomis
number
appropri
place
case
report
form
incomplet
outcom
data
attrit
bia
symptom
high
risk
appendix
time
allevi
symptom
itt
popul
summari
info
itt
howev
extent
miss
data
unknown
outcom
incomplet
outcom
data
attrit
bia
complic
influenza
high
risk
incomplet
outcom
data
complic
like
given
inadequaci
present
way
info
complic
collect
summari
ask
patient
self
report
complic
day
day
followup
visit
end
studi
incomplet
outcom
data
attrit
bia
safeti
data
low
risk
ae
could
classifi
either
symptom
influenza
complic
influenza
ae
report
inconsist
trial
report
outcom
patient
differ
categori
select
report
report
bia
high
risk
secondari
ill
patientreport
bodi
clinic
studi
report
state
complic
requir
antibiot
treatment
specifi
priori
even
final
version
protocol
full
text
predefin
list
secondari
ill
ie
mention
pneumonia
bronchiti
sinus
otiti
protocol
complic
anyth
antibiot
treatment
accord
protocol
crf
mention
specif
secondari
ill
name
addit
protocol
prespecifi
secondari
ill
first
appear
rap
core
report
modul
protocol
indic
data
would
collect
absenc
mention
secondari
ill
outcom
even
tertiari
easili
explic
addit
decis
itti
selec
tion
primari
outcom
report
may
select
report
bia
start
could
break
balanc
group
bia
may
factor
patient
select
select
bia
report
select
report
bia
although
prespecifi
particip
took
dose
studi
drug
subsequ
discov
laboratoryconfirm
influenza
standard
popul
n
present
itti
popul
except
restrict
took
least
dose
studi
drug
itt
popul
n
particip
took
least
dose
studi
drug
follow
request
regul
popul
includ
hypothesi
test
primari
efficaci
endpoint
popul
major
protocol
violat
deviat
laboratoryconfirm
influenza
receiv
least
first
schedul
dose
within
hoursfirst
dose
within
hour
went
take
dose
analysi
accord
treatment
receiv
antivir
therapi
influenza
within
week
prior
studi
entri
particip
clinic
studi
investig
drug
within
week
prior
studi
entri
administr
influenza
vaccin
less
month
prior
studi
entri
use
antivir
drug
influenza
rimantadin
ribavirin
zanamivir
amantadin
permit
studi
clinic
relev
histori
abus
alcohol
drug
present
hour
post
onset
feel
unwel
definit
patient
popul
analysi
itti
popul
n
particip
analys
accord
group
randomis
provid
receiv
least
dose
studi
treatment
laboratoryconfirm
influenza
viru
infect
itt
popul
consist
particip
itti
popul
also
includ
particip
laboratoryconfirm
influenza
took
least
dose
studi
medic
particip
analys
group
randomis
safeti
popul
n
particip
randomis
receiv
least
dose
studi
medic
least
safeti
followup
whether
withdrawn
prematur
particip
receiv
therapi
intend
analys
accord
therapi
receiv
standard
popul
n
randomis
particip
without
major
protocol
violat
deviat
laboratoryconfirm
influenza
receiv
least
first
schedul
dose
within
hour
receiv
first
dose
within
hour
went
take
dose
particip
analys
accord
treatment
receiv
particip
analys
accord
assign
treatment
provid
receiv
least
dose
studi
treatment
followup
efficaci
data
laboratoryconfirm
influenza
viru
infect
determin
post
entri
studi
itt
popul
n
particip
took
least
dose
studi
medic
followup
efficaci
data
irrespect
influenza
viru
infect
particip
analys
accord
group
randomis
safeti
popul
n
particip
receiv
least
dose
studi
medic
receiv
least
safeti
followup
whether
withdrawn
prematur
particip
analys
accord
treatment
receiv
standard
popul
n
use
summari
efficaci
paramet
particip
major
protocol
violat
deviat
laboratoryconfirm
influenza
receiv
least
first
schedul
dose
within
hour
receiv
first
dose
within
hour
went
take
dose
particip
analys
accord
treatment
receiv
adult
year
age
norway
sweden
year
age
chronic
cardiac
exclud
chronic
idiopath
hypertens
pulmonari
disord
includ
bronchopulmonari
dysplasia
asthma
exclud
cystic
fibrosi
sever
enough
requir
regular
medic
followup
hospit
care
studi
follow
clarif
also
given
pulmonari
disord
defin
coad
perman
reduc
asymptomat
patient
previou
valv
replac
bypass
surgeri
also
elig
symptom
consist
influenza
fever
patient
age
year
fever
patient
age
year
plu
respiratori
symptom
cough
sore
throat
nasal
symptom
constitut
symptom
chill
sweat
feel
feverish
malais
feel
unwel
headach
myalgia
ach
pain
prostrat
fatigu
present
first
dose
may
taken
later
hour
post
onset
feel
need
await
residenti
care
women
childbear
potenti
provid
neg
urin
pregnanc
test
prior
drug
dose
agre
utilis
effect
method
contracept
throughout
studi
period
reproduct
cycl
follow
cessat
studi
therapi
male
patient
whose
partner
childbear
potenti
agre
use
effect
method
contracept
throughout
studi
month
complet
trial
ad
amend
protocol
exclus
criteria
uncontrol
diseas
renal
vascular
neurolog
metabol
diabet
thyroid
disord
adren
diseas
hepat
cirrhosi
defin
diseas
requir
chang
therapi
hospitalis
within
week
preced
first
dose
studi
drug
creatinin
clearanc
measur
estim
mlmin
frank
jaundic
transaminas
valu
within
greater
grade
iii
scale
new
york
heart
associ
nyha
class
iv
coad
stage
iii
major
transplant
recipi
immunosuppress
therapi
inhal
steroid
system
steroid
less
equival
mgday
prednisolon
allow
pregnant
breastfeed
femal
activ
cancer
basal
cell
carcinoma
squamou
cell
carcinoma
skin
previou
histori
cancer
remiss
requir
therapi
permit
hiv
infect
allergi
excipi
capsul
paracetamol
previou
episod
acut
upper
respiratori
tract
infect
urti
otiti
bronchiti
sinus
receiv
antibiot
urti
otiti
sinus
bronchiti
antivir
therapi
influenza
within
week
prior
studi
day
particip
clinic
studi
investig
drug
within
week
prior
studi
entri
clinic
relev
histori
abus
alcohol
drug
present
hour
post
onset
feel
unwel
definit
patient
popul
analysi
itti
popul
n
patient
least
dose
studi
medic
laboratoryconfirm
influenza
viru
infect
data
analys
accord
treatment
assign
randomis
itt
popul
n
randomis
patient
receiv
least
dose
studi
medic
safeti
popul
n
randomis
particip
receiv
least
dose
studi
medic
least
postbaselin
safeti
assess
standard
popul
n
particip
itti
popul
without
major
protocol
violat
receiv
least
first
schedul
dose
within
hour
receiv
first
dose
within
hour
went
take
dose
allergi
excipi
capsulesparacetamol
acut
upper
respiratori
tract
infect
urti
otiti
media
bronchiti
sinus
antibiot
therapi
urti
otiti
media
bronchiti
sinus
antivir
therapi
influenza
within
week
studi
entri
use
antivir
drug
rimantadin
ribavirin
zanamivir
amantadin
previou
concomit
treatment
neuraminidas
inhibitor
inhal
oral
particip
clinic
studi
investig
drug
within
week
studi
entri
clinic
relev
histori
abus
alcohol
drug
definit
patient
popul
analysi
itti
popul
n
primari
analysi
popul
efficaci
particip
analys
accord
group
randomis
provid
receiv
least
dose
studi
treatment
laboratoryconfirm
influenza
viru
infect
particip
protocol
violat
deviat
retain
itti
popul
itt
popul
n
particip
took
least
dose
studi
medic
particip
analys
accord
group
randomis
safeti
popul
n
randomis
particip
receiv
least
dose
studi
medic
least
safeti
followup
whether
withdrawn
prematur
data
particip
analys
accord
therapi
receiv
standard
popul
n
randomis
particip
major
protocol
violat
deviat
laboratoryconfirm
influenza
viru
infect
receiv
least
first
schedul
dose
within
hour
receiv
first
dose
within
hour
went
take
total
dose
particip
analys
accord
treatment
receiv
protocol
amend
protocol
amend
b
protocol
amend
b
origin
symptom
sign
common
sequela
influenza
report
advers
event
protocol
amend
symptom
sign
common
complic
exclud
report
advers
event
unless
fulfil
criteria
report
seriou
advers
event
criteria
secondari
ill
protocol
amend
b
also
ad
requir
male
particip
whose
partner
childbear
potenti
use
effect
contracept
studi
month
complet
studi
follow
roch
current
standard
oper
procedur
protocol
amend
protocol
amend
c
made
chang
secondari
efficaci
paramet
secondari
efficaci
paramet
reflect
antivir
effect
treatment
chang
durat
viral
shed
proport
particip
shed
viru
day
chang
made
intermitt
sampl
schedul
use
studi
meant
true
durat
viral
shed
could
assess
exactli
wherea
proport
particip
shed
viru
could
determin
incid
secondari
ill
requir
antibiot
includ
new
secondari
endpoint
secondari
ill
defin
sinus
lrti
otiti
media
bronchiti
pneumonia
method
analysi
proport
particip
shed
viru
proport
particip
predefin
secondari
ill
fisher
exact
test
ad
statist
method
protocol
includ
addit
exclus
criterion
around
previou
concomit
treatment
neuraminidas
inhibitor
studi
period
northern
hemispher
centr
recruit
flu
season
southern
hemispher
centr
recruit
flu
season
randomis
doubleblind
placebocontrol
trial
residenti
home
elderli
peopl
particip
recruit
local
outbreak
detect
defin
case
immedi
vicin
within
day
case
home
locat
number
centr
usa
centr
uk
centr
franc
centr
belgium
centr
netherland
centr
studi
design
investig
whether
oseltamivir
suppress
main
clinic
symptom
fever
cough
patient
laboratoryconfirm
influenza
timetoev
analys
time
zero
defin
coincid
initi
treatment
endpoint
defin
section
involv
allevi
symptom
allevi
occur
start
period
symptom
less
equal
mild
remain
less
equal
least
hour
primari
outcom
primari
efficaci
paramet
proport
patient
allevi
cough
none
mild
least
hour
without
fever
less
hour
initi
studi
medic
secondari
outcom
symptom
efficaci
paramet
reflect
durat
ill
length
time
allevi
symptom
calcul
time
studi
drug
initi
length
time
area
curv
auc
symptom
calcul
particip
withdraw
prior
allevi
symptom
censor
last
assess
efficaci
paramet
reflect
extent
sever
ill
auc
symptom
calcul
time
studi
drug
initi
time
symptom
allevi
score
calcul
twice
daili
total
separ
symptom
form
symptom
scale
auc
score
calcul
patient
use
trapezoid
rule
baselin
symptom
defin
assess
prior
first
studi
drug
intak
even
though
might
time
proport
particip
afebril
oral
temperatur
less
hour
hour
hour
proport
patient
fever
day
fever
defin
oral
temperatur
higher
assess
day
interv
first
day
proport
patient
allevi
cough
fever
less
reduct
symptom
score
allevi
cough
allevi
myalgia
allevi
cough
fever
less
ecg
collect
subset
intens
patient
day
day
day
measur
taken
day
day
abnorm
result
observ
previou
visit
ecg
test
part
protocol
mention
part
substudi
pdf
pg
blank
crf
search
bronchiti
secondari
identifi
case
bronchiti
classifi
harm
preexist
condit
modul
tabl
content
page
pdf
page
report
list
complic
h
l
metaanalysi
show
confid
interv
without
recognis
point
estim
incomplet
outcom
data
attrit
bia
safeti
data
narr
seriou
advers
event
dropout
report
centr
id
redact
select
report
report
bia
high
risk
undat
amend
text
indic
substudi
select
intens
popul
basi
viral
isol
baselin
report
crf
pdf
page
select
patient
qualifi
intens
patient
case
report
form
ecg
taken
baselin
day
day
intens
patient
nose
throat
swab
taken
viru
cultur
screen
studi
day
patient
also
blood
sampl
laboratori
safeti
measur
taken
day
day
indic
day
result
reason
chang
sampl
virolog
baselin
restrict
select
intens
patient
collect
pharmaeconom
data
questionnair
updat
econom
social
benefit
treat
prevent
influenza
age
care
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
heterogen
tau
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
review
neuraminidas
inhibitor
prevent
treat
influenza
adult
children
tamiflu
relenzarelenzarelenza
nda
tamiflu
tamiflu
relenzarelenzarelenza
nda
tamiflu
relenzarelenzarelenza
nda
zanamivir
trial
citat
trial
id
sourc
fda
file
page
number
separ
comma
applic
indic
trial
cite
regulatori
file
blank
space
indic
citat
known
trial
studi
search
folder
tamiflu
relenzarelenzarelenza
nda
file
name
left
blank
studi
present
folder
oseltamivir
trial
citat
trial
id
sourc
nice
file
page
number
separ
comma
applic
indic
trial
cite
file
blank
space
indic
citat
known
trial
studi
search
folder
roch
submiss
number
volum
page
mention
mean
code
studi
cite
time
number
volum
tamiflu
nice
submiss
allevi
defin
fever
temperatur
cough
record
none
mild
musclejoint
ach
pain
sore
throat
feverishnesschil
headach
record
absentminim
basi
assum
risk
eg
median
control
group
risk
across
studi
provid
footnot
correspond
risk
confid
interv
base
assum
risk
comparison
group
rel
effect
intervent
ci
neg
risk
differ
indic
harm
posit
risk
differ
indic
benefit
ci
confid
interv
rr
risk
ratio
nntb
number
need
treat
benefit
nnth
number
need
treat
harm
basi
assum
risk
eg
median
control
group
risk
across
studi
provid
footnot
correspond
risk
confid
interv
base
assum
risk
comparison
group
rel
effect
intervent
ci
neg
risk
differ
indic
harm
posit
risk
differ
indic
benefit
ci
confid
interv
rr
risk
ratio
nntb
number
need
treat
benefit
nnth
number
need
treat
harm
data
basi
assum
risk
eg
median
control
group
risk
across
studi
provid
footnot
correspond
risk
confid
interv
base
assum
risk
comparison
group
rel
effect
intervent
ci
ci
confid
interv
rr
risk
ratio
public
health
drug
drug
consider
quantiti
public
money
invest
andor
essenti
drug
list
clinic
studi
report
detail
report
clinic
trial
usual
submit
regul
follow
prescrib
ich
format
roch
follow
modular
structur
see
appendix
report
sever
hundr
page
long
contain
detail
plan
design
conduct
protocol
analysi
report
analysi
plan
rap
result
trial
compliharm
term
describ
event
defin
either
complic
harm
accord
ambigu
criteria
appear
includ
time
analysi
time
either
unspecifi
inconsist
among
trial
whether
particip
infect
influenza
oseltamivir
treatment
trial
potenti
harm
complic
could
caus
medic
influenza
infect
eg
vomit
henc
classif
compliharm
time
lock
date
april
document
would
review
januari
version
review
cutoff
made
necessari
sheer
scale
data
hold
initi
fund
review
full
clinic
studi
report
treatment
trial
includ
kaiser
et
al
paper
abl
access
modul
regulatori
comment
approxim
page
total
funderstipul
deadlin
produc
review
progress
shorten
understand
issu
evolv
receiv
notif
balanc
studi
report
unlik
access
deadlin
would
receiv
substanti
quantiti
regulatori
document
ema
four
tranch
held
second
face
face
meet
april
receiv
first
tranch
clinic
studi
report
consist
thousand
page
bring
total
hold
page
decid
resourc
review
document
within
current
fund
impos
data
time
lock
document
receiv
date
would
review
resourc
balanc
document
page
includ
review
toc
tabl
content
regulatori
review
comment
industri
submiss
toc
indic
trial
cite
document
page
mani
time
toce
annot
version
toc
comment
annot
preliminari
form
basi
weav
import
aspect
review
narr
see
also
tabl
tabl
tabl
tabl
trial
id
mean
identifi
trial
usual
made
letter
number
wv
time
id
bear
letter
suffix
indic
last
version
protocol
follow
trial
eg
wv
ie
trial
carri
follow
amend
h
regulatori
inform
term
compris
clinic
studi
report
data
regulatori
comment
review
modul
basic
structur
roch
trial
report
see
appendix
today
term
modul
refer
compon
regulatori
submiss
set
intern
confer
harmonis
technic
requir
registr
pharmaceut
human
use
ich
ich
clinic
studi
report
one
modul
regulatori
submiss
access
web
report
clinic
trial
programm
studi
search
unpublish
hitherto
unseen
data
set
requir
construct
reason
accur
list
studi
drug
question
roch
investig
brochur
mention
studi
awar
reinforc
idea
becom
clear
essenti
need
develop
list
trial
singl
authorit
uptod
complet
list
clinic
trial
conduct
human
use
drug
seem
exist
think
next
updat
decid
use
public
major
treatment
trial
evid
tamiflu
remain
unpublish
found
discrep
csr
publish
equival
mostli
clinic
studi
report
much
detail
comprehens
short
journal
articl
enabl
thorough
critic
analysi
trial
also
decid
expand
scope
includ
evid
relat
peopl
age
except
immunesuppress
individu
de
facto
amount
creation
one
new
review
new
protocol
subsum
protocol
publicli
post
decemb
today
obviou
sourc
inform
clinic
studi
report
would
trial
registri
compani
websit
trial
ni
carri
incept
wide
accept
centralis
registri
compani
websit
compani
websit
still
extens
list
trial
download
clinic
studi
report
peopl
never
heard
clinic
studi
report
media
coverag
effort
decid
construct
list
use
multipl
crossreferenc
method
construct
list
begin
clinic
trial
identifi
previou
review
updat
end
ad
addit
trial
human
multipl
sourc
includ
manufactur
submiss
regul
drug
product
inform
sheet
previou
publish
review
health
technolog
assess
hta
document
public
manufactur
regist
burch
cooper
jefferson
tappenden
turner
wwwclinicaltrialsgov
wwwrochetrialscom
regulatori
document
also
aid
identif
unknown
trial
final
also
conduct
tradit
databas
grey
literatur
search
appendix
identifi
previous
unknown
trial
one
first
thing
learn
ensur
list
includ
duplic
entri
assign
trial
uniqu
trial
id
author
good
choic
uniqu
trial
id
differ
author
present
across
differ
version
trial
author
clinic
studi
report
differ
public
aris
clinic
trial
detail
connect
public
good
option
uniqu
trial
id
studi
publish
trial
companyspecif
code
public
clinic
trial
registri
number
neither
simplifi
recognit
terminolog
use
manufactur
protocol
id
uniqu
trial
id
list
go
use
suffici
detail
enabl
us
decid
whether
met
inclus
criteria
uniqu
trial
id
gather
follow
detail
identifi
record
trial
discov
note
complet
list
trial
possibl
contact
manufactur
sent
draft
list
ask
check
accuraci
complet
list
roch
glaxosmithklin
gsk
biocryst
learn
hitherto
unknown
trial
occasion
exist
unknown
trial
detect
week
month
thought
complet
list
may
inevit
given
trial
identif
often
take
place
unpredict
way
exampl
read
detail
regulatori
report
engag
prolong
correspond
roch
gsk
request
seri
regulatori
document
freedom
inform
polici
us
food
drug
administr
fda
european
medicin
agenc
ema
substanti
comment
made
roch
protocol
publicli
avail
one
form
anoth
sinc
decemb
specif
appli
ema
new
releas
polici
clinic
studi
report
hold
relat
oseltamivir
gsk
zanamivir
result
deliveri
start
late
march
clinic
studi
report
contain
modul
plu
one
complet
report
oseltamivir
trial
see
tabl
doshi
none
avail
zanamivir
ema
play
part
market
authoris
form
basi
version
date
complet
data
search
april
roch
provid
us
partial
clinic
studi
report
despit
five
request
full
clinic
studi
report
materi
obtain
roch
includ
first
section
socal
modul
core
report
full
clinic
studi
report
contain
four
five
modul
appendix
oseltamivir
treatment
trial
includ
kaiser
metaanalysi
contain
provid
modul
trial
protocol
list
amend
origin
report
analysi
plan
modul
compris
page
roch
made
avail
materi
indic
intend
answer
request
clarif
aspect
trial
avail
miss
part
complet
clinic
studi
report
addit
report
english
treatment
trial
sponsor
shanghai
roch
pharmaceut
ltd
regardless
success
request
obtain
full
clinic
studi
report
decid
updat
review
avail
materi
subsequ
updat
addit
data
becam
avail
search
public
databas
add
signific
inform
follow
chang
polici
ema
prompt
similar
effort
nordic
cochran
centr
gotzsch
receiv
addit
eight
clinic
studi
report
page
respons
freedom
inform
request
addit
page
clinic
studi
report
page
regul
comment
arriv
search
deadlin
materi
receiv
ema
relat
oseltamivir
ema
access
inform
zanamivir
nation
authoris
product
europ
correspond
xavier
luria
march
david
mackay
juli
present
hold
modul
oseltamivir
trial
request
gsk
receiv
promis
individu
patient
data
mani
clinic
studi
report
use
review
obtain
via
freedom
inform
request
still
await
fda
decis
regard
similar
request
sent
fda
januari
abl
download
page
summari
basi
approv
sba
document
fda
websit
ema
page
japanes
sba
index
content
construct
extend
tabl
content
give
summari
file
therebi
facilit
navig
complex
document
tabl
content
construct
postul
given
huge
work
involv
review
lot
regulatori
file
includ
clinic
studi
report
need
new
instrument
indic
part
import
other
thu
focus
effort
experi
varieti
method
report
earlier
version
review
devis
use
us
satisfactori
instrument
critic
assess
clinic
studi
report
entireti
intend
publish
separ
ema
releas
coupl
document
fda
sba
drug
form
basi
version
eventu
publish
januari
review
report
effort
get
bottom
issu
effect
ni
apprais
evid
unpublish
clinic
studi
report
see
glossari
appendix
regulatori
document
contain
comment
review
call
bodi
clinic
studi
regulatori
comment
regulatori
inform
document
either
creat
regul
knowledg
first
cochran
review
ever
conduct
basi
regulatori
document
due
fund
timelin
sizeabl
amount
regulatori
inform
alreadi
avail
us
decid
review
materi
avail
april
meant
review
fda
sba
materi
core
report
modul
possess
ema
data
releas
receiv
time
method
mixtur
establish
novel
reflect
size
task
lack
experi
deal
larg
amount
detail
regulatori
inform
lack
complet
set
clinic
studi
report
exampl
scan
titl
abstract
done
doubl
select
studi
inclus
list
construct
search
done
quadrupl
disagr
resolv
discuss
mani
studi
titl
case
brief
descript
content
thu
assign
three
categori
trial
definit
includ
definit
exclud
trial
need
inform
exclud
studi
definit
meet
inclus
criteria
basi
avail
inform
eg
titl
describ
trial
pharmacokinet
studi
appropri
request
inform
trial
sponsor
usual
copi
clinic
studi
report
minu
particip
identif
trial
definit
includ
need
inform
contact
firstcorrespond
author
publish
version
trial
basi
experi
review
data
extract
manag
reflect
lack
establish
method
review
regulatori
materi
subdivid
extract
apprais
analysi
data
twostag
exercis
includ
studi
analysi
phase
judg
report
reliabl
complet
help
structur
inform
use
consort
statementbas
extract
form
aim
assembl
concis
version
clinic
studi
report
includ
import
method
well
defin
extract
relev
outcom
colourcod
origin
text
flag
uncertainti
lack
clariti
need
inform
inaccess
part
clinic
studi
report
process
exclud
six
peramivir
trial
inform
manufactur
clinic
studi
report
would
availableth
review
base
oseltamivir
clinic
studi
core
report
brief
zanamivir
studi
report
former
came
ema
latter
part
gsk
submiss
uk
nation
institut
health
care
excel
nice
bmj
pass
onto
us
togeth
sba
materi
protocol
detail
would
handl
mass
inform
simpl
reason
one
ever
done
quit
liter
learn
go
along
understand
structur
content
clinic
studi
report
evolv
creat
test
five
postprotocol
hypothes
see
appendix
origin
find
report
best
exampl
find
unnatur
high
influenza
posit
rate
treatment
trial
case
pool
lack
viral
circul
hypothesis
screen
influenza
posit
carri
prior
enrol
peopl
influenzalik
ill
born
evid
avail
us
know
far
simpler
explan
like
care
select
time
period
trial
particip
enrol
base
surveil
data
suggest
high
influenza
activ
led
recruit
small
number
particip
mani
centr
high
likelihood
influenza
posit
time
limit
inform
avail
review
analys
base
itt
popul
found
reliabl
analysi
unit
oseltamivir
appear
effect
antibodi
product
peopl
influenza
lead
imbal
number
subject
influenzainfect
socal
itti
subpopul
effect
introduc
confound
otherwis
welldesign
doubleblind
trial
effect
clearli
identifi
modest
shorten
influenzalik
ill
symptom
less
day
led
us
believ
oseltamivir
aspecif
power
effect
symptom
mediat
action
influenza
virus
possibl
via
antiinflammatori
mechan
trial
clearli
design
commerci
focu
mind
claim
made
manufactur
especi
effect
interrupt
transmiss
pneumonia
support
evid
possess
present
day
soon
public
review
bmj
agre
publish
correspond
roch
gsk
ema
center
diseas
control
prevent
cdc
record
attempt
retriev
full
report
without
condit
attach
understand
basi
promot
drug
especi
oseltamivir
public
health
bodi
receiv
full
report
resum
review
remaind
materi
receiv
mainli
consist
modul
roch
terminolog
prestudi
document
modul
contain
inform
origin
deni
us
roch
studi
protocol
amend
randomis
list
blank
case
report
form
crf
certif
analysi
describ
appear
content
activ
control
capsul
time
statist
analysi
plan
sap
crf
contain
rawest
form
record
data
individu
particip
level
tool
review
synthesis
inform
creat
instrument
made
three
part
separ
function
first
part
templat
brief
summari
descript
trial
format
fit
revman
characterist
includ
studi
cist
tabl
mainli
descript
second
part
apprais
trial
follow
cochran
risk
bia
format
third
part
reconstruct
trial
timelin
provid
checklist
posit
document
variou
element
protocol
protocol
amend
studi
period
date
last
part
aim
check
intern
consist
coher
element
number
screen
number
randomis
intervent
compar
across
differ
document
start
earliest
avail
version
protocol
form
also
contain
suggest
look
inform
base
experi
gain
review
descript
review
clinic
studi
report
differ
drug
biolog
doshi
design
tool
also
ask
whether
access
modul
inform
later
full
studi
report
chang
percept
trial
specif
risk
bia
assess
found
access
suppos
full
studi
report
provid
clariti
remov
rational
unclear
risk
bia
judgement
ideal
remov
concept
risk
leav
bia
least
certain
studi
design
element
attrit
bia
either
design
element
introduc
bia
case
full
oseltamivir
clinic
studi
report
review
construct
tool
one
contain
protocol
predat
begin
particip
enrol
two
statist
analysi
plan
clearli
predat
particip
enrol
three
clearli
date
protocol
amend
clinic
studi
report
report
clear
date
unblind
latter
part
receiv
manufactur
ten
thousand
page
full
clinic
studi
report
publish
paper
complet
clinic
studi
report
publicli
avail
therefor
one
review
author
rh
ask
jmhlw
juli
disclos
document
report
evid
base
approv
oseltamivir
indic
jmhlw
sent
rh
letter
refus
date
septemb
explan
disclosur
document
might
hurt
right
posit
fair
benefit
competit
corpor
concern
wait
six
month
take
action
hope
requir
clinic
studi
report
would
forthcom
manufactur
happen
rh
file
suit
overturn
jmhlw
decis
osaka
japan
district
court
particip
flow
diagram
strongli
recommend
group
number
particip
randomli
assign
receiv
intend
treatment
analys
primari
outcom
two
review
author
assess
studi
studi
alloc
randomli
three
pair
review
author
list
includ
studi
oseltamivir
zanamivir
six
peramivir
randomli
creat
program
edgar
ii
brown
everi
studi
openli
alloc
group
accord
number
initi
includ
six
peramivir
trial
randomisationalloc
sequenc
subsequ
decid
proceed
inform
manufactur
clinic
studi
report
would
avail
registr
us
food
drug
administr
fda
correspond
bill
sheridan
august
one
review
author
tj
assign
attempt
reconstruct
clinic
studi
report
fda
document
two
week
time
lock
see
glossari
appendix
receiv
first
batch
clinic
studi
report
ema
formerli
emea
contain
addit
four
clinic
studi
report
includ
one
complet
fourmodul
clinic
studi
report
studi
want
includ
time
random
alloc
achiev
write
trial
id
one
set
ticket
ask
extern
research
alloc
group
name
written
anoth
set
ticket
author
pair
separ
extract
data
clinic
studi
report
studi
includ
stage
review
one
copi
clinic
studi
report
differ
sourc
exampl
clinic
studi
report
submit
regulatori
bodi
clinic
studi
report
pharmaceut
compani
independ
extract
data
copi
compar
result
aim
record
tabul
disagr
data
extract
sourc
differ
sourc
extract
data
use
modifi
consort
statementbas
extract
templat
appendix
modifi
consortbas
extract
templat
aim
assembl
concis
version
clinic
studi
report
would
includ
import
method
well
defin
extract
relev
outcom
consortbas
extract
templat
includ
featur
would
expect
found
publish
trial
report
far
greater
detail
reconstruct
includ
introduct
discuss
section
extract
follow
trial
activ
drug
advers
event
occur
similar
frequenc
differ
treatment
group
could
relat
lactos
vehicl
inhal
fda
reason
analog
review
medic
content
avail
clinic
studi
report
oseltamivir
trial
detail
inform
compar
content
physic
characterist
batch
number
tabl
roch
use
word
match
strictli
correct
two
principl
present
placebo
capsul
dehydrochol
acid
dibas
calcium
phosphat
dihydr
list
present
activ
oseltamivir
capsul
could
locat
reason
choic
clinic
studi
report
substanc
may
gastrointestin
action
consum
larg
enough
quantiti
basi
formul
two
hypothes
associ
incid
gastrointestin
harm
placebo
contain
dehydrochol
acid
oseltamivir
trial
associ
incid
asthmarel
event
placebo
contain
lactos
powder
zanamivir
trial
test
hypothesi
assess
oseltamivir
trial
clinic
studi
report
modul
gastrointestin
tract
git
harm
includ
nausea
vomit
diarrhoea
well
particip
withdraw
studi
due
advers
event
metaanalys
result
studi
use
invers
varianc
randomeffect
method
assess
heterogen
use
chi
test
use
tau
estim
betweenstudi
varianc
investig
whether
placebo
contain
dehydrochol
acid
may
associ
gastrointestin
harm
compar
advers
event
rate
placebo
group
oseltamivir
trial
placebo
contain
dehydrochol
acid
advers
event
rate
placebo
group
zanamivir
trial
placebo
contain
dehydrochol
acid
comparison
done
inform
use
data
obtain
fda
label
oseltamivir
zanamivir
fda
fda
well
trial
clinic
studi
report
sensit
analysi
assum
similar
gastrointestin
advers
event
rate
placebo
group
oseltamivir
trial
observ
placebo
group
zanamivir
trial
repeat
metaanalysi
describ
also
specul
withdraw
placebo
group
due
gastrointestin
advers
event
possibl
relat
dehydrochol
acid
remov
sensit
analysi
hypothesi
assess
asthmarel
event
nine
zanamivir
trial
clinic
studi
report
metaanalys
result
studi
use
invers
varianc
randomeffect
method
assess
heterogen
use
chi
test
use
tau
estim
betweenstudi
varianc
investig
whether
placebo
contain
lactos
powder
may
associ
asthmarel
event
inform
compar
event
rate
placebo
group
zanamivir
trial
placebo
contain
lactos
powder
event
rate
placebo
group
oseltamivir
trial
placebo
contain
lactos
powder
sensit
analysi
assum
similar
asthmarel
event
rate
placebo
group
zanamivir
trial
observ
placebo
group
oseltamivir
trial
repeat
metaanalysi
describ
hypothesi
oseltamivir
zanamivir
affect
antibodi
product
treatment
trial
rational
oseltamivir
influenza
treatment
trial
specifi
primari
efficaci
analysi
popul
influenzainfect
popul
randomis
intentiontotreat
itt
base
popul
influenzainfect
popul
known
itti
intentiontotreatinfect
clinic
studi
report
determin
postrandomis
base
result
laboratori
test
cultur
andor
antibodi
rise
compar
pair
sera
particip
sampl
cultur
first
sampl
sera
taken
commenc
trial
product
second
third
sera
taken
patient
treat
trial
medic
vital
placebo
activ
group
patient
odd
classifi
influenzainfect
otherwis
comparison
influenzainfect
group
potenti
affect
bia
essenti
nonrandomis
comparison
trial
medic
affect
product
antibodi
select
influenzainfect
popul
partli
base
antibodi
product
confound
take
trial
medic
roch
state
multipl
occas
smith
ward
section
serolog
ingest
oseltamivir
affect
antibodi
product
fda
support
state
studi
natur
acquir
experiment
influenza
treatment
tamiflu
impair
normal
humor
antibodi
respons
infect
fda
howev
notic
unequ
number
individu
influenzainfect
popul
subgroup
numer
trial
addit
takahashi
et
al
report
oseltamivir
significantli
suppress
respiratori
mucos
secretori
immunoglobulin
ig
respons
antigen
ag
specif
antibodi
ab
product
also
induct
agspecif
iga
abform
cell
anim
experi
takahashi
take
oseltamivir
affect
product
igg
antibodi
well
may
affect
select
influenzainfect
popul
also
unsur
implic
immunis
influenza
vaccin
accord
fda
influenza
vaccin
interact
studi
conduct
oseltamivir
fda
test
hypothesi
compar
odd
particip
itt
popul
subsequ
classifi
influenzainfect
odd
particip
itt
popul
fourfold
rise
antibodi
placebo
activ
arm
trial
ingest
oseltamivir
affect
antibodi
product
expect
odd
classifi
influenzainfect
placebo
activ
arm
therefor
test
null
hypothesi
odd
fourfold
rise
antibodi
placebo
activ
arm
metaanalys
result
studi
use
invers
varianc
randomeffect
method
assess
heterogen
use
chi
test
use
tau
estim
betweenstudi
varianc
trial
includ
analysi
oseltamivir
treatment
trial
analys
kaiser
plu
oseltamivir
zanamivir
treatment
trial
clinic
studi
report
modul
addit
analysi
also
assess
oseltamivir
trial
conduct
china
shanghai
roch
pharmaceut
ltd
partial
clinic
studi
report
hypothesi
oseltamivir
affect
antibodi
product
postexposur
secondari
prophylaxi
trial
rational
accord
clinic
studi
report
trial
programm
assess
effect
oseltamivir
postexposur
prophylaxi
pep
consist
two
trial
modul
trial
togeth
copiou
fda
note
trial
avail
us
time
lock
howev
pep
trial
standard
care
placebocontrol
exclud
review
doubleblind
clusterrandomis
trial
contact
cluster
index
case
randomis
oseltamivir
mg
day
placebo
seven
day
trial
form
integr
part
pivot
trial
packag
supplementari
applic
review
prophylaxi
use
oseltamivir
mg
peopl
age
year
age
submit
fda
may
approv
novemb
fda
clinic
studi
report
modul
manufactur
claim
trial
provid
evid
drug
capac
prevent
influenza
contact
interrupt
transmiss
index
case
sinc
index
case
left
untreat
except
paracetamol
rescu
pack
hard
see
claim
made
interrupt
transmiss
claim
two
compon
reduct
viral
spread
index
case
measur
nasal
shed
influenza
virus
prevent
onset
influenza
contact
latter
claim
base
definit
prevent
influenza
case
mixtur
symptom
sign
laboratori
confirm
ie
viral
cultur
upper
airway
andor
least
fourfold
rise
antibodi
titr
measur
baselin
two
three
week
later
result
trial
later
form
basi
claim
drug
effect
interrupt
transmiss
person
person
allow
time
arriv
vaccin
event
pandem
interrupt
transmiss
claim
provid
power
rational
stockpil
oseltamivir
see
exampl
vol
nice
ro
success
interrupt
transmiss
influenza
within
household
suggest
ro
oseltamivir
would
control
spread
influenza
close
commun
associ
high
risk
transmiss
nurs
home
ro
also
effect
interrupt
viru
transmiss
within
household
interrupt
transmiss
indic
accept
agenc
world
health
organ
us
center
diseas
control
prevent
cdc
us
fda
refus
regist
allow
public
base
indic
beyond
treatment
prophylact
effect
symptom
fda
review
evid
studi
protocol
modul
togeth
fda
critic
explain
rational
fda
support
manufactur
claim
design
trial
allow
comparison
effect
treat
index
case
oseltamivir
versu
placebo
index
case
medic
repeat
viral
cultur
perform
particip
viral
cultur
perform
baselin
particip
thereaft
particip
influenzalik
ill
symptom
see
schedul
assess
contact
case
fda
medic
offic
report
fda
particip
present
followup
symptom
influenza
throat
nasal
swab
taken
order
confirm
presenc
absenc
influenza
infect
fda
therebi
miss
potenti
asymptomat
infect
peopl
howev
recent
review
transmiss
studi
found
convinc
evid
spread
presymptomat
asymptomat
subject
patroz
might
explain
fda
caution
sanction
claim
oseltamivir
review
clinic
studi
report
modul
identifi
problem
conduct
report
trial
discrep
within
clinic
studi
report
studi
protocol
protocol
version
h
mention
viral
shed
measur
appear
postprotocol
addit
would
explain
unsystemat
natur
viral
excret
measur
remark
fda
ie
taken
symptomat
contact
primari
popul
analysi
call
ittiinab
popul
contact
itt
influenzainfect
index
case
neg
virolog
baselin
although
defin
protocol
select
present
result
intentiontotreat
contact
influenzainfect
index
case
infect
baselin
ittiinab
popul
effect
exclud
placebo
oseltamivir
particip
effect
select
cluster
formal
test
sensit
analysi
potenti
weak
choic
discuss
clinic
studi
report
carri
analysi
use
fisher
exact
test
show
statist
evid
placebo
oseltamivir
group
cluster
size
distribut
differ
base
household
infect
index
case
p
tabl
analys
popul
influenza
statu
index
case
instead
unit
randomis
index
case
benefici
effect
clusterrandomis
potenti
lost
introduc
unknown
bias
analysi
addit
generalis
conclus
may
easili
appli
clinic
practic
test
suspect
influenza
case
often
practic
crosscheck
definit
ittiinab
report
protocol
pep
trial
exclud
review
yield
differ
definit
pdf
page
primari
outcom
studi
incid
influenza
occur
among
contact
influenzainfect
index
case
intenttotreatindexinfect
popul
throughout
clinic
studi
report
trial
mani
appar
contradictori
statement
import
aspect
trial
exampl
mani
viral
swab
pair
sera
test
carri
text
page
modul
report
contact
laboratoryconfirm
clinic
influenza
ittiinab
popul
diagnosi
confirm
cultur
tabl
show
contact
shed
viru
day
two
eight
tabl
report
placebo
contact
oseltamivir
contact
neg
virolog
suggest
test
day
two
eight
howev
viral
test
took
place
baselin
thereaft
symptomat
particip
number
contact
influenza
diagnos
serolog
unclear
appear
five
minu
inconsist
highlight
one
fundament
conceptu
problem
understand
whole
oseltamivir
prophylaxi
trial
programm
mode
action
drug
interpret
text
suggest
oseltamivir
prevent
infect
affect
influenza
antibodi
respons
state
claim
oseltamivir
affect
antibodi
respons
made
manufactur
howev
antibodi
respons
part
definit
influenza
unsur
possibl
oseltamivir
could
prevent
influenza
stop
symptom
appear
antibodi
rise
time
leav
antibodi
product
unaffect
reason
decid
test
whether
administr
oseltamivir
pep
affect
product
antibodi
influenza
virus
distribut
chang
antibodi
baselin
followup
compar
arm
trial
contact
index
case
analysi
perform
use
wilcoxon
twosampl
test
separ
type
antibodi
trial
addit
analysi
proport
contact
fourfold
greater
rise
influenzaspecif
antibodi
titr
antibodi
compar
group
use
chi
test
antibodi
data
avail
index
case
left
untreat
antibodi
test
may
undertaken
day
day
day
day
contact
day
blood
sampl
influenza
antibodi
analysi
store
measur
influenza
antibodi
level
contact
attend
followup
visit
day
analysi
base
data
ittiinab
popul
page
appendix
clinic
studi
report
modul
hypothesi
number
trial
centr
centr
withdraw
affect
proport
placebo
patient
subsequ
diagnos
influenza
infect
origin
outcom
effect
size
hypothesi
oseltamivir
treatment
trial
associ
order
randomis
nasopharyng
swab
ie
randomis
particip
first
swab
swab
first
randomis
proport
placebo
patient
subsequ
diagnos
influenza
infect
origin
outcom
effect
size
rational
proport
itt
popul
treatment
trial
ni
subsequ
diagnos
infect
influenza
higher
usual
seen
cours
winter
season
routin
clinic
care
although
high
peak
occur
limit
period
know
treatment
trial
centr
activ
recruit
subject
influenza
outbreak
local
detect
use
standardis
surveil
techniqu
postul
unreport
procedur
may
also
use
trial
obtain
high
proport
influenza
ili
case
two
procedur
may
use
use
rapid
influenza
test
screen
patient
base
neg
result
drop
centr
recruit
low
proport
infect
patient
use
rapid
test
patient
prior
randomis
report
least
one
zanamivir
treatment
trial
oseltamivir
trial
mean
exclud
infect
hong
kong
centr
pilot
surveil
suburban
london
winter
nice
oseltamivir
paediatr
trial
exclud
respiratori
syncyti
viru
rsv
infect
addit
schedul
test
vari
trial
oseltamivir
trial
swab
perform
either
randomis
randomis
least
one
oseltamivir
treatment
trial
report
viral
cultur
perform
centr
south
america
fda
result
observ
reformul
hypothesi
follow
number
centr
centr
withdraw
affect
proport
placebo
patient
subsequ
diagnos
influenza
infect
origin
outcom
primari
outcom
effect
size
oseltamivir
treatment
trial
hypothesi
oseltamivir
treatment
trial
associ
order
randomis
nasopharyng
swab
ie
randomis
particip
first
swab
swab
first
randomis
proport
placebo
patient
subsequ
diagnos
influenza
infect
test
hypothesi
use
spearman
rank
method
estim
correl
averag
number
patient
recruit
per
centr
proport
placebo
patient
subsequ
diagnos
influenza
infect
placebo
patient
use
proport
patient
subsequ
diagnos
influenza
infect
show
later
review
evid
oseltamivir
interfer
antibodi
product
antibodi
respons
use
diagnos
influenza
infect
analys
number
centr
drop
studi
inform
variabl
avail
modul
clinic
studi
report
includ
trial
inform
patient
recruit
centr
report
modul
current
access
hypothesi
gener
attempt
explain
seemingli
high
proport
influenzainfect
influenzalik
ill
case
treatment
trial
howev
formal
test
hypothesi
one
clinic
studi
report
report
randomis
first
swab
second
see
also
appendix
result
postprotocol
analys
also
report
figur
andor
tabl
format
hypothesi
test
sensit
analysi
whether
incid
gastrointestin
harm
may
associ
exposur
particip
placebo
contain
dehydrochol
acid
data
obtain
oseltamivir
trial
clinic
studi
report
shown
tabl
overal
crude
advers
event
incid
placebo
group
oseltamivir
trial
nausea
vomit
diarrhoea
compar
crude
incid
nine
zanamivir
treatment
trial
placebo
group
nausea
vomit
report
combin
outcom
clinic
studi
report
diarrhoea
two
studi
compar
three
treatment
group
oseltamivir
mg
bid
oseltamivir
mg
bid
placebo
maintain
blind
trial
particip
took
two
pill
twice
daili
therefor
particip
oseltamivir
mg
bid
group
took
one
placebo
tablet
twice
daili
note
trial
evid
doserespons
effect
placebo
incid
diarrhoea
oseltamivir
mg
bid
oseltamivir
mg
bid
placebo
p
howev
evid
found
similar
trend
trial
p
unabl
carri
similar
analysi
paediatr
treatment
trial
detail
content
placebo
prepar
avail
see
tabl
randomeffect
metaanalysi
data
tabl
provid
follow
result
nausea
increas
odd
advers
event
due
oseltamivir
ci
p
vomit
increas
odd
advers
event
due
oseltamivir
ci
p
diarrhoea
decreas
odd
advers
event
due
oseltamivir
ci
p
withdraw
treatment
due
advers
event
evid
differ
treatment
group
ci
p
carri
sensit
analysi
assum
placebo
rate
gastrointestin
advers
event
oseltamivir
trial
base
observ
placebo
group
similar
zanamivir
trial
overal
rate
nausea
vomit
diarrhoea
placebo
group
zanamivir
treatment
trial
adult
adolesc
compar
oseltamivir
treatment
trial
adult
adolesc
rate
respect
base
fdareport
data
fda
fda
convers
common
advers
event
headach
cough
dizzi
similar
incid
placebo
group
zanamivir
oseltamivir
treatment
trial
fda
fda
treatment
trial
children
rate
nausea
vomit
diarrhoea
placebo
group
zanamivir
treatment
trial
compar
oseltamivir
treatment
trial
children
rate
respect
conserv
estim
oseltamivir
placebo
increas
rate
nausea
twofold
risk
ratio
rr
vomit
rr
diarrhoea
rr
compar
placebo
arm
zanamivir
trial
base
adult
adolesc
trial
could
conserv
specul
substanc
oseltamivir
trial
placebo
increas
nausea
vomit
diarrhoea
respect
could
also
consid
conserv
assumpt
plausibl
lactos
powder
use
placebo
zanamivir
trial
also
induc
gastrointestin
symptom
especi
patient
lactos
intoler
adjust
actual
rate
event
oseltamivir
trial
placebo
group
consist
zanamivir
trial
placebo
group
rate
report
fda
fda
fda
rerun
randomeffect
metaanalysi
obtain
follow
result
nausea
increas
odd
advers
event
due
oseltamivir
ci
p
test
heterogen
p
vomit
increas
odd
advers
event
due
oseltamivir
ci
p
test
heterogen
p
diarrhoea
increas
odd
advers
event
due
oseltamivir
ci
p
test
heterogen
p
estim
effect
size
nausea
vomit
increas
base
sensit
analysi
effect
diarrhoea
revers
indic
oseltamivir
possibl
associ
increas
odd
advers
event
result
analysi
support
altern
interpret
fda
final
carri
sensit
analysi
withdraw
treatment
due
advers
event
assum
withdraw
due
gastrointestin
event
placebo
group
total
nine
patient
oseltamivir
trial
placebo
group
withdrew
due
gastrointestin
event
withdraw
includ
follow
result
obtain
base
randomeffect
metaanalysi
withdraw
treatment
due
advers
event
evid
differ
treatment
group
ci
p
test
heterogen
p
conclud
particip
placebo
arm
oseltamivir
treatment
trial
experi
higher
rate
gastrointestin
advers
event
compar
zanamivir
counterpart
zanamivir
trial
inclus
criteria
similar
oseltamivir
trial
fever
two
addit
symptom
influenzalik
ill
ili
observ
plausibl
explain
increment
role
influenza
infect
genesi
heterogen
possibl
differ
report
gastrointestin
advers
event
placebo
group
zanamivir
oseltamivir
trial
due
differ
collect
event
howev
common
advers
event
headach
cough
dizzi
similar
rate
placebo
group
zanamivir
oseltamivir
trial
despit
result
sensit
analysi
imposs
without
clear
statement
dosag
rational
use
assess
role
dehydrochol
acid
possibl
calcium
phosphat
causat
high
incid
gastrointestin
advers
event
hypothesi
data
obtain
zanamivir
treatment
trial
clinic
studi
report
shown
tabl
nine
zanamivir
trial
incid
asthma
includ
asthma
exacerb
placebo
group
compar
placebo
group
oseltamivir
trial
randomeffect
metaanalysi
data
tabl
provid
follow
result
combin
outcom
asthma
event
asthma
decreas
odd
advers
event
due
zanamivir
ci
p
carri
sensit
analysi
assum
placebo
rate
asthmarel
advers
event
zanamivir
trial
base
observ
similar
oseltamivir
trial
assum
rate
asthma
event
placebo
group
nine
zanamivir
trial
similar
observ
oseltamivir
trial
obtain
follow
result
base
randomeffect
metaanalysi
asthma
evid
differ
treatment
group
ci
p
test
heterogen
p
conclud
zanamivir
trial
placebo
recipi
appear
higher
incid
asthmarel
event
oseltamivir
counterpart
inclus
criteria
similar
trial
programm
find
like
due
sever
influenza
infect
associ
exposur
lactos
powder
possibl
activ
principl
point
remark
fda
hypothesi
oseltamivir
zanamivir
affect
antibodi
product
treatment
trial
relev
trial
show
strong
consist
evid
patient
randomis
activ
treatment
reduc
odd
classifi
influenzainfect
ci
p
evid
heterogen
heterogen
chi
test
df
p
estim
betweenstudi
varianc
tau
see
tabl
also
strong
evid
patient
randomis
activ
treatment
reduc
odd
fourfold
higher
rise
antibodi
titr
ci
p
evid
heterogen
heterogen
chi
test
df
p
estim
betweenstudi
varianc
tau
see
tabl
contrast
zanamivir
trial
show
evid
patient
randomis
activ
treatment
reduc
odd
classifi
influenzainfect
ci
p
evid
heterogen
heterogen
chi
test
df
p
estim
betweenstudi
varianc
tau
see
tabl
result
import
implic
oseltamivir
treatment
trial
programm
ongo
trial
influenzainfect
popul
select
postrandomis
posttrial
termin
basi
laboratori
find
itt
particip
symptomat
entri
aetiolog
unknown
howev
oseltamivir
appear
affect
antibodi
product
perhap
test
may
particip
oseltamivir
group
infect
influenza
diagnos
antibodi
rise
therefor
count
influenzainfect
popul
may
subsequ
exclud
efficaci
analysi
also
possibl
strength
antibodi
product
limit
qualifi
influenza
infectioninduc
antibodi
rise
fourfour
fold
baselin
effect
select
stronger
respond
influenzainfect
subgroup
oseltamivir
arm
would
mean
best
antibodi
produc
select
may
led
inflat
treatment
estim
efficaci
influenzainfect
popul
investig
possibl
calcul
correl
odd
classifi
infect
oseltamivir
group
compar
placebo
group
size
primari
treatment
effect
time
allevi
symptom
itti
popul
treatment
trial
particip
recruit
basi
symptom
influenzalik
ill
accord
mechan
action
propos
manufactur
infect
particip
given
oseltamivir
hour
symptom
onset
antibodi
respons
given
effect
randomis
similar
placebo
recipi
nonrespond
weak
respond
spread
evenli
across
trial
arm
treatment
trial
oseltamivir
show
evid
treatment
effect
primari
outcom
studi
includ
analysi
includ
two
trial
clinic
full
studi
report
includ
trial
increas
variat
two
variabl
use
analysi
addit
two
trial
exclud
total
itti
sampl
size
particip
treatment
trial
chronic
ill
adult
show
evid
treatment
effect
result
show
strong
evid
correl
spearman
rank
correl
p
tabl
correl
highli
neg
indic
lower
odd
classifi
itti
oseltamivir
group
compar
placebo
group
associ
larger
treatment
effect
primari
outcom
studi
contrast
evid
correl
odd
classifi
infect
oseltamivir
group
compar
placebo
group
tabl
size
treatment
effect
itt
popul
spearman
rank
correl
p
limit
analysi
data
itt
popul
two
trial
avail
tabl
thu
influenzainfect
comparison
potenti
confound
action
drug
oseltamivir
probabl
zanamivir
essenti
nonrandomis
comparison
analys
base
itt
popul
oseltamivir
treatment
trial
analys
data
consid
inclus
systemat
review
base
itt
safeti
popul
analysi
hypothesi
show
odd
fourfold
rise
antibodi
ci
oseltamivir
group
compar
placebo
henc
much
bigger
effect
compar
treatment
trial
due
insuffici
inform
provid
clinic
studi
report
unabl
take
account
cluster
analysi
henc
confid
interv
possibl
underestim
howev
analysi
take
account
cluster
unlik
chang
conclus
result
show
oseltamivir
prophylaxi
associ
lower
odd
fourfold
rise
antibodi
appear
due
differ
distribut
antibodi
rise
antibodi
hib
antibodi
see
tabl
tabl
tabl
tabl
summari
conclus
drawn
avail
evid
effect
drug
viral
transmiss
mode
action
prophylaxi
appear
mainli
ascrib
symptom
suppress
control
uncertainti
around
possibl
effect
drug
especi
given
interact
product
antibodi
reject
hypothesi
current
unabl
test
hypothesi
reject
hypothesi
evid
correl
averag
recruit
subject
per
centr
proport
placebo
patient
subsequ
diagnos
influenza
infect
spearman
correl
p
tabl
show
averag
recruit
particip
per
centr
rang
appear
low
intern
multicentr
trial
two
studi
fail
reach
recruit
target
two
clinic
studi
report
made
multipl
trial
due
origin
trial
poor
recruit
tabl
addit
proport
placebo
patient
subsequ
diagnos
influenza
infect
rang
impli
littl
betweentri
variat
current
unabl
test
hypothesi
one
oseltamivir
clinic
studi
report
three
trial
report
randomis
first
swab
second
studi
proport
placebo
patient
confirm
influenzainfect
compar
seven
clinic
studi
report
swab
carri
first
randomis
second
proport
placebo
patient
confirm
influenzainfect
rang
mean
henc
seem
swab
randomis
made
differ
treatment
trial
programm
practic
report
howev
one
clinic
treatment
studi
report
randomis
prior
swab
avail
us
power
detect
differ
proport
placebo
patient
subsequ
diagnos
influenza
infect
low
hope
abl
retest
hypothesi
data
becom
avail
titl
confus
expect
review
unpublish
trial
complement
review
publish
trial
would
longer
clearer
could
call
neuraminidas
inhibitor
prevent
treat
influenza
healthi
adult
childrena
review
clinic
studi
report
publish
unpublish
trial
section
intervent
might
work
could
reorgan
along
line
metabol
oseltamivir
phosphat
op
tamiflu
prodrug
oseltamivir
carboxyl
oc
effect
form
op
dissoci
gastrointestin
tract
form
oseltamivir
ot
absorb
metabolis
oc
hepat
carboxylesteras
hce
trial
event
state
revman
softwar
automat
add
cell
tabl
studi
sensit
analys
note
point
agre
appropri
realist
sensit
analys
conduct
feedback
wolfgang
beckerbrues
januari
summari
dear
tom
jefferson
read
review
ni
prevent
treat
influenza
interest
import
work
chapter
import
review
found
small
mistak
concern
worldwid
stockpil
oseltamivir
mention
chf
billion
worth
oseltamivir
jack
would
enorm
amount
prior
emerg
influenza
andrew
jack
wrote
cite
financi
time
may
govern
around
world
stockpil
treatment
date
swell
sale
sinc
start
larg
basi
prepar
pandem
viru
yet
appear
billion
sfr
repres
sale
stockpil
wolfgang
beckerbrues
physician
pharmacist
thank
extent
stockpil
close
guard
secret
estim
probabl
never
know
summari
write
comment
recent
updat
metaanalysi
jefferson
colleagu
publish
cochran
collabor
request
clarif
sever
point
well
suggest
addit
analys
would
help
term
take
greater
advantag
use
databas
fulli
support
access
jefferson
interest
investig
publish
unpublish
data
rct
oseltamivir
zanamivir
analys
analysi
focus
rct
ambulatori
patient
uncompl
influenza
vast
major
previous
healthi
period
pandem
consequ
would
urg
investig
extend
effort
popul
dataset
examin
risk
benefit
use
neuraminidas
inhibitor
nai
treatment
prophylaxi
furthermor
author
acknowledg
limit
analys
explicitli
avoid
inappropri
extrapol
popul
influenza
event
rct
adequ
address
differ
diseas
pathogenesi
relat
viru
host
factor
well
time
treatment
import
effect
util
antivir
agent
intervent
specif
comment
recommend
addit
analys
follow
use
intent
treat
itt
ittiinfect
group
exclus
focu
current
treatment
analysi
itt
popul
readili
rectifi
shortcom
outcom
three
group
relev
itt
ittinfect
ittnoninfect
present
reader
examin
clinic
effect
efficaci
key
endpoint
well
event
without
document
influenza
nai
treatment
would
expect
provid
benefit
noninfluenza
ill
present
ittinfect
outcom
analysi
underestim
possibl
benefici
drug
effect
assess
noninfect
group
provid
valuabl
control
also
enabl
determin
whether
potenti
drugdiseas
advers
interact
nai
treatment
noninfluenza
patient
note
earlier
pool
analysi
physiciandiagnos
lower
respiratori
tract
complic
lead
antibiot
use
found
signific
benefit
oseltamivir
influenzainfect
patient
enrol
influenza
infect
detect
cultur
serolog
sampl
size
consider
sever
outcom
influenza
infect
suffici
uncommon
previous
healthi
peopl
even
larg
rct
combin
multipl
rct
would
unlik
detect
confid
point
appli
uncommon
endpoint
like
microbiolog
document
bacteri
complic
rare
advers
effect
treatment
consequ
conclus
evid
trial
nai
reduc
risk
pneumonia
hospitalis
death
overst
evid
consid
analysi
insuffici
properli
address
question
us
cdc
estim
agerel
influenzarel
hospitalis
mortal
rate
season
epidem
pandem
shrestha
jefferson
colleagu
use
event
estim
other
make
calcul
necessari
sampl
size
detect
reduct
sever
outcom
nai
therapi
control
rct
across
rang
clinic
relev
effect
size
eg
reduct
relat
fashion
also
provid
quantit
estim
abil
detect
outcom
exist
databas
comment
precis
power
captur
particular
endpoint
complic
ambulatori
patient
clinic
relev
endpoint
previous
healthi
atrisk
person
warrant
investig
regard
influenzarel
complic
frequent
previous
healthi
children
adult
respiratori
tract
infect
otiti
media
bronchiti
lead
antimicrob
use
usual
sever
typic
microbiolog
document
respect
etiolog
physiciandiagnos
complic
lead
antibiot
use
outcom
import
clinic
public
health
implic
ie
cost
antibiot
resist
side
effect
also
suffici
frequent
demonstr
effect
antivir
show
benefit
adult
earlier
pool
analys
avail
rct
data
inhal
zanamivir
oral
oseltamivir
oseltamivir
effect
confirm
recent
metaanalysi
anoth
recent
cochran
report
confirm
effect
otiti
media
children
wang
given
larg
amount
data
avail
investig
would
valuabl
contribut
also
explor
clinic
outcom
greater
detail
clarifi
use
term
like
sever
outcom
although
uncommon
popul
enrol
rct
endpoint
radiograph
document
pneumonia
microbiolog
document
infect
hospitalis
death
clear
list
separ
without
proven
influenza
infect
import
hospitalis
endpoint
would
help
examin
allcaus
hospitalis
also
relev
subgroup
base
like
causat
eg
event
influenza
document
like
implic
includ
exacerb
comorbid
vs
other
like
accid
elect
surgeri
condit
unlik
influenzarel
addit
event
exacerb
underli
condit
eg
asthma
copd
diabet
chf
medic
import
influenza
outpati
comorbid
examin
data
observ
studi
typic
patient
risk
sever
outcom
older
peopl
infant
young
children
underli
chronic
condit
includ
rct
regard
current
analysi
limit
placeboor
activecontrol
rct
larg
done
previous
healthi
person
consid
multipl
observ
studi
differ
countri
consist
show
protect
effect
sever
outcom
like
pneumonia
hospitalis
particularli
comorbid
well
reduc
mortal
patient
hospitalis
consider
amount
new
treatment
data
gener
mani
countri
pandem
found
time
nai
treatment
associ
lower
risk
intens
care
admiss
death
refer
list
avail
upon
request
data
analys
weaker
rct
data
subject
bia
observ
studi
address
key
endpoint
atrisk
serious
ill
popul
includ
patient
admit
hospit
time
initi
therapi
avail
rct
address
furthermor
standard
care
evolv
placebocontrol
rct
patient
group
would
accept
investig
ethic
committe
decis
jefferson
colleagu
consid
critic
analys
larg
amount
observ
data
modern
techniqu
mean
incorpor
key
inform
mani
import
patient
group
avail
data
suggest
medic
import
benefit
earli
nai
therapi
find
observ
data
inform
antivir
treatment
sever
ill
patient
data
avail
discuss
includ
observ
data
mean
conclus
effect
uncommon
event
sever
advers
event
detect
almost
inevit
made
explicit
design
conclus
current
report
influenza
diagnosi
serolog
result
jefferson
report
rais
question
possibl
inhibitori
effect
oseltamivir
therapi
influenzaspecif
serolog
rise
introduct
bia
outcom
analysi
analys
might
help
assess
possibl
compar
primari
endpoint
ill
allevi
oseltamivir
placebo
subgroup
cultureposit
irrespect
serolog
find
enrol
separ
cultureneg
serolog
evid
infect
note
one
prior
studi
oseltamivir
treatment
pandem
patient
although
season
influenza
patient
suggest
earli
treatment
could
reduc
antibodi
respons
cowl
jefferson
colleagu
examin
agerel
frequenc
hai
seroconvers
gmt
titr
rise
influenzacultur
posit
ill
separ
hai
rise
absenc
cultur
posit
cours
still
avail
would
interest
test
cultureneg
enrol
sampl
rtpcr
rct
data
gener
multipl
season
differ
influenza
b
virus
circul
influenza
b
neuraminidas
gener
less
suscept
oseltamivir
carboxyl
sever
observ
studi
indic
oseltamivir
less
effect
influenza
bthan
influenza
ainfect
children
sugaya
sato
would
use
examin
primari
outcom
relat
viru
type
vs
b
possibl
subtyp
vs
document
infect
expand
point
treatment
endpoint
interest
sinc
enrol
rct
outpati
would
use
explor
endpoint
reflect
patient
recoveri
impact
healthcar
system
eg
nonschedul
return
visit
complic
advers
event
perhap
import
time
allevi
endpoint
use
registr
trial
might
time
resumpt
usual
activ
return
premorbid
statu
author
rais
possibl
oseltamivir
might
nonspecif
antipyret
effect
one
anim
model
studi
also
suggest
possibl
advers
immunomodulatori
effect
oseltamivir
rsv
infect
consequ
would
interest
examin
cours
fever
resolut
much
earlier
event
cough
resolut
symptom
oseltamivirand
placebotr
patient
without
document
influenza
infect
addit
would
valuabl
examin
correspond
lack
thereof
influenza
virolog
measur
eg
enrol
viru
titr
time
cultur
neg
chang
viral
titr
time
symptom
resolut
measur
oseltamivir
placebo
group
variou
costeffect
analys
nai
therapi
lowrisk
popul
publish
wide
diverg
outcom
larg
depend
input
assumpt
use
larg
databas
refin
analysi
incorpor
direct
indirect
product
loss
cost
influenza
would
inform
advers
event
treatment
regard
drug
toler
import
examin
frequenc
report
advers
event
also
assess
indic
sever
interfer
complianc
eg
symptom
day
patient
report
sever
prematur
cessat
studi
drug
comparison
ae
placebo
group
across
zanamivir
oseltamivir
studi
need
interpret
caution
sinc
studi
perform
differ
influenza
season
virus
locat
differ
protocol
case
record
form
differ
investig
one
headhead
rct
treatment
compar
drug
publish
date
knowledg
design
includ
placebo
group
duval
particular
comparison
children
page
need
ageadjust
major
differ
enrol
zanamivir
year
older
oseltamivir
trial
year
older
frequenc
gastrointestin
manifest
much
higher
younger
children
influenza
acut
ill
prophylaxi
endpoint
interest
analysi
prophylaxi
outcom
associ
discuss
requir
clarif
statement
page
say
fda
also
allow
indic
interfer
viral
transmiss
within
household
key
concept
behind
postexposur
prophylaxi
key
concept
behind
postexposur
prophylaxi
prevent
ill
expos
person
primari
endpoint
prophylaxi
studi
symptomat
laboratoryconfirm
influenza
ill
fda
regulatori
agenc
approv
nai
postexposur
prophylaxi
household
also
longer
durat
preexposur
chemoprophylaxi
review
khazemi
jefferson
analysi
seem
focu
exclus
effect
chemoprophylaxi
prevent
spread
influenza
endpoint
presum
determin
evid
cultur
serolog
confirm
infect
irrespect
ill
one
endpoint
interest
studi
primari
outcom
medic
interest
prevent
influenza
ill
expos
abund
rct
data
well
observ
data
pandem
inhal
zanamivir
oral
oseltamivir
statist
signific
medic
import
effect
prevent
influenzaspecif
ill
note
develop
serolog
evid
infect
without
ill
advantag
receiv
chemoprophylaxi
like
immun
event
protect
futur
infect
ill
strain
addit
sever
oseltamivir
rct
shown
signific
lesser
effect
influenza
infect
prophylaxi
recipi
author
present
relev
endpoint
analysi
prophylaxi
trial
advers
effect
prophylaxi
prophylaxi
studi
particularli
use
assess
drug
toler
symptom
acut
ill
present
treatment
studi
confound
prolong
durat
drug
exposur
howev
essenti
examin
frequenc
report
advers
event
also
indic
sever
possibl
interfer
complianc
eg
symptom
day
patient
report
sever
prematur
cessat
studi
drug
exampl
jefferson
post
state
similarli
publish
prophylaxi
trial
hayden
known
trial
id
describ
headach
occur
similar
proport
subject
three
group
per
cent
indic
japanes
regulatori
document
reach
differ
conclus
review
advers
event
tabul
prophylaxi
studi
tabl
provid
sponsor
indic
proport
subject
report
headach
otherwis
specifi
might
relat
studi
drug
unrel
report
exclud
treatment
phase
similar
across
placebo
oseltamivir
mg
oseltamivir
mg
twice
daili
dose
group
report
indic
mild
moder
intens
selflimit
indic
publish
paper
studi
withdraw
ae
ill
occur
infrequ
across
group
n
n
note
specifi
caus
aerel
withdraw
includ
three
report
headach
associ
symptom
placebo
group
contrast
report
headach
reason
withdraw
receiv
oseltamivir
gastrointestin
complaint
account
withdraw
oseltamivir
mg
oseltamivir
mg
twice
daili
recipi
total
number
patient
prematur
studi
withdraw
reason
across
three
group
respect
overal
sever
ae
report
placebo
oseltamivir
mg
oseltamivir
mg
twice
daili
recipi
unabl
includ
detail
paper
space
limit
interpret
remain
excess
clinic
relev
oseltamivirrel
headach
occur
studi
type
detail
ae
analysi
incorpor
sever
measur
provid
necessari
context
interpret
possibl
import
ae
peer
review
question
rais
opinion
express
earlier
cochran
report
nai
jefferson
colleagu
result
debat
sometim
confus
among
practition
polici
maker
regard
appropri
use
nai
season
pandem
influenza
respons
given
import
issu
would
help
futur
updat
proper
independ
review
post
public
collabor
cochran
methodolog
public
independ
peer
review
well
understood
mani
peopl
thank
opportun
provid
comment
look
forward
see
respons
dr
jefferson
colleagu
point
use
term
advers
event
throughout
document
rather
harm
advers
reaction
latter
term
impli
causal
may
may
appropri
keep
method
previou
review
use
data
journal
public
propos
analysi
access
multipl
clinic
studi
report
csr
oseltamivir
zanamivir
knowledg
first
time
data
avail
outsid
manufactur
regul
allow
explor
event
detail
possibl
use
limit
inform
safeti
report
journal
public
potenti
allow
us
address
concern
arisen
post
market
period
possibl
relationship
neuraminidas
inhibitor
oseltamivir
particular
neuropsychiatr
harm
document
avail
us
contain
list
summari
advers
event
record
trial
includ
narr
summari
seriou
advers
event
advers
event
lead
studi
withdraw
advers
event
classifi
relationship
studi
drug
also
intens
mild
moder
sever
lifethreaten
death
durat
event
report
also
lump
bodi
system
gastrointestin
neurolog
etc
csr
oseltamivir
zanamivir
includ
analysi
csr
prophylaxi
treatment
adult
treatment
children
analys
separ
advers
event
initi
descript
compar
entir
treatment
followup
period
potenti
stratifi
ontreat
offtreat
period
appear
may
differ
treatment
group
common
event
intens
overal
incid
compar
incid
treatment
group
cutoff
base
power
analysi
assum
patient
total
approxim
mani
patient
access
oseltamivir
treatment
trial
adult
well
oseltamivir
prophylaxi
trial
adult
power
detect
odd
ratio
level
signific
due
lack
data
compar
uncommon
event
compar
event
lump
bodi
system
treatment
group
find
evid
differ
incid
group
lump
bodi
system
conduct
analysi
appropri
analysi
determin
whether
differ
incid
due
common
event
includ
bodi
system
exampl
case
neurolog
bodi
system
found
evid
differ
treatment
group
would
remov
common
neurolog
event
headach
repeat
analysi
well
analysi
describ
section
also
conduct
subgroup
analysi
event
sever
intens
seriou
event
event
lead
studi
withdraw
use
definit
sever
seriou
specifi
csr
howev
check
classif
use
inform
avail
csr
includ
line
list
event
narr
provid
seriou
event
also
event
lead
studi
withdraw
disagr
origin
classif
record
reclassif
assess
sensit
analysi
given
unlik
suffici
event
conduct
separ
statist
analysi
level
bodi
system
compar
overal
distribut
event
bodi
system
treatment
group
check
valid
data
advers
event
contain
csr
conduct
descript
comparison
incid
advers
event
prophylaxi
treatment
trial
unclear
method
collect
classifi
advers
event
trial
potenti
advers
event
could
classifi
symptom
influenza
efficaci
outcom
complic
influenza
advers
event
henc
inform
comparison
incid
advers
event
trial
particip
influenza
influenzalikeil
trial
particip
influenza
may
help
show
advers
event
could
underreport
take
account
factor
age
particip
durat
treatment
exposur
inform
analys
addit
clear
advers
event
report
advers
event
includ
elsewher
csr
eg
efficaci
section
includ
data
advers
event
analys
also
construct
tabl
show
definit
specifi
csr
classifi
potenti
advers
event
advers
event
complic
symptom
influenza
alreadi
report
antibodi
product
lower
oseltamivir
group
placebo
group
systemat
review
treatment
trial
oseltamivir
updat
analysi
includ
addit
oseltamivir
trial
well
assess
antibodi
product
zanamivir
trial
assess
antibodi
product
prophylaxi
trial
oseltamivir
zanamivir
follow
method
first
identifi
particip
influenzalik
ill
ili
pyrexia
proport
similar
activ
group
placebo
group
proport
particip
four
time
higher
increas
antibodi
compar
group
number
trial
includ
two
activ
treatment
arm
differ
dose
studi
medic
given
particip
arm
trial
investig
doserespons
relationship
common
advers
event
defin
initi
analysi
descript
report
number
percentag
event
treatment
group
potenti
differ
pool
percentag
treatment
group
eg
two
standard
error
differ
percentag
conduct
formal
metaanalysi
indic
may
also
conduct
addit
analys
take
account
event
intens
andor
durat
method
present
prespecifi
prior
formal
analysi
data
limit
method
may
fail
detect
differ
rare
advers
event
event
compar
along
type
event
within
bodi
system
therefor
process
conduct
formal
analysi
may
gener
hypothes
conduct
addit
exploratori
analys
case
clearli
label
analys
exploratori
interpret
find
accordingli
peopl
influenza
self
limit
ill
howev
diseas
time
lead
seriou
complic
pneumonia
hospitalis
treatment
neuraminidas
inhibitor
reduc
risk
sever
outcom
would
import
public
health
benefit
anoth
potenti
import
public
health
benefit
would
abil
antivir
interrupt
person
person
transmiss
influenza
current
evid
outcom
scarc
inconclus
posit
balanc
effect
complic
viral
spread
versu
harm
profil
main
reason
use
ni
public
health
context
especi
oral
administ
oseltamivir
analysi
base
intentiontotreat
itt
safeti
popul
prior
review
discov
compel
evid
itti
subpopul
deem
influenzainfect
popul
balanc
treatment
group
roch
oseltamivir
trial
addit
estim
itt
popul
generalis
clinic
practic
routin
test
influenza
common
mani
countri
even
use
remain
variabl
accuraci
analysi
conduct
separ
prophylaxi
trial
treatment
trial
adult
treatment
trial
children
list
outcom
given
includ
potenti
outcom
believ
clinic
import
howev
number
may
formal
compar
review
insuffici
number
event
eg
mortal
adequ
measur
report
eg
drug
resist
summari
http
editorialunitcochraneorgcochranereviewneuraminidaseinhibitorsinfluenza
receiv
feedback
roch
full
document
access
via
link
host
cochran
editori
unit
ceu
websit
review
author
submit
repli
roch
feedback
march
post
ceu
websit
submit
barri
clinch
jame
smith
andi
kenwright
bernadett
surujb
member
associ
victim
tamiflurel
encephalopathi
group
victim
whose
children
famili
member
seriou
reaction
take
tamiflu
includ
sudden
death
accident
death
due
abnorm
behaviour
seriou
sequela
disabl
letter
would
like
respect
request
group
establish
causal
tamiflu
abnorm
behaviour
sudden
death
sequela
learnt
essenti
medicin
list
amend
tamiflu
move
core
complementari
list
use
restrict
sever
ill
due
confirm
suspect
influenza
viru
infect
critic
ill
hospit
patient
moreov
next
expert
committe
might
consid
tamiflu
delet
unless
new
inform
support
use
season
pandem
outbreak
provid
understand
systemat
review
group
issu
april
opinion
submit
serv
major
evid
promot
amend
futur
possibl
delet
tamiflu
essenti
medicin
model
list
member
associ
victim
deepli
appreci
conduct
import
systemat
review
influenc
polici
know
outlin
result
systemat
review
dr
rokuro
hama
japanes
doctor
one
member
cochran
team
translat
import
part
review
japanes
upload
websit
http
wwwnpojiporg
accord
translat
result
systemat
review
summar
follow
tamiflu
reduc
time
first
allevi
symptom
adult
day
day
effect
asthmat
children
real
target
efficaci
although
healthi
children
tamiflu
group
allevi
symptom
one
day
earlier
placebo
group
tamiflu
reduc
product
antibodi
influenza
tamiflu
decreas
hospit
evid
tamiflu
reduc
influenza
like
ill
tamiflu
induc
harm
effect
nausea
vomit
headach
neurolog
symptom
kidney
disord
diabetichyperglycemia
pain
extrem
zanamivir
advers
effect
particular
neuropsychiatr
symptom
significantli
report
tamiflu
group
placebo
group
prophylaxi
trial
doserespons
relationship
also
seen
treatment
trial
abnorm
behaviour
list
one
advers
reaction
tamiflu
japanes
label
tamiflu
sinc
henc
believ
accident
death
due
abnorm
behaviour
use
tamiflu
recogn
death
case
caus
side
effect
tamiflu
reliev
govern
submit
applic
damag
relief
pharmaceut
medic
devic
agenc
pmda
reject
state
associ
tamiflu
use
also
believ
sudden
death
sleep
may
consequ
side
effect
tamiflu
anim
die
suddenli
administr
tamiflu
anim
experi
therefor
appli
damag
relief
sudden
death
case
well
pmda
reject
reason
famili
file
case
pmda
cancel
decis
three
famili
one
sudden
death
two
accident
death
abnorm
behavior
lost
case
suprem
court
court
accept
claim
pmda
caus
sudden
death
accident
death
due
abnorm
behavior
caus
influenza
relat
encephalopathi
tamiflu
use
tamiflu
effect
brain
evid
suggest
causal
anim
clinic
epidemiolog
studi
howev
sensori
function
cognit
function
conscious
rat
disturb
mortal
rat
sudden
death
rise
dose
tamiflu
increas
shown
review
articl
mechan
suddenonset
type
reaction
tamiflu
hama
et
al
high
dose
tamiflu
stop
anim
respir
follow
cardiac
arrest
kimura
haji
et
al
induc
low
bodi
temperatur
ono
et
al
epidemiolog
studi
suggest
associ
tamiflu
use
delirium
unconsci
fujita
et
al
also
epidemiolog
studi
sudden
deterior
lead
death
within
hour
tamiflu
use
far
frequent
report
relenza
use
find
suggest
close
associ
judg
neglect
conclud
causal
associ
base
sole
claim
pmda
wit
extrem
abnorm
cours
die
develop
sequela
preciou
children
famili
member
base
experi
convinc
caus
event
tamiflu
howev
mere
lay
peopl
scientif
mean
prove
group
could
establish
causal
tamiflu
abnorm
behaviour
sudden
death
sequela
would
greatli
appreci
need
member
group
will
provid
inform
famili
case
thank
much
understand
kind
assist
advanc
sincer
member
associ
victim
tamiflurel
encephalopathi
affili
involv
organis
financi
interest
subject
matter
comment
ms
ryuko
hatano
affili
associ
victim
tamiflu
relat
encephalopathi
role
repres
dear
ms
hatano
thank
queri
sympath
posit
howev
unfortun
enough
inform
respond
specif
request
establish
causal
tamiflu
abnorm
behaviour
sudden
death
sequela
follow
explain
address
specif
request
offer
thought
possibl
relev
inform
speak
base
cochran
review
systemat
review
publish
conduct
statist
test
everi
type
advers
event
record
clinic
trial
studi
may
led
fals
posit
fals
neg
well
undermin
reliabl
associ
might
otherwis
abl
detect
therefor
write
review
approach
metaanalyz
seriou
advers
event
advers
event
lead
studi
withdraw
withdraw
advers
event
within
clinic
studi
report
defin
bodi
system
well
small
group
common
advers
event
defin
fda
drug
label
oseltamivir
importantli
event
metaanalys
death
seriou
advers
event
bodi
system
event
overal
incid
less
metaanalys
outcom
fewer
event
total
abnorm
behaviour
sudden
death
sequela
per
se
overal
incid
greater
therefor
conduct
statist
test
review
howev
conduct
statist
test
make
causal
infer
regard
advers
event
may
possibl
relev
concern
prof
del
mar
board
member
two
compani
commercialis
research
bond
univers
part
respons
provic
chancellor
research
receiv
fee
editori
guidelin
development
work
royalti
book
receipt
institut
grant
nhmrc
au
nihr
uk
hta
uk
privat
donor
support
editori
base
cochran
ari
group
dr
hama
receiv
royalti
two
book
publish
titl
tamiflu
harm
afraid
order
escap
druginduc
encephalopathi
dr
hama
provid
scientif
opinion
expert
testimoni
advers
reaction
case
relat
oseltamivir
gefitinib
dr
howick
receiv
expens
payment
john
hopkin
american
societi
neurophysiolog
monitor
ebm
consult
dr
howick
receiv
fund
wellcom
trust
medic
research
council
uk
econom
social
scienc
research
council
uk
current
nation
institut
health
research
nonclin
research
fellow
receiv
payment
canadian
medic
associ
journal
write
book
review
receiv
royalti
public
book
blackwellwiley
dr
heneghan
receiv
payment
run
educ
cours
univers
oxford
univers
oxford
isi
consult
servic
extern
teach
train
also
receiv
royalti
book
evid
base
toolkit
seri
blackwel
bmj
book
dr
onakpoya
addit
interest
disclos
dr
thompson
addit
interest
disclos
dr
jone
addit
interest
disclos
dr
spencer
addit
interest
disclos
dr
nunan
addit
interest
disclos
dr
mahtani
addit
interest
disclos
sourc
support
suppli
nation
institut
health
research
nihr
uk
review
prepar
support
nihr
uk
grant
made
number
chang
text
process
turn
protocol
review
reflect
evolv
understand
issu
rel
long
period
work
review
underway
chang
review
titl
reflect
natur
evid
old
titl
neuraminidas
inhibitor
prevent
treat
influenza
healthi
adult
children
review
clinic
studi
report
also
rewritten
object
twice
tighten
text
bring
line
initi
intent
clarifi
mean
old
object
review
clinic
studi
report
csr
identifi
publish
unpublish
randomis
control
trial
rct
relev
regulatori
data
effect
harm
ni
influenza
age
group
review
publish
unpublish
clinic
studi
report
relev
regulatori
data
effect
harm
ni
influenza
age
group
compar
publish
review
chang
emphasi
object
unpublish
studi
report
decid
start
concentr
regulatori
inform
similarli
comparison
publish
versu
unpublish
data
import
worthwhil
effort
origin
object
possibl
misl
reader
import
work
alway
conceptualis
lowprior
task
could
carri
time
follow
review
unpublish
data
also
avoid
use
acronym
thought
cumbersom
confus
reader
initi
intent
review
clinic
studi
report
regulatori
comment
make
subsequ
call
regulatori
inform
edit
reflect
chang
intent
slowli
evolv
understand
problem
face
solut
address
problem
one
mani
exampl
transit
world
studi
identifi
name
year
nicholson
one
trial
identifi
seri
letter
number
easi
review
underway
identifi
sever
unforeseen
issu
placebo
content
effect
oseltamivir
antibodi
test
relev
hypothes
carri
postprotocol
analys
present
origin
protocol
deriv
protocolst
intent
assess
programm
singl
trial
report
entireti
appendix
may
ad
amend
review
data
analys
oseltamivir
trial
modul
clinic
outcom
advers
event
ad
feedback
section
text
explain
rational
method
appli
regulatori
inform
receiv
time
lock
could
implement
time
current
review
see
also
appendix
may
amend
see
feedback
sinc
januari
version
complet
review
regulatori
inform
becam
avail
origin
time
lock
assess
addit
evid
oseltamivir
modul
evid
advers
event
follow
exposur
ni
clinic
relev
outcom
crossreferenc
individu
list
contain
modul
hold
relev
full
clinic
studi
report
make
publicli
access
review
